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i. Abstract 
 
Retinitis Pigmentosa (RP) is the name given to a group of hereditary diseases causing 
progressive and degenerative blindness. RP affects over 1 in 4000 individuals, making it the 
most prevalent inherited retinal disease worldwide, yet currently there is no cure. In 2011, 
our group released a paper detailing the protective effects of the synthetic progestin 
‘Norgestrel’. A common component of the female oral contraceptive pill, Norgestrel was 
shown to protect against retinal cell death in two distinct mouse models of retinal 
degeneration: in the Balb/c light damage model and the Pde6brd10 (rd10) model. Little was 
known of the molecular workings of this compound however and thus this study aimed to 
elucidate the protective manner in which Norgestrel worked.  
 
To this aim, the 661W cone photoreceptor-like cell line and ex vivo retinal explanting was 
utilised. We found that Norgestrel induces a increase in neuroprotective basic fibroblast 
growth factor (bFGF) with subsequent downstream actions on the inhibition of glycogen 
synthase kinase 3β. Progesterone receptor expression was subsequently characterised in 
the C57 and rd10 retinas and in the 661W cell line. Norgestrel caused nuclear trafficking of 
progesterone receptor membrane complex one (PGRMC1) in 661W cells and thus 
Norgestrel was hypothesised to work primarily through the actions of PGRMC1. This 
trafficking was shown to be responsible for the critical upregulation of bFGF and PGRMC1-
Norgestrel binding was proven to cause a neuroprotective bFGF-mediated increase in 
intracellular calcium.  
 
vii 
 
The protective properties of Norgestrel were further studied in the rd10 mouse model of 
retinitis pigmentosa. Using non-invasive diet supplementation (80mg/kg), we showed that 
Norgestrel gave significant retinal protection out to postnatal day 40 (P40). Overactive 
microglia have previously been shown to potentiate photoreceptor cell loss in the 
degenerating rd10 retina and thus we focussed on Norgestrel-mediated changes in 
photoreceptor-microglial crosstalk. Norgestrel acted to dampen pro-inflammatory 
microglial cell reactivity, decreasing chemokine (MCP1, MCP3, MIP-1α, MIP-1β) and 
subsequent damaging cytokine (TNFα, Il-1β) production. Critically, Norgestrel up-regulated 
photoreceptor-microglial, fractalkine-CX3CR1 signalling 1000-fold in the P20 rd10 mouse. 
Known to prevent microglial activation, we hypothesise that Norgestrel acts as a vital anti-
inflammatory in the diseased retina, driving fractalkine-CX3CR1 signalling to delay retinal 
degeneration. 
 
This study stands to highlight some of the neuroprotective mechanisms utilised by 
Norgestrel in the prevention of photoreceptor cell death. We identify for the first time, not 
only a pro-survival pathway activated directly in photoreceptor cells, but also a Norgestrel-
driven mediation of an otherwise damaging microglial cell response. All taken, these results 
form the beginning of a case to bring Norgestrel to clinical trials, as a potential therapeutic 
for the treatment of RP.  
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Chapter 1. Introduction: Steroid 
induced neuroprotection of the 
diseased and damaged retina 
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1. 1. Retinal degenerations 
 
Many eye diseases are classified as retinal degenerations. This blanket term refers to a 
number of retinal dystrophies including retinitis pigmentosa (RP), age-related macular 
degeneration (AMD) and diabetic macular edema (DME), all of which result in a progressive 
loss of photoreceptor cells. Retinal degeneration can be triggered by a number of different 
genetic aetiologies (Daiger et al., 2013), though common disease features include night-
blindness or nyctalopia, visual field loss and subsequent deterioration of visual acuity – 
shown in the case of retinitis pigmentosa in figure 1.1.1.  
 
1.1.1. Phenotype of retinitis pigmentosa 
Retinitis pigmentosa encompasses a set of hereditary diseases causing degenerative 
blindness. Initial symptoms occur independent of age and thus RP diagnosis may occur 
anywhere from early infancy to late adulthood (Koenekoop et al., 2003). Caused by several 
different genomic mutations (McLaughlin et al., 1993), the same mutation can manifest 
itself very differently across any number of different individuals. In general, however, RP is 
characterised by the early loss of rod photoreceptors followed by a slow, progressive 
Figure 1.1.1. Images to show the progression of visual field loss in retinitis pigmentosa. (A) Normal Vision. (B) 
Early retinitis pigmentosa: mild peripheral visual field loss with good central vision. (C) Late retinitis pigmentosa: 
marked peripheral visual field loss resulting in "tunnel vision" (Images taken from Carter, 2016). 
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deterioration of the cone photoreceptor cells. Pigmentary changes typically arise following 
photoreceptor degeneration in RP and are a result of the release of pigment by cells of the 
adjacent retinal pigment epithelium (RPE). These pigmented deposits are 
opthalmoscopically visible in advanced stages of the disease and are referred to as ‘bone-
spicule formations’ due to their branching patterns (Figure 1.1.2).  
 
1.1.2. Genetic basis of retinitis pigmentosa 
Mutations in a large variety of genes have been linked to autosomal-dominant (adRP), 
autosomal-recessive (arRP), X-linked RP (xlRP) (Table 1.1.1) and digenically inherited RP. 
AdRP and arRP comprise approximately 20% of RP cases whilst xlRP is responsible for 
approximately 10% (Hartong et al., 2006). Although rare, digenic inheritance of the disease 
also occurs, as shown in the study of three familial cases of RP (Kajiwara et al., 1994). In this 
study, mutations were discovered in the unlinked photoreceptor-specific genes rod outer 
segment protein 1 (ROM1) and peripherin/RDS (retinal degeneration slow; peripherin 2). 
Interestingly, in these families only double heterozygotes developed RP and thus the first 
report of digenic inheritance in a human disease was discovered (Kajiwara et al., 1994). 
Figure 1.1.2. Images to show the fundus of a patient with retinitis pigmentosa vs. a healthy individual. (A) Normal 
retina: No retinal pigmentation, a bright optic disc and plump retinal blood vessels are visible. No evidence of macular 
degeneration. (B) Late retinitis pigmentosa: widespread marked retinal pigmentation, a pale optic disc and thin retinal 
blood vessels can be seen. Macular thinning/degeneration occurs in the late stages of RP and results in reduced 
central vision. 
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Whilst many cases of RP are inherited, isolated instances also occur in about 40% of 
patients, mostly due to spontaneous mutation.  
 
Form of retinitis 
pigmentosa 
Number of 
identified genes 
Mapped and identified genes 
Autosomal-
dominant 
(adRP)  
27 ARL3, BEST1, CA4, CRX, FSCN2, GUCA1B, HK1, IMPDH1, 
KLHL7, NR2E3, NRL, PRPF3, PRPF4, PRPF6, PRPF8, 
PRPF31, PRPH2, RDH12, RHO, ROM1, RP1, RP9, RPE65, 
SEMA4A, SNRNP200, SPP2, TOPORS 
Autosomal-
recessive (arRP) 
57 ABCA4, AGBL5, ARL6, ARL2BP, BBS1, BBS2, BEST1, 
C2orf71, C8orf37, CERKL, CLRN1, CNGA1, CNGB1, 
CRB1, CYP4V2, DHDDS, DHX38, EMC1, EYS, FAM161A, 
GPR125, HGSNAT, IDH3B, IFT140, IFT172, IMPG2, 
KIAA1549, KIZ, LRAT, MAK, MERTK, MVK, NEK2, 
NEUROD1, NR2E3, NRL, PDE6A, PDE6B, PDE6G, 
POMGNT1, PRCD, PROM1, RBP3, RGR, RHO, RLBP1, 
RP1, RP1L1, RPE65, SAG, SLC7A14, SPATA7, TTC8, 
TULP1, USH2A, ZNF408, ZNF513  
X-linked (xlRP) 3 OFD1, RP2, RPGR 
 
Table 1.1.1. List of all genes associated with inherited forms of autosomal-dominant (adRP), autosomal-
recessive (arRP) and X-linked retinitis pigmentosa (xlRP) (“RetNet: Summaries,” 2016) 
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1.1.3. Retinitis pigmentosa-induced changes in visual processing 
There are two types of photoreceptor: rods and cones. These cells are responsible for 
converting light energy in to information to be processed by the visual system. Rod cells 
contain long cylindrical outer segments, have many disks and have a high concentration of 
pigment, all features enabling rods to be extremely light sensitive. In low light, visual 
processing occurs solely due to rod signalling, for these cells can be triggered by a single 
photon. Rods cannot mediate colour vision and thus colours cannot be seen at low light 
levels: only one type of photoreceptor cell is active. This is also why nyctalopia is one of the 
initial symptoms of RP. Rods are lost first in RP and so few rods are left to process visual 
signals, leading to night-blindness. Alternately, cones require significantly brighter light (i.e. 
a larger numbers of photons) in order to produce a signal and are primarily responsible for 
spatial acuity and for colour vision. Central vision is lost as cones of the central retina 
degenerate, thus central vision is lost secondarily to peripheral vision (Wong, 1993). The 
human retina contains about 120 million rod cells and 6 million cone cells - the cellular 
structure of the retina being illustrated in figure 1.1.3.   
Figure 1.1.3. Simplified schematic of the retina. Illustrates the variety of cell types found in the retina along 
with their connections. (Taken from Roche et al., 2016) 
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Visual processing occurs via a tightly controlled photo-transduction cascade. Packets of 
light energy in the form of photons are absorbed and processed by rhodopsin molecules in 
the membrane discs of rod outer segments (Figure 1.1.4). Once activated, rhodopsin makes 
repeated contact with the G-protein transducin to further activate a cGMP 
phosphodiesterase (cGMP PDE). The resultant hydrolysis of cGMP - the second messenger 
in the photo-transduction cascade, closes cGMP-gated channels leading to hyper-
polarisation of the cell and subsequent signalling. Rhodopsin kinase will phosphorylate 
rhodopsin, inducing a termination of the photo-transduction cascade (Leskov et al., 2000).  
Rod cGMP-specific 3',5'-cyclic phosphodiesterase subunit beta is the beta subunit of the 
protein complex PDE6 that is encoded by the Pde6b gene. This gene is included in the array 
of genes that cause RP (Table 1.1.1), mutations of which account for 4-5% of autosomal-
recessive cases. cGMP is an essential component in the rod signal transduction pathway 
(Cote, 2004; Kennan et al., 2005) and as such, PDE6 is crucial in transmission and 
amplification of visual signal. Specifically, the beta subunit is essential for normal 
Figure 1.1.4. Representation of molecular steps in photoactivation (taken from Corneveaux, 2016. Modified 
from Leskov et al., 2000). Shown is the outer membrane disk found in a rod cell. Step 1: Incident photon (hν) is 
absorbed and activates rhodopsin via a conformational change to R*. Step 2: R* contacts with G-protein 
transducin molecules. This contact activates the molecule to G*, catalyzing its activation to by the release of 
bound GDP in exchange for cytoplasmic GTP. Step 3: This release expels the G-protein β and γ subunits leaving 
the α subunit. Step 4: G* α subunit binds inhibitory γ subunits of phosphodiesterase (PDE) activating its α and 
β subunits. Activated PDE hydrolyzes cGMP. Step 5: Guanylyl cyclase (GC) synthesizes cGMP. Reduced levels of 
cytosolic cGMP cause cyclic nucleotide gated channels to close preventing further influx of Na+ and Ca2+. 
 
 
6 
 
functioning of this protein and mutations in this subunit have been shown to cause retinal 
degeneration.  
 
1.1.4. Genetic mouse models of retinitis pigmentosa 
Clearly, our understanding of the genetic abnormalities leading to RP is increasing. 
However, the mechanism by which the many mutations described lead to cell death has yet 
to be elucidated. Unfortunately, the direct study of human RP is hindered by the difficulty 
in obtaining relevant human tissue samples. Consequently, a number of animal models 
now exist harbouring the same mutations found in humans, thereby representing the 
human disease both genetically and phenotypically.  
 
Perhaps the best characterized mouse model of retinal degeneration is the naturally 
occurring rd1 (retinal degeneration) mouse. These mice carry a defect in the beta subunit 
of cGMP PDE, resulting in photoreceptor degeneration. Long recognised, the rd1 mouse 
has proved to be an essential tool in furthering our understanding of the disease (Pittler & 
Baehr, 1991). Unfortunately, this model experiences a rapid loss of photoreceptors, 
overlapping with postnatal development of the retina. As such, this has resulted in 
limitations to its use (Sanyal & Bal, 1973; Carter-Dawson et al., 1978). The development of 
potential treatments is difficult using this mouse model; there is only a narrow time frame 
before onset of disease, which coincides with retinal development.  
 
Alternately, the rd10 mouse model of RP, which possesses a mutation in pde6b (Chang et 
al., 2002, 2007; Han et al., 2013), has proven to be a suitable model for studying the course 
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of degeneration and developing treatments. This is because unlike in the rd1 mouse, 
photoreceptors are lost in the rd10 at a rate that closely resembles human disease 
progression. A loss of rods is observed from postnatal day (P)18 in the rd10 and peaks ~P21 
(Gargini et al., 2007; Barhoum et al., 2008; Samardzija et al., 2012; Roche et al., 2016). This 
is accompanied by morphological changes in rod and cone outer segments as well as a loss 
of photoreceptor axon terminals at P20 (Barhoum et al., 2008; Roche et al., 2016). 
Therefore, the nuclear and plexiform layers in the retina have established their mature 
state (Caley et al., 1972) before the onset of photoreceptor loss. Degeneration of 
photoreceptors follows a clear gradient from the central to the peripheral regions of the 
retina, with a delay of 2-3 days observed between these regions (Gargini et al., 2007; Roche 
et al., 2016). (Barhoum et al., 2008; Roche et al., 2016). Degeneration also occurs more 
rapidly in the central retina in comparison to the periphery (Barhoum et al., 2008). Similar 
to human RP, rods are lost first with cones persisting into adulthood (Gargini et al., 2007; 
Barhoum et al., 2008; Roche et al., 2016).  
 
In the rd10 retina, cells other than photoreceptors are also affected at time-points 
coinciding with photoreceptor loss. A shortening of horizontal cell processes, reduced 
bipolar cell connectivity with both the outer nuclear layer (ONL) and retinal ganglion cell 
(RGC) layer, as well as a reduction in the size of amacrine cell appendages were observed in 
the central retina at P20 (Barhoum et al., 2008; Puthussery et al., 2009; Roche et al., 2016). 
Therefore, although the primary insult is present in rods, other retinal cell types are also 
affected by the mutation during the course of photoreceptor degeneration. 
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1.2. Steroid-induced neuroprotection 
 
Although recent advances in molecular tools have facilitated the successful implementation 
of gene therapy for some forms of retinal degenerations (Cashman et al., 2015; Guo et al., 
2015; Wu et al., 2015; Zhang et al., 2015); retinal diseases can be highly heterogeneous. 
For example, mutations in more than 50 genes are known to cause non-syndromic retinitis 
pigmentosa and nearly 3100 mutations have been reported in these genes (Daiger et al., 
2013). Therefore, a neuroprotective, mutation-independent treatment strategy is highly 
desirable in the fight against degenerative blindness. As such, the concept of 
‘neuroprotection’ is one therapy currently under investigation for the treatment of retinal 
disease (Doonan & Cotter, 2012; Trifunović et al., 2012). Quite simply, neuroprotective 
strategies in the retina aim to conserve the photoreceptor layer, leading to preservation of 
photoreceptor cell function. These strategies involve the administration of differing 
molecules ranging from growth factors (O’Driscoll et al., 2008), to antioxidants (Payne et 
al., 2014), to steroids (Ishikawa et al., 2014), the focus of this study. 
 
Steroids are a family of organic compounds containing a four cycloalkane ring core (Figure 
1.2.1). There are hundreds of different types of steroids present in nature and all have 
varied function. In the human body however, the majority of steroids are derived from the 
membrane lipid ‘cholesterol’, which can form a number of different steroids derivatives 
through a series of enzymatic modifications. In this review of the current literature, we will 
focus on two such steroid groups associated with retinal cell neuroprotection: 
glucocorticoids and sex steroids.  
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Glucocorticoids are a class of corticosteroid. Binding to the glucocorticoid receptor 
(Edelman, 2010), the name glucocorticoid comes from the role that they play in glucose 
metabolism regulation, their synthesis in the adrenal cortex and the steroid structure: 
Glucose + cortex + steroid. Three glucocorticoids used therapeutically in the retina are 
dexamethasone (DEX), trimacinolone acetonide (TA) and fluocinolone acetonide (FA) 
(Figure 1.2.1). Similar to other corticosteroids, these glucocorticoids are renowned for their 
anti-inflammatory properties and it was this characteristic that first led to their use in the 
retina several decades ago (Edelman, 2010). More recently, increased clinical use has 
shown these glucocorticoids to have neuroprotective properties in retinal cells, though far 
less is known of the molecular mechanism leading to this protection. 
Alternately, the sex steroids can be divided into three functional groups: oestrogens, 
progestogens and androgens. The late 1970’s saw the emergence of this area of research 
Figure 1.2.1. Chemical structures of steroids with recognised 
neuroprotective potential in the retina. 
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(Toran-Allerand, 1976, 1980; Toran-Allerand et al., 1983) and oestrogen and progestins 
have since been shown to promote neuronal survival and growth (Garay et al., 2008; 
Mannella et al., 2009). Whilst androgens were investigated in relation to eye diseases in 
the 1950’s (Gurling, 1955), these studies were not continued and so will not be discussed in 
this review. Instead, a comparison of the two sex steroid groups: oestrogen and 
progestogen, will be focussed upon.  
 
The glucocorticoids and sex steroids share a very similar structure (Figure 1.2.1). As such, it 
is likely that there are observations and subsequent advances to be made from studying 
the two steroid groups in parallel. Through emphasizing similarities and differences 
between glucocorticoids: dexamethasone (DEX), trimacinolone acetonide (TA) and 
fluocinolone acetonide (FA) and sex steroids: oestrogen, progesterone; insights gained 
from one group will be highlighted with the aim of aiding future studies of the other. 
Through this, we hope to facilitate the development of the sex steroids as neuroprotective 
therapies for retinal diseases. 
 
1.3. Glucocorticoids as retinal neuroprotectants  
  
1.3.1. Glucocorticoids: Evidence for protection 
In certain retinal degeneration disease models, glucocorticoids have been shown to be 
neuroprotective to photoreceptors. For example, in the rodent light damage model, 
dexamethasone (DEX) prevents photoreceptor cell death (Fu et al., 1992; Wenzel et al., 
2001, 2003; Hao et al., 2002; She et al., 2008). Trimacinolone acetonide (TA) is protective to 
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photoreceptors in a rabbit model of subretinal haemorrhage (Bhisitkul et al., 2008) and 
preserves the inner segment/outer segment photoreceptor interface in patients with 
diabetic macular edema (DME) (Shin et al., 2012). Glybina et al. also demonstrated specific 
protection of photoreceptors using retinal implants of fluocinolone acetonide (FA) in two 
inherited retinal degeneration models, the Royal College of Surgeons (RCS) rat model 
(2009) and the s-334ter-4 rat model (2010). These studies (Table 1.3.1) were completed 
over the same time period as several different human clinical trials of varying degrees of 
success and all looked at the potential for glucocorticoids to act as anti-inflammatories in 
the eye. These studies have been nicely reviewed by Cebeci & Kir (2015).  
 
Clinical trials used various formulations of these steroids, demonstrating protection of 
vision in humans. DEX is five and twenty times more potent an anti-inflammatory agent 
than TA and FA respectively (Jermak et al., 2007; Edelman, 2010), however its short half-life 
and high solubility means that it is not retained in the eye (Kwak & D’Amico, 1992). To 
combat this, Ozurdex (Allergan, Irvine, CA, USA), a slow-release DEX intravitreal implant, 
was developed. At 0.46mm in diameter and 6mm in length, this rod-like implant is used to 
treat patients with uveitis and to protect vision in patients with diabetic macular edema 
(DME) and macular edema (ME) related to branch or central retinal vein occlusion (Haller 
et al., 2010, 2011). Approved by the FDA in 2009 and the European Commission in 2010, 
long term evaluation of patients receiving multiple implants are now available and seem 
promising (Moisseiev et al., 2013). 
 
TA, due its more lipophilic nature, is better retained post-injection within the eye (Beer et 
al., 2003). Abraldes et al. (2009) reviewed all the clinical trials of TA in the treatment of 
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DME and found that TA can increase visual acuity in certain cases. For example, ‘I-vation’ 
(SurModics, Eden Prairie, MN, USA), a helical sustained-release implant containing 0.925µg, 
demonstrated the effectiveness of TA in treating DME. Major complications involving 
increased intraocular pressure (IOP) and cataract development (Dugel et al., 2009) 
however, meant that phase 2b trials were terminated (“Clinicaltrials.gov. A Study of 
MK0140 in Diabetic Patients with Macular Edema.,” 2016). Finally, similar to Ozurdex and I-
vation, there has been a slow-release implant of FA developed, ‘Retisert’ (Bausch & Lomb, 
Rochester, NY, USA). This implant had some success in clinical trials for uveitis, however as 
with TA’s ‘I-vation’, patients showed increased cataract formation and raised IOP which has 
consequently restricted its use (Schwartz & Flynn, 2011). 
 
In general, advanced research in this area is directed towards the development of slow-
release systems (Glybina et al., 2009, 2010; Schwartz & Flynn, 2011). These enable steroids 
to be retained better within the eye, thereby reducing the number of intravitreal injections 
required and consequently decreases associated complications. In addition to this, 
intravitreal implants systems negate the need for a vehicle; i.e. the solution in which the 
steroid suspended before injection. These vehicles can often cause complications: a case 
well illustrated by the first studies of TA. When TA was first injected intravitreously, it was 
suspended in benzyl-alcohol using a product originally designed for intramuscular injection 
to treat dermatological conditions. These studies not only found the vehicle to be toxic to 
the retina (Macky et al., 2007), but also found TA itself to be toxic at high doses (4 - 20mg 
of TA in 0.1mL injection). TA is only safe and neuroprotective in humans at the lower dose 
of 0.5 - 1mg (Yu et al., 2006). Difficulties associated with administration of individual 
systems, serve to highlight the need for specific testing of various drug delivery routes – 
rather than simply trialling the compound itself.  
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 In all of the aforementioned trials, visual acuity was improved through corticosteroid 
administration. Accordingly, there must have been some degree of photoreceptor 
protection. The trouble with this deduction however, is that many of these trials were 
completed in patients suffering from Macular Edema (ME) (Beer et al., 2003; Haller et al., 
2010). ME occurs when fluid and protein deposits collect on or under the macula of the 
eye, resulting in poor communication between the photoreceptors and other retinal 
neurons. This means that photoreceptors lose out on vital signalling and thus loss of vision 
occurs thereafter (National Eye Institute, 2015). Since ME is not associated with 
photoreceptor death in its early stages, it is difficult to determine if glucocorticoids affect 
photoreceptor cells directly. Glucocorticoids promote a healthy retina through excess fluid 
reduction. Therefore, the photoreceptors are not as stressed and so are less likely to die, as 
normally occurs in the later stages of this disease. Both human studies into ME and animal 
trials into other retinal diseases, agree that glucocorticoids can protect vision. However, 
the mechanism of action by which this occurs, be it directly or indirectly on the 
photoreceptors, has not yet been elucidated.  
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Steroid Model Used Dose + Route of Admin. Degree of Protection; 
Variable 
Ref. 
DEX Mouse light damage 52mg/kg in single IP injection Complete; ONL 
Complete; ERG 
(Wenzel et 
al., 2001) 
Mouse light damage 52mg/kg in single IP injection Qualitative; retinal 
neuronal layer integrity  
(Hao et al., 
2002) 
Dog light damage 3 x SC injections 
(2 @ 0.18mg/kg, 
1 @ 1.8mg/kg) 
None found in retinal 
sections 
(Gu et al., 
2009) 
TA Rabbit subretinal 
haemorrhage 
2mg in single intravitreal injection Quantitative; ONL (Bhisitkul et 
al., 2008) 
Human-Diabetic 
macular edema 
4mg in single intravitreal injection Quantitative; IS/OS as 
measured by OCT 
(Shin et al., 
2012) 
FA Royal College of 
Surgeons Rat 
0.2µg/day equivalent release from 
intravitreal implant 
Quantitative; ONL 
Quantitative; ERG 
(Glybina et 
al., 2009) 
S334ter-4 rat 0.2µg/day equivalent release from 
intravitreal implant 
Quantitative; ONL  
Quantitative; ERG 
(Glybina et 
al., 2010) 
Oestrogen 
and 
derivatives 
Rat light damage 2.5mg Qualitative; retina (O’Steen, 
1977) 
S334ter-3 rats 2µL of 10mM in single intravitreal 
injection 
Quantitative; ONL (Dykens et 
al., 2004) 
Rat light damage 500µg/kg in single IP injection Qualitative; ONL 
Qualitative; ERG 
(Yu et al., 
2004) 
Progestins RD10 mouse 100mg/kg IP injection on alternate 
days 
Quantitative; ONL  
Qualitative; ERG 
(Doonan et 
al., 2011) 
Mouse light damage 100mg/kg IP injection every 3 days Qualitative; ONL  (Doonan et 
al., 2011) 
Rat retinal ischemia 
reperfusion 
4mg/kg in 2 x IP injections Qualitative; INL  (Lu et al., 
2008) 
 
Table 1.3.1. Summary of studies which used the steroids under review as therapeutics in models of retinal 
degeneration. (ERG: electroretinogram; INL: inner nuclear layer; IP: intraperitoneal; IS/OS: inner segment/outer 
segment of photoreceptors; OCT: optical coherence tomography; ONL: outer nuclear layer; SC: subcutaneous; 
Qualitative: study reports images only; Quantitative: study undertook statistics which proved to be significant) 
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1.3.2. Glucocorticoids: Mechanism of action 
Retinal cells have a bi-modal response to glucocorticoids, due to signalling through differing 
glucocorticoid receptor (GR) isoforms (Chrousos & Kino, 2005; Oakley & Cidlowski, 2011). 
Alternative splicing of the GR gene transcript generates two C-terminal glucocorticoid 
receptor isoforms: GRα and the classic GR. The GR gene also has several initiation sites, 
which can give rise to isoforms of differing lengths: GRβ, GRγ, GR-A and GR-P (Oakley & 
Cidlowski, 2011). The classical GR and GRα initiate a response through genomic signalling 
(Edelman, 2010). This mechanism allows for ligand-receptor complex binding and 
sequential internalisation to the nucleus. Here, they will bind to glucocorticoid response 
elements, directly regulating the transcription of various genes. For example, GRα may 
inhibit key transcription factors, nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) 
(Zanchi et al., 2010). As with many steroid hormones however, glucocorticoids may also 
activate a non-genomic signalling system. This means that a membrane-bound form of GR 
may directly activate an intracellular signalling cascade, thus transmitting signalling 
information at a much faster speed than the slower classical GR signalling (Groeneweg et 
al., 2012). Precisely how these two signalling mechanisms result in increased cell survival is 
still ill-defined, though what is known will be discussed below.  
 
With regard to the direct action of glucocorticoids on photoreceptors, Wenzel et al. 
attempted to explicate their mechanism through use of the light damaged mouse model of 
retinal degeneration. This is a method whereby adult, albino Balb/c mice are exposed to a 
bright a damaging light over a length of time and their photoreceptors degenerate as a 
result (Doonan et al., 2011). Wenzel et al. found that intraperitoneal injection of DEX 
activated the GR, which in turn reduced the levels of the transcription factor, activator 
16 
 
protein-1 (AP-1) within the retina (Wenzel et al., 2001) (Figure 1.3.1A). Interestingly 
however, AP-1 has conversely been shown under certain conditions to induce 
photoreceptor death (Wenzel et al., 2005). Hao et al. further investigated this mechanism 
in mice. They found that DEX only protected against bright light death, where AP-1 was 
strongly implicated. In dim light induction however, where AP-1 did not play a role, DEX 
had no effect (2002).  
 
In contrast to these mouse investigations, a study completed in dogs using bright light 
showed no protection of photoreceptors with dexamethasone, though the concentration 
of DEX used was far less than in the aforementioned mouse trials (Gu et al., 2009). This dog 
trial found again that despite a DEX-induced decrease in AP-1 activation, and an inhibited 
phosphorylation of c-Fos and extracellular signal-regulated kinases 1/2 (ERK1/2) (Figure 
1.3.1B); neither intraocular or systemic injection of DEX could protect against light-induced 
photoreceptor degeneration. Gu et al. hypothesised that the discrepancy in DEX efficacy 
between the mouse and dog studies had to do with the differing role that AP-1 may play in 
photoreceptor cell death. Certainly since these studies were completed, AP-1 has been 
Figure 1.3.1. Known signalling pathways of 
dexamethasone in the retina. (A) 
Dexamethasone (D) activates the glucocorticoid 
receptor (GR) and inhibits activator protein-1 
(AP-1), which prevents cell death (Wenzel et al., 
2001). This was determined in a mouse light 
damage model. (B) Light damage causes cell 
death in a dog model and this is concurrent with 
an increase in the phosphorylation (p) of ERK1/2 
and c-fos and an increase in AP-1 activity. Whilst 
dexamethasone inhibits these three events, it 
has no effect on cell death (Gu et al., 2009). 
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recognised to promote cell death or survival, depending on its dimer composition (Meng & 
Xia, 2011). Therefore, it is too simplistic to say that AP-1 activation will always lead to cell 
death. Thus DEX-induced reduction of AP-1 may not always be neuroprotective to 
photoreceptor cells (Figure 1.3.1).  
 
In a recent study, it was shown that DEX administration to light-damaged Balb/c mice 
significantly increased levels of protective retinal BCL-XL in photoreceptor inner segments 
(Cubilla et al., 2013) – as is the case in other tissues whereby DEX has anti-apoptotic actions 
(Kfir-Erenfeld et al., 2010). In comparison, high levels of cleaved caspase-3 and Bax, both 
drivers of apoptosis (Peng et al., 2014); and phosphorylated histone H2AX, a marker of DNA 
breakage and repair (van Attikum & Gasser, 2009) were found in mifepristone GR 
antagonist-treated controls (Cubilla et al., 2013). This study is one of the first to elucidate 
the signalling pathways associated with DEX-induced photoreceptor cell survival in vivo.  
 
Whilst it is evident that some progress is being made in understanding the actions of DEX in 
promoting neuronal survival, very little is known about the intracellular signalling 
mechanisms of TA and FA in neurons. Using microarrays (Smit-McBride et al., 2011) and 
through analysis of selected genes (Rehak et al., 2011), both have been shown to regulate 
genes in a characteristic anti-inflammatory manner. However, these studies did not 
manage to determine the pathway leading to transcription changes. FA can bind to the GR 
(Ayalasomayajula et al., 2009), but it is not known if this promotes retinal cell survival. 
What is known however, is that when TA has cytotoxic effects (i.e. at high doses), they are 
independent of classical GR signalling (Chung et al., 2007), suggesting a toxic non-GR 
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mechanism. Unfortunately, due to the lack of published studies in this area, it is impossible 
to conclude how TA and FA might signal to protect photoreceptor cells directly.  
 
As mentioned previously, it is believed that many of the effects that glucocorticoids have 
on photoreceptors, may occur indirectly. This is through their actions on other retinal cell 
types, with downstream consequences on the photoreceptors. Glucocorticoids have been 
widely used to inhibit inflammation, a finding recently validated in the retina (Edelman, 
2010). For example, Glybina et al. found that a retinal implant releasing the equivalent of 
0.2µg/day FA was effective in protecting photoreceptors in the RCS and the transgenic 
S334ter-4 rat models (2009, 2010). They demonstrated that this protection results from a 
decrease in activation and recruitment of microglia to damaged photoreceptors – a process 
now commonly accepted to potentiate photoreceptor cell degeneration (Zhao et al., 2015; 
Roche et al., 2016). This diminished microglial response leads to reduced production of pro-
inflammatory cytokines and ultimately prolongs photoreceptor cell survival (Yang et al., 
2007; Zhang et al., 2012; Martínez-Fernández de la Cámara et al., 2014; Peng et al., 2014). 
TA has also been found to reduce the number of microglial cells within the retina in 
response to a variety of different injurious stimuli (Uckermann et al., 2005; Singhal et al., 
2010; Shen et al., 2014). Taken together, these results suggest that the glucocorticoids are 
highly successful mediators of damaging microglial cell activation in the retina.  
 
Microglia are not the only glial cell type in the retina. The retina also has glial cells known as 
‘Müller glial cells’ – which again, as with all glial cells, serve as support cells for the neurons 
of the eye (Roche et al., 2016). Spanning the width of the retina, these cells respond in a 
corticosteroid-specific manner. For example, TA has no influence on Müller cell gliosis 
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(Uckermann et al., 2005) – a process occurring after neuronal damage. Reactive gliosis is 
characterised through Müller glial cell proliferation and changes in specific gene 
expression. This consequently may lead to glial scarring and inhibition of axonal 
regeneration (Dyer & Cepko, 2000). Alternately, DEX has been shown not only to supress 
reactive gliosis by Müller glial cells (Gu et al., 2009), but through the GR, may also alter 
their mitochondrial metabolism (Psarra et al., 2003). Two studies have also demonstrated 
that DEX and TA can modify the number of ion and water channels expressed by Müller 
glial cells, changing their osmotic swelling capacity, thereby aiding the resolution of edema 
(Smit-McBride et al., 2011; Zhao et al., 2011). The effects of glucocorticoids on retinal cell 
types other than photoreceptors reflects their use in clinical trials. Through modification of 
glial cell signalling, the glucocorticoids contribute to an anti-inflammatory-response in the 
retina, a process which has been proven conclusively to delay photoreceptor cell death 
(Yang et al., 2007; Zhang et al., 2012; Martínez-Fernández de la Cámara et al., 2014; Peng 
et al., 2014).  
 
In addition to retinal cells, intravitreally administered steroids may impact other ocular cell 
types. In a comprehensive microarray study of the human trabecular meshwork, Fan et al. 
found that 1mg/mL of TA up-regulated 36 genes and down-regulated 21 others (Fan et al., 
2008). This was dose dependent, as 0.1mg/mL resulted in fewer gene alterations. Whilst 
gene alterations within trabecular cells may not impact on photoreceptors directly, they 
contribute to the overall health of the eye, as indicated by the association between their 
malfunction and glaucoma (Tektas & Lütjen-Drecoll, 2009). This paper by Fan et al. is also 
important for another reason. It directly compared genes altered by TA and 
dexamethasone in the same cell line. Even though the structural differences between these 
two glucocorticoid molecules are relatively small (Figure 1.2.1), they differentially regulate 
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several genes. TA changed the expression of 57 genes in total, 7 of which it shared with 
DEX; whilst DEX affected a separate 19 genes (Fan et al., 2008).  
 
All taken, the evidence presented in the preceding paragraphs serves to illustrate what 
little is known about the pro-survival signalling mechanisms employed by glucocorticoids 
within the retina. Nevertheless, glucocorticoid-induced increases in visual acuity is evident 
in near on all of the discussed studies and thus highlights the potential of these compounds 
to provide a successful therapy for certain inflammatory retinal diseases. 
 
1.4. Sex steroids as retinal neuroprotectants 
 
1.4.1. Sex steroids: Evidence for protection 
Steroid hormones and their metabolites in the central nervous system have been shown to 
have neuroprotective properties (Compagnone, 2008; Borowicz et al., 2011). Commonly 
referred to as ‘neurosteroids’, the sex steroids oestrogen and progesterone are now well 
documented to provide protection in several different systems. Progesterone, for instance, 
has been trialled for a treatment of spinal cord injury, brain ischemia, stroke, Alzheimer’s 
disease and perhaps most prominently, traumatic brain injury (Gonzalez Deniselle et al. 
2002a, 2002b; Gonzalez et al. 2005; Compagnone 2008; Espinosa-García et al. 2014; Yousuf 
et al. 2014; Qin et al. 2015). Indeed studies highlighting its viability in a number of different 
models of TBI have ensured progesterone’s entry into human clinical trials for TBI (Stein 
2011; Stein 2013; Stein et al. 2015). Alternately, oestrogen has also been trialled for 
protection against spinal cord injuries, cognitive decline following cerebral ischemia and 
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several neurodegenerative disorders (Chakrabarti et al., 2014; Liu, Mu, et al., 2015; 
Stanojlović et al., 2015). These studies seem promising, making it likely that oestrogen will 
soon be assessed clinically.  
 
Clearly, both progesterone and oestrogen are emerging as potential therapeutics in the 
treatment of neurodegenerative disorders. As such, research in to the protective properties 
of these compounds has moved to the retina. Oestrogen and its derivatives in particular 
have shown promising results in a number of systems and models of retinal disease. These 
include the s334ter-3 transgenic model of retinitis pigmentosa (Dykens et al., 2004), light 
damaged rats (Yu et al., 2004), 661W cone photoreceptor cells (Nixon & Simpkins, 2012), 
human Müller glial cells (Li et al., 2006) and rat retinal neuronal primary cultures (Yu et al., 
2004; Li et al., 2013) (Table 1.3.1). Interestingly, despite the success of progesterone 
treatment in disorders of the CNS, conflicting data exists as to the protective potential of 
progesterone in the eye. As such retinal studies have been slower to start. ‘Norgestrel’, a 
synthetic progesterone analogue has been shown to exert neuroprotective effects both in 
vitro and ex vivo (Byrne et al., 2016); and in two distinct models of retinitis pigmentosa: the 
rd10 mouse model, in a preventative situation; and the light damage model, in a rescue 
situation (Doonan et al., 2011; Doonan & Cotter, 2012). Progesterone was also shown to 
prevent against photoreceptor cell death in the rd1 mouse (Sánchez-Vallejo et al., 2015) 
and to inhibit osmotic swelling following ocular ischemia (Neumann et al., 2010; Allen et 
al., 2015).  
 
Whilst there have been no human clinical trials wherein oestrogen or progesterone has 
been specifically administered to preserve vision, some trials have been designed to take 
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into consideration hormone replacement therapy. This is where women are supplemented 
with exogenous hormones. In 2008 for example, a large scale study was carried out in 
74,996 postmenopausal women. This study looked at the incidence of age-related macular 
degeneration (AMD) in those taking postmenopausal hormone (PMH) consisting of a 
combined treatment of progesterone and oestrogen; and those who had previously taken 
oral contraceptives. Most interestingly, PMH users had a notable 48% lower risk 
of neovascular AMD compared with those were not using PMH. Moreover, the risk of 
developing neovascular AMD was lowest amongst PMH users who had used oral 
contraceptives in the past (Feskanich et al., 2008).  
 
In 2001, a study of 58 women looked at the effect of the PMH ‘Tibolone’, a steroid drug 
with progesterone, oestrogen and weak androgenic actions. This research showed that the 
functional status of neurovisual transmissions was significantly improved after a three-
month daily dose of 2.5mg Tibolone (Laçin et al., 2001). Interestingly however, no 
difference in effects on visual acuity, IOP, tear functions and visual evoked potential were 
seen in a more prolonged experiment totalling six months, just a few years on (Verit et al., 
2006). Most recently, the effects of PHM were investigated with respect to blood flow and 
protection of the optic nerve. Researchers found that PMH-users (of both oestrogen-only 
and oestrogen plus progesterone PMH users) had a significantly increased retinal perfusion 
and greater preservation of the optic nerve fibre layer compared to control (Deschênes et 
al., 2010). These studies suggest a neuroprotective role of PMH in the retina. Taken 
together with a number of neuronal based studies showing that PMH users have a 
decreased risk of developing neurodegenerative disease, e.g. Alzheimer’s (Pintzka & 
Håberg, 2015), Parkinson’s (Bourque et al., 2009) and stroke (Hale & Shufelt, 2015), these 
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data lead us to conclude that the area of PMH supplementation for retinal protection post-
menopause, deserves further attention.  
 
1.4.1.1. Oestrogen specific neuroprotection 
With regard to oestrogen-specific retinal neuroprotection, one of the earliest studies was 
carried out using the phytoestrogen ‘Genistein’. This naturally occurring, oestrogen-like 
compound, was found to prevent neuronal degeneration in the inner retina of rats; as a 
result of ischemic injury (Hayashi et al., 1997). The most potent endogenous oestrogen, 
17β-estradiol, was soon after found to prevent excitotoxin, pregnenolone sulphate (PS)-
induced retinal cell death in male Wistar rats, through prevention of a PS-induced 
reduction in pro-forms of caspase-3 and caspase-2 (Cascio et al., 2002). 17β-estradiol was 
subsequently and sequentially found to protect against hydrogen peroxide-induced cell 
death in primary cell cultured retinal neurons (Yu et al., 2004) and in ARPE-19 human 
retinal pigment epithelial cells (Yu et al., 2005; Giddabasappa et al., 2010); against retinal 
ganglion cell loss in the DBA/2J mouse model of inherited glaucoma (Zhou et al., 2007); and 
against glutamate-induced neurotoxicity (5mM) in 661W cells, a mouse cone 
photoreceptor-like cell line.  
 
In 2004, Yu et al. tested both 17α-estradiol and 17β-estradiol in vivo, using light-damaged, 
ovariectomized (an animal model for menopause), female Sprague-Dawley albino rats. 
Systemic administration of 17β-estradiol was found to significantly protect the structure 
and function of light-damaged rat retinas, inhibiting photoreceptor apoptosis. The positive 
results obtained both in vitro and in vivo for cellular protection following oestrogen 
administration, paved the way for human clinical studies of postmenopausal women taking 
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oestrogen-only PMH. Fraser-Bell et al. found that exogenous oestrogen was protective 
against soft drusen formation, associated with dry AMD (2006). This finding was similar to a 
study carried out around the same time by Haan et al., whereby oestrogen was 
administered concomitantly with progestin to postmenopausal women. Combined, these 
steroids effectively conferred against soft drusen formation and neovascular AMD (2006). 
In 2012, clinical trials using oestrogen derivative ‘phytoestrogen’ for the treatment of post-
menopausal dry eye verified the safety and efficacy of direct oestrogen-to-eye 
administration in humans (Scuderi et al., 2012). All taken, these studies suggest that 
exogenous oestrogen should be further explored as a potential treatment for retinal cell 
survival. 
 
1.4.1.2. Progesterone specific neuroprotection 
Despite clear protective effects in the brain, conflicting studies exist as to the efficacy of 
progesterone in retinal cell neuroprotection. Early research into the actions of 
progesterone in the eye began in the 1970’s (Chader & Reif-Lehrer, 1972; Macaione et al., 
1973). In 1977, one of the first major experiments using the light-damage model of retinal 
degeneration was carried out in ovariectomized albino rats. Rats were treated with 2.5mg 
progesterone before exposure to damaging light; however, no difference was seen in 
photoreceptor cell death in progesterone-treated rats compared to control (O’Steen, 
1977). The negative results of this study ensured that interest in the neuroprotective 
efficacy of progesterone in the retina waned in following years, until its sudden 
reappearance in retinal literature in the mid 2000’s (Káldi & Berta, 2004; Yu et al., 2004; 
Swiatek-De Lange et al., 2007). Much of this research demonstrated that progesterone 
could not protect against cell death in photoreceptors (Káldi & Berta, 2004; Yu et al., 2004) 
and indeed may actually promote vascular endothelial growth factor (VEGF) induced 
25 
 
neovascularization within retina (Swiatek-De Lange et al., 2007). And yet, despite these 
results, promising studies have recently been released detailing the potential of 
progesterone to suppress retinal cell death.  
 
Research from our group has extrapolated the capabilities of the oral-contraceptive 
‘levonorgestrel’ (commonly referred to as ‘Norgestrel’) to protect damaged photoreceptors 
(Doonan et al., 2011; Doonan & Cotter, 2012; Byrne et al., 2016). These studies verify 
previous literature looking at progesterone-induced protection in models of diabetic and 
ischemic retinopathies. In 2008, two 4mg/kg intraperitoneal injections of progesterone 
were shown to preserve the inner nuclear and nerve fibre layers (Table 1.3.1) in a rat 
model of retinal ischemia-reperfusion (Lu et al., 2008). Following on from this, 
progesterone was shown to reduce swelling of retinal glial cells in models of diabetic and 
ischemic retinopathies – implying a consequential overall reduction of cytotoxic retinal 
edema (Neumann et al., 2010) and most recently, proved to be protective to damaged 
photoreceptors in the rd1 mouse model (Sánchez-Vallejo et al., 2015).  
 
These retinal studies, along with research undertaken by the broader neuroscience 
research field (Gonzalez Deniselle et al., 2002a, 2002b; Gonzalez et al., 2005; Compagnone, 
2008; Stein, 2011, 2013; Espinosa-García et al., 2014; Yousuf et al., 2014; Qin et al., 2015; 
Stein et al., 2015), provide ample evidence for progesterone’s protective role in 
neurodegeneration. Indeed, in a recent paper by Allen et al., authors detail how 
progesterone is protective following middle cerebral artery occlusion (MCAO) - causing 
transient ischemia in the retina and brain. Allen et al. also showed however, that 
progesterone cannot protect against rodent anterior ischemic optic neuropathy (rAION), 
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which induces permanent monocular optic nerve stroke (2015). Simply, they postulate that 
the disparity in these data may arise from mechanistic differences with injury type and the 
therapeutic action of progesterone. A hypothesis that may fit the conflicting results seen in 
other studies.  
 
1.4.2. Sex steroids: Mechanism of action 
Knowledge of the mechanisms underlying the protection provided by oestrogen, 
progesterone and their derivatives are arguably more advanced than that of 
glucocorticoids. However, the temporal sequencing of the precise intracellular signalling 
events remain to be resolved (Lebesgue et al., 2009). In the following sections, we will 
attempt to divulge the potential mechanisms through which these steroids exert their 
neuroprotective effects.  
 
1.4.2.1. Oestrogen specific mechanism of action 
In brief, there are four possible mechanisms through which oestrogen may have its effects, 
though they are not mutually exclusive:  
a. Genomic signalling via its cognate nuclear receptors, oestrogen receptors α and β 
(ERα/ERβ) 
b. Non-genomic signalling through membrane receptors, i.e. its cognate receptor, 
GPR30, and atypical oestrogen receptors 
c. Through its free radical scavenging properties 
d. Where the molecule itself integrates into and stabilizes membranes (Figure 1.4.1) 
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The evidence for each of these four mechanisms, highlighting the studies completed in the 
retina, will be given in the following paragraphs. For additional information about the 
protective effects of oestrogen in brain diseases, the reader is referred to recent and 
comprehensive reviews (Brann et al., 2007; Raz et al., 2008; Lebesgue et al., 2009). 
 
Generally, it is accepted that oestrogen acts through its two nuclear receptors ERα/ERβ to 
up-regulate growth factors (Brann et al., 2007). In three studies involving retinal pigment 
epithelial cells, ranging from the human ARPE-19 cell line to animal knock out mouse 
models; investigators found that ERβ was essential to conferring maximal protection from 
oestrogen (Elliot et al., 2008, 2010; Giddabasappa et al., 2010). However, although in these 
three cases ERβ was the critical receptor, the ultimate response to oestrogen varied from 
changing matrix metalloproeinase-2 activity (Elliot et al., 2008, 2010), to the upregulation 
of antioxidant genes (Giddabasappa et al., 2010). 
Figure 1.4.1. Recognised neuroprotective 
signaling pathways of oestrogen (E). (1) 
Intercalation of oestrogen into cellular 
membranes, via its phenolic ring, stabilizes 
these membranes (Dicko et al., 1999; Liang et 
al., 2001; Dykens et al., 2004). (2) Interaction 
with its cognate cytoplasmic receptors 
(oestrogen receptors: ER), which act as ligand 
dependent transcription factors, upregulating 
pro-survival factors, e.g. pigment epithelium 
derived factor (PEDF), and down regulating 
pro-death factors (Li et al., 2006, 2013). (3) 
Interaction with membrane receptors 
resulting in changes in phosphorylation (p) of 
pro-survival signalling pathways, such as 
PI3K/AKT (Yu et al., 2004; Lebesgue et al., 
2009; Nixon & Simpkins, 2012). (4) 
Scavenging of reactive oxygen species (ROS), 
thereby limiting oxidative stress (Moosmann 
& Behl, 1999; Brann et al., 2007). (1-3 have 
been confirmed in the retina and 4 is highly 
probable to occur there also.) 
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In retinal ganglion cells, the situation is less clear. One study showed that 17β-estradiol 
(βE2) ligand binding to the ER was critical preventing glaucoma development in the DBA/2J 
mouse, a mouse model of an inherited (pigmentary) glaucoma. In this research, mice pre-
treated with tamoxifen, an oestrogen receptor (ERα/β) antagonist, did not see any 
improvement in ganglion cell survival following βE2-administration (Zhou et al., 2007). 
Similarly, two separate studies showed the capability of oestrogen receptor (ERα/β) 
inhibitor ICI 182-780, to reduce the protection conferred by oestrogen in two rat models of 
glaucoma (Hayashi et al., 2007; Russo et al., 2008).  
 
Unfortunately, Kumar et al. found that the same inhibitor had no effect on the protection 
elicited by oestrogen in a retinal ganglion cell line (2005) - though the results of this study 
and all other studies employing the RGC-5 retinal ganglion cell, must now be regarded 
carefully. The RGC-5 cell line has since been found to be nearly identical to the 661W cone 
photoreceptor cell line and thus is likely not to be a representative of retinal ganglion cells 
in vivo (Krishnamoorthy et al., 2013; Molecular Vision, 2013; Al-Ubaidi, 2014). On a similar 
note however, a large scale human clinical study (3842 participants) showed that in men, 
polymorphisms in ERβ were associated with a higher risk of open angle glaucoma (de 
Voogd et al., 2008). All taken, whilst these studies implicate the oestrogen family of 
receptors in ganglion cell survival, they do not differentiate between ERα versus ERβ 
mediated signalling. Nor do they conclusively show the direct role that these receptors play 
in anti-apoptotic signalling. Indeed, in the following paragraphs, we will dissect the 
possibility that the actions of oestrogen in pro-survival signalling may instead be primarily 
independent of ERα/β.  
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Oestrogen is a female hormone. Therefore, to improve the suitability of using a feminizing1 
hormone as a therapy in neuronal disease for both sexes, efforts have ensued to generate 
non-feminizing derivative. These derivatives have been structurally altered to prevent their 
binding to ERα/β, for it is this interaction that will propagate the “feminizing” effects. 
Consequently, any such altered oestrogen derivative must now confer its protection in an 
ER-independent manner.  
 
There is evidence for membrane oestrogen receptors performing a neuroprotective role 
within photoreceptors. Nixon and Simpkins used the 661W photoreceptor cell line to show 
that an agonist of GPR30 protected against a glutamate insult (2012). However, they also 
demonstrated that oestrogen and two of its analogues did not activate GPR30 or ERα/β. 
Besides GPR30, oestrogen is known to bind to other types of membrane receptors 
(Lebesgue et al., 2009). Yu et al. demonstrated that the insulin receptor β (IRβ) was partly 
responsible for the pro-survival effects of oestrogen in primary cultures of retinal cells and 
in the rat light damage model (2004). Whilst they did not elucidate specifically how 
oestrogen activates IRβ, they hypothesised that Src may play a role. Downstream from this 
receptor, they demonstrated the phosphoinositide 3-kinase–AKT signalling pathway is 
important in protecting photoreceptors.  
 
The studies discussed above all stand to highlight that the receptor with which oestrogen 
interacts is important in determining how protection is achieved. Nonetheless, this 
                                                          
1 Feminising effects of oestrogen include breast growth, decreases sexual libido and sperm formation, 
redistribution of body fat, skin softening and decreased hair growth (“Oestrogen Hormone Information (2) | The 
Gender Centre Inc.,” 2016).  
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interaction does not form the focus of every study in this area. There are two studies for 
example, which did not determine the receptor used by oestrogen in the retina, but still 
demonstrated a positive, neuroprotective effect. In the first, it was found that exogenous 
oestrogen resulted in the differential regulation of 69 genes in human Müller cell cultures 
(Li et al., 2006). These included some genes with known links to survival signalling, such as 
mitogen-activated protein 3 and pigment epithelium derived factor. A separate study 
demonstrated different downstream effectors of this sex steroid (Li et al., 2013). Pre-
treatment of primary retinal cultures with oestrogen resulted in a downregulation of 
apoptotic BAX and caspase 3/9, which ultimately resulted in a reduction of mitochondrial-
regulated cell death. Certainly, Zhou et al. found the signalling following 17β-estradiol (βE2) 
administration to the DBA/2J mouse model of glaucoma, to be diverse and far reaching. 
They showed that βE2 treatment reduced retinal ganglion cell apoptosis, preventing the 
subsequent loss of retinal neurofibers. They demonstrated the ability of βE2 to activate 
pro-survival AKT and cAMP-responsive-element-binding-protein, increase the expression of 
anti-oxidant molecule thioredoxin-1 and also to decrease the activation of mitogen-
activated protein kinases and NF-κB. Finally, they found that βE2 administration 
successfully inhibited pro-inflammatory interleukin-18 release (Zhou et al., 2007). All taken, 
these data suggest the critical role that oestrogen may play in the regulation of multiple 
biochemical events.  
 
The final ways in which oestrogen can confer protection to retinal neurons is interestingly 
not through interacting with any specific receptor, but simply due to its molecular 
structure. This occurs via two distinct mechanisms. Oestrogen can act as a free radical 
scavenger (Moosmann & Behl, 1999; Brann et al., 2007), thereby protecting against 
oxidative stress. Whilst this has yet to be proven in retinal tissues, the effect should not be 
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tissue specific. Alongside this, oestrogen is also known to protect cells through integrating 
into cellular membranes (Dicko et al., 1999; Liang et al., 2001). This mechanism was 
investigated in retinal cells by Dykens et al., who found that MITO-4565, an oestrogen 
derivative, has protective properties in a model of retinitis pigmentosa (2004). It 
accomplishes this through integrating into cellular membranes and preventing the spread 
of lipid peroxidation, thus preserving membrane integrity. Key to the protection of cells 
was the ability of MITO-4565 to stabilize mitochondrial membranes, thereby reducing the 
likelihood of cells undergoing mitochondrial collapse and associated apoptosis. In order for 
an oestrogen derivative to possess this membrane intercalation capability, it must possess 
a steroid A-ring phenol (Dicko et al., 1999; Liang et al., 2001) (Figure 1.2.1). This was also 
found to hold true in the retina, as when Dykens et al. substituted the phenol ring of MITO-
4565 with a methoxy group, its neuroprotective properties were abrogated (2004). 
 
1.4.2.2. Progesterone specific mechanism of action 
In amongst the multifaceted capabilities of progesterone, is its capacity to inhibit apoptosis 
and inflammation (Roglio et al. 2008; Choksuchat et al. 2009; Yu et al. 2010) – critical in the 
prevention of most retinal diseases. As with most neurosteroids, progesterone acts through 
specific binding to cellular receptors (Friberg et al., 2009). Classical progesterone signalling 
occurs throughout the central nervous system through the classic progesterone receptors A 
and B (PR A/B). These receptors are widely expressed and can modulate a variety of 
different physiological functions (Wen et al., 1994; Lange, 2008). Regulating gene 
transcription (Li et al., 1997; Hanna et al., 2010), PRs A/B are found at the plasma 
membrane but will localise to the nucleus upon ligand-binding (Lange, 2008). Just like 
oestrogen however, progesterone is a complex hormone and can also regulate its pro-
survival activities through a variety of non-classical receptors (Pang and Thomas 2011; 
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Moussatche and Lyons 2012; Petersen et al. 2013; Qin et al. 2015). The progesterone 
receptor membrane component (PGRMC) family, featuring PGRMC1 and PGRMC2 (Cahill, 
2007; Lösel et al., 2008) and the Progestin and AdipoQ (PAQR) family of receptors, 
featuring membrane progesterone receptors α, β and γ (mPRα, mPRβ and mPRγ) (Zhu, 
Bond, et al., 2003); have both been shown to facilitate survival signalling in neuronal cells 
(reviewed in Cahill, 2007; Brinton et al., 2008; Pang & Thomas, 2011).  
 
In addition to these ‘typical’ progesterone receptors, Neumann et al. demonstrated that in 
the retina, progesterone may act via atypical membrane receptors also. They identified 
these to be metabotropic glutamate receptors: the purinergic (P2Y1) receptor and the 
adenosine A1 receptor. They postulated that this is because exogenous progesterone 
results in the release of glutamate and ATP thereby activating these receptors and 
facilitating the reduction in glial cell swelling (2010). Therefore, these receptors are unlikely 
to form the apex of signalling in this model. All taken, it is probable that one receptor type 
does not act in isolation in response to progestins. Instead, it is likely that both the nuclear 
and membrane receptors are responsible for triggering different cell-survival signalling 
cascades, over different temporal scales. This would stand to reason, for this has already 
been shown to be the case with oestrogen.  
 
Progesterone lacks oestrogen’s phenol ring (Figure 1.2.1). Since it is this phenol ring that 
enables oestrogen to assimilate into cellular membranes (Dicko et al., 1999; Liang et al., 
2001), progesterone has a limited capacity to integrate (Liang et al., 2001). Progesterone, 
unlike oestrogen (Moosmann & Behl, 1999; Brann et al., 2007), also has no proven 
antioxidant capabilities. Progesterone and its derivatives have however, been show to 
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induce an upregulation in pro-survival growth factors such as basic fibroblast growth factor 
(bFGF) (Guthridge et al., 1992; Doonan et al., 2011) and leukaemia inhibitory factor (Byrne 
et al., 2016). In fact it is the relationship between progesterone and bFGF which plays a 
central role in the regulation of granulosa cell survival (Peluso & Pappalardo, 1999). We 
suggest therefore that it is progesterone’s capability to promote this pro-survival signalling 
that will maintain cellular viability (Peluso & Pappalardo, 1999) and prevent the cleavage of 
pro-apoptotic PARP and Caspase 3 (Gómez-Vicente et al., 2005; Miller et al., 2006). The 
direct link between these pro-survival signalling events and their associated progesterone 
receptor interaction however, has not yet been elucidated.  
 
1.5. Discussion 
 
Retinal eye diseases are common and far reaching. Prevalent worldwide, the number of 
genetic mutations associated with retinal degeneration make the development of 
individual therapeutic gene-therapies a daunting and likely impossible task. Promising 
studies have emphasised the potential that both glucocorticoids and sex steroids have in 
providing retinal neuroprotection (Table 1.3.1). Thus we have endeavoured here to review 
the literature relating to these two distinct steroidal groups. Glucocorticoids have been 
trialled clinically for human retinal diseases. Arguably less is known of their signalling 
mechanisms than of the sex steroids. However, we hope that through their study, we can 
learn lessons to take through with us to develop the sex steroids as a treatment for retinal 
degenerations.  
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Outside of their structural differences, the main distinctions between these two steroidal 
groups lie in their clinical use and in their known signalling mechanisms (Figures 1.3.1, 
1.4.1). For example, from examining glucocorticoid clinically, it is obvious that steroids 
provide enhanced therapeutic potential when administered via a slow release mechanism. 
Both DEX and FA benefited from incorporation into polymers, enabling enhanced retention 
within the vitreous (Haller et al., 2010, 2011; Schwartz & Flynn, 2011). Through the use of 
slow release systems, fewer ophthalmological interventions are required by the patient, 
thereby reducing the probabilities of complications such as cataract development or 
increased intraocular pressure. If the non-feminising derivatives of oestrogen or the 
synthetic progestins are to be developed into clinical therapies for retinal degenerations, 
their potential would be improved through utilizing an equivalent delivery mechanism.  
Despite the evidence that DEX can protect photoreceptors in the light damage model of 
retinal degeneration (Fu et al., 1992; Wenzel et al., 2001, 2003; Hao et al., 2002; She et al., 
2008), these results have been disputed (Gu et al., 2009) and as such, this protection is 
likely dependent on the process of AP-1-induced cell death (Figure 1.3.1). So, whilst 
glucocorticoids undoubtedly benefit the retina in inflammatory diseases, this may not 
translate into protection for retinal degenerations. On the other hand, estradiols protect 
photoreceptors in various retinal degeneration models (Dykens et al., 2004; Yu et al., 2004; 
Li et al., 2006, 2013; Nixon & Simpkins, 2012). They possess four separate, well proven 
signalling mechanisms by which they protect neurons (Figure 1.4.1), three of which are 
proven to play a role in the retina (Yu et al., 2004; Nixon & Simpkins, 2012; Li et al., 2013). 
Given the amount of pre-clinical data on non-feminizing estradiols, it is probable that the 
sex-steroids could be of significant therapeutic value in some retinal diseases, but further 
research and subsequent clinical trials are needed.  
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Finally, the benefits of devoting some time to delineating the underlying signalling 
mechanisms must be stressed. Although the previous paragraph emphasized that there 
already appears to be ample evidence to pursue a clinical trial of estradiols in retinal 
degenerations, there are still many grey areas in steroidal pro-survival signalling. As an 
example it is appropriate to return to the role of DEX and AP-1 in photoreceptor 
degeneration. Without the follow-up studies by Gu et al. (2009) and Hao et al. (2002), it 
appeared that DEX was an ideal candidate for a retinal degeneration therapy (Wenzel et al., 
2001). Through comparing the three studies (Figure 1.3.1), it became apparent that DEX 
would only be appropriate when photoreceptor death was reliant on the activation of AP-1. 
The studies into developing non-feminizing estradiols exhibit a similar theme. Through 
extensive and detailed research, it was evident that the phenolic ring of oestrogen provides 
neuroprotection (Dicko et al., 1999; Liang et al., 2001; Dykens et al., 2004), which was 
subsequently incorporated into effective derivatives. Whilst it is important to move 
forward with clinical trials using proven neuroprotective steroids, useful information may 
also be gained from continuing basic research into their signalling mechanisms.  
 
In summary, the potential of glucocorticoids, estradiols and progestins to be 
neuroprotectants in retinal degenerations is evident from the literature. There are however 
valuable lessons about drug delivery to be ascertained from the administration of 
glucocorticoids in the treatment of inflammatory ocular conditions. These should be 
studies carefully and applied to the sex steroids oestrogen and progesterone, before 
commencement of large-scale clinical trials. Obviously there is still work to be done in 
explicating the exact mechanism of cell survival behind each of these compounds. 
However, in general, there appears to be a great deal of evidence supporting their use in 
retinal disease prevention. The current investigations into these steroids highlight that the 
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health of the retina as a whole is essential to photoreceptor maintenance and each of the 
steroids accomplishes this through interacting with different retinal cell types. Therefore, 
we suggest that there is great potential in developing at least one of these steroids in the 
quest to find an effective, neuroprotective based therapy for degenerative retinal diseases. 
 
  
  
Chapter 2. Materials and Methods 
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2.1. Antibodies 
Gene Supplier Catalogue # Host Dilution 
WB 
Dilution               
IF 
PARP CST 9542 Rabbit 
Polyclonal 
1:1000  
Caspase-3 CST 9662 Rabbit 
Polyclonal 
1:1000  
Phospho-PI3 
Kinase p85 
(Tyr458)/p55 
(Tyr199) 
CST 4228 Rabbit 
Polyclonal 
1:1000  
Beclin-1 CST 3738 Rabbit 
Polyclonal 
1:1000  
LC3B CST 2775 Rabbit 
Polyclonal 
1:1000  
Phospho-Akt 
(Ser473) 
CST 4060 Rabbit 
Monoclonal 
1:2000  
Akt CST 9272 Rabbit 
Polyclonal 
1:1000  
Phospho-p44/42 
MAPK (Erk1/2) 
(Thr202/Tyr204) 
CST 9106 Mouse 
Monoclonal 
1:2000  
p44/42 MAPK 
(ERK1/2) 
CST 4696 Mouse 
Monoclonal 
1:1000  
Phospho-GSK-3β 
(Ser9) 
CST 9336 Rabbit 
Polyclonal 
1:1000  
GSK-3β CST 9315 Rabbit 
Monoclonal 
1:1000 1:200 
GAPDH CST 5174 Rabbit 
Monoclonal 
1:1000  
PI3-Kinase p110α BD BD611398 Mouse 
Monoclonal 
1:500  
Basic FGF BD BD610073 Mouse 
Monoclonal 
1:250  
FGF2/basic FGF, 
clone bFM-2 
Millipore 05-118 Mouse 
Monoclonal 
 1:200 
PR A/B Abcam ab2764 Mouse 
monoclonal 
1:200 1:100 
PGRMC1 Sigma HPA002877 Rabbit 
polyclonal 
1:500 1:100 
PGRMC2 Santa 
Cruz 
sc-104609 Goat polyclonal 1:200 1:200 
mPRα Santa 
Cruz 
sc-50111 Goat polyclonal 1:200 1:100 
mPRβ Abcam ab46534 Rabbit 
polyclonal 
1:500 1:100 
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mPRγ Abcam ab79517 Rabbit 
polyclonal 
1:500 1:100 
Tubulin Sigma T5168 Mouse 
monoclonal 
1:10,000  
Actin Sigma A5441 Mouse 
monoclonal 
1:10,000  
Histone H3 Abcam ab1220 Mouse 
monoclonal 
1:5000  
Calreticulin Abcam ab2907 Rabbit 
polyclonal 
1:1000  
Rhodopsin Millipore AB9279 Rabbit   1:200 
FITC PNA Vector 
Labs 
FL-1071 -  1:500 
Iba1 Wako 019-19741 Rabbit 
polyclonal 
 1:500 
Iba1 Novus Bio NB100-1028 Goat polyclonal  1:400 
CD68 AbD 
Serotec 
MCA1957GA Rat monoclonal  1:500 
iNos CST 13120 Rabbit 
monoclonal 
 1:200 
MRC1 Abcam AB64693 Rabbit 
polyclonal 
 1:1,000 
Cone Arrestin Millipore AB15282 Rabbit 
polyclonal  
 1:1,000 
GFAP Sigma G3893 Mouse 
monoclonal 
 1:300 
Glutamine 
Synthetase 
Millipore MAB302 Mouse 
monoclonal 
 1:100 
NFM Abcam AB7794 Mouse 
monoclonal 
 1:500 
Syntaxin 1 Millipore AB5820 Rabbit 
polyclonal 
 1:500 
Calbindin Swant CB-38a Rabbit 
monoclonal 
 1:500 
CHX10 Santa 
Cruz 
sc-21690 Goat polyclonal  1:100 
Fractalkine Abcam AB25088 Rabbit 
polyclonal 
 1:1,000 
CX3CR1 Abcam AB8021 Rabbit 
polyclonal 
 1:100 
 
Table 2.1.1. List of antibodies used throughout the course of this thesis. WB: Western Blotting, IF: 
Immunofluorescence, CST: Cell Signalling Technology (Boston, MA, USA), BD: BD Biosciences Europe (Oxford, 
UK), Millipore: Millipore Ireland B.V. (Cork, Ireland), Abcam (Cambridge, UK), Sigma (Boston, MA, USA), Santa 
Cruz: Santa Cruz Biotechnology Inc. (Dublin, Ireland), Vector Labs: Vector Laboratories LTD (Peterborough, UK), 
Wako: Wako Chemicals USA, Inc. (Richmond, VA, USA), Novus Bio: Novus Biologicals (Abingdon, UK), AbD 
Serotec: Bio-Rad (Oxford, UK), Swant: Swiss Antibodies (Marly, Switzerland).  
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2.2. Primers  
 
 
 
Table 2.2.1. List of primers used throughout the course of this thesis. All primers are from Qiagen (West Sussex, 
UK).  
Gene Qiagen Primer Product Size RefSeq ID# 
Actin QT00095242 149 NM_007393 
GAPDH QT01658692 144 NM_008084  
HPRT QT00166768 168 NM_013556  
bFGF QT00128135 138 NM_008006 
PR A/B QT00114534 118 NM_008829 
PGRMC1 QT00250887 131 NM_016783 
PGRMC2 QT00258608 111 NM_027558 
mPRα QT00138145 78 NM_027995 
mPRβ QT00123886 67 NM_028829 
mPRγ QT01067612 67 NM_028748 
iNOS QT01547980 131 XM_001004823 
Arginase QT00134288 109 NM_007482 
Mannose Receptor QT00103012 132 NM_008625 
HMGB1 QT00247786 78 NM_010439 
IL-1α QT00113505 110 NM_010439 
MIP1Alpha QT00248199 107 NM_011337 
MIP1Beta QT00154616 110 NM_013652 
MCP1 QT00167832 118 NM_011333 
MCP3 QT00171458 117 NM_013654 
Fractalkine QT00128345 98 NM_009142 
CX3CR1 QT00259126 63 NM_009987 
IL-1β QT01048355 150 NM_008361 
IL-6 QT00098875 128 NM_031168 
TNF-α QT00104006 112 NM_013693 
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2.3. Reagents, inhibitors and antagonists 
Protein Reagent/ 
Inhibitor/ 
Antagonist 
Supplier Catalogue # Stock 
Concentration 
Vehicle 
GSK3β SB216763 Tocris 1616 50mM DMSO 
PI3K/AKT LY294002 CST 9001 50mM DMSO 
PKA H-89 Sigma B1427 50mM DMSO 
ERK1/2 UO126 Sigma U120 50mM DMSO 
PGRMC1 AG205 Sigma A1487 10mM DMSO 
Ryanodine 
Receptor  
Dantrolene 
(Antagonist) 
Sigma D9175 10mM DMSO 
EGTA Calcium 
Chelator 
Sigma E3889 0.5M Water 
 
Table 2.3.1. List of inhibitors used throughout the course of this thesis. Tocris: Tocris Bioscience (Bristol, UK), 
CST: Cell Signalling Technology (Boston, MA, USA), Sigma (Boston, MA, USA). 
 
2.4. Mice   
All animals were handled and maintained following the Association for Research in Vision 
and Ophthalmology statement for the Use of Animals in Ophthalmic and Vision Research. 
Experiments were approved by University College Cork Animal Experimentation Ethics 
Committee and were supplied by the Biological Services Unit, University College Cork. All 
animals were humanely euthanized by cervical dislocation (Hwang & Iuvone, 2013). All 
experiments performed in the course of this study were carried out using both male and 
female C57BL/6 wild-type and homozygous rd10/rd10 (B6.CXBI-Pde6brd10/J) mice.  
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2.5. Retinal explant culture 
C57BL/6 were sacrificed at postnatal day 30 (P30) by cervical dislocation and decapitated. 
The removed heads were wiped clean with tissue soaked in 70% ethanol and transported in 
to a laminar flow cabinet. From this point on, all handling was performed aseptically. The 
eyes were enucleated (Jin & Xiang, 2012) and placed in to R16 medium (recipe from P.A. 
Ekstrom, Wallenberg, Retina Centre, Lund University, Lund, Sweden). R16 media is made 
up by dissolving one vial of R16 Dry Powder Medium (Basal) (07490743A) (Invitrogen Life 
Technologies, Paisley, UK) in 800ml sterile dH2O. This solution is made to a complete 
medium through hormones and vitamins supplementation (Table 2.5.1 – all from Sigma), 
10% bovine serum albumin and 1% penicillin streptomycin (both Sigma) to a final volume of 
1L and will last for up to three weeks at 4°C (Caffé et al., 2002). The powder is composed of 
41 ingredients that can be classified in salts, amino acids, sugars and vitamins (Table 2.5.2).  
 Concentration  Concentration 
NaSeO3 30nM Thiocitic acid 0.22μM 
MnCl2 5nM Retinol 0.35μM 
CuSO4 10nM Retinyl acetate 0.3μM 
NaHCO3 33.3μM Tocopherol 2.32μM 
Biotin 0.4μM Tocopherol acetate 3.59μM 
Ethanolamine 16.4μM Linoleic acid 3.57μM 
Transferrin   0.125μM Linolenic acid 3.59μM 
Progesterone 0.02μM L-Cysteine 45μM 
Insulin 3.33nM Glutathione 3.25μM 
T3 3.1nM Na Pyruvate 454.4μM 
Corticosterone 57.7nM Glutamine 171μM 
Thiamine HCL 8.2μM Vitamin C 567.76μM 
Vitamin B12 0.23μM   
 
Table 2.5.1. Supplements for R16 medium 
 
42 
 
 
Table 2.5.2. Composition of R16 dry powder medium (basal) 
 
The lens, anterior segment, vitreous body, retinal pigment epithelium and sclera were 
removed and the retina was flat mounted, photoreceptor side down on top of a 
nitrocellulose insert (Millipore, Billerica, MA) in six well culture dishes (Starstedt AG & Co., 
Wexford, Ireland). Explants were cultured in 1.2mL of complete R16 media. Explants were 
 Concentration  Concentration 
L-Alanine  23μM  Glucose 19.1mM  
L-Arginine HCl  494μM  D(+)-Galactose  83μM  
L-Asparagine H2O  23μM  D(+)-Mannose  56μM  
L-Cystine Na2  134μM  Choline chloride  43.5μM  
L-Glycine  292μM  Pyridoxal HCl  13.4μM  
L-Histidine HCl.H2O  158μM  CaCl2.2H2O  1.28mM  
L-Isoleucine  546μM  Fe(NO3)3.9H2O  0.17μM  
L-Leucine  562μM  FeSO4.7H2O  0.68μM  
L-Lysine HCl  585μM  KCl  4.29mM  
L-Methionine  142μM  MgSO4.7H2O  680μM  
L-Phenylalanine  276μM  NaH2PO4.2H2O  610μM  
L-Proline  68μM  Na2HPO4  230μM  
L-Serine  292μM  ZnSO4.7H2O  0.70μM  
L-Threonine  562μM  Folic acid  6.79μM  
L-Tryptophan  55μM  i-Inositol  48.7μM  
L-Tyrosine  275μM  Nicotinamide  22.2μM  
L-Valine  562μM  Hypoxanthine  6.75μM  
Putrescine  180μM  Riboflavine  0.74μM  
L-Carnitine  12.4μM  Thymidine  0.67μM  
NaCl  103mM  D-calcium pantothenate  5.77μM  
Cytidine 5'-diphospho 
ethanolamine  
1.28mg/ml  Cytidine 5'-disphospho 
choline  
2.56mg/ml  
Sodium phenol red  5.0mg/ml    
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pre-treated with 20μM Norgestrel (N2260) (Sigma), 0.5μM PKA specific inhibitor H89 
(B1427) (Sigma), 10μM PGRMC1 specific inhibitor AG205 (A1487) (Sigma) or the equivalent 
dimethyl sulphoxide (DMSO) (D2650) (Sigma) control for 1 hour before treatment with 
300μM of the nitric oxide donor sodium nitroprusside (SNP) (228710) (Sigma) over 24 
hours. 
 
2.6. Terminal dUTP nick-end Labelling (TUNEL) of 
fragmented DNA 
DNA strand breaks in retinal cell nuclei were detected by terminal dUTP nick end-labelling 
(TUNEL) (Portera-Cailliau et al., 1994). Retinal explants were fixed in 4% PFA for 10 minutes 
followed by cryoprotection in 30% sucrose overnight at 4°C. In all cases, four sections of 
7μm were cut using a cryostat (Leica CM1950; Leica Co., Meath, Ireland) and placed on to 
one slide. 30μm sections were then sliced between these and methodically taken, ensuring 
sections were obtained from the entire retina. Frozen sections were incubated with 
terminal deoxynucleotidyl transferase (M1875) (Promega, Kilkenny, Ireland) and 
fluorescein-12-dUTP (#11373242910) (Roche, Lewes, UK) according to manufacturer’s 
instructions and nuclei were counterstained with Hoechst 33342 (1μg/mL) (Sigma). 
Sections were incubated at 37°C for 1 hour in a humidified chamber and following several 
washes in phosphate-buffered saline (PBS; pH 7.4), were mounted in mowiol (Calbiochem, 
Nottingham, UK). Sections were viewed under a fluorescence microscope (Leica DM LB2). 
For each treatment, at least three animals were used and three fields per section (central, 
central-peripheral and peripheral retina) (x40 magnification) of at least three different 
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sections were evaluated. Incubated sections were taken from both the central and 
peripheral retina.  
 
2.7. Cell culture and treatments 
Experiments were carried out using the mouse photoreceptor-derived 661W cell line. This 
cell line was generously provided by Dr Muayyad Al-Ubaidi (Department of Cell Biology, 
University of Oklahoma, Health Sciences Centre, Oklahoma City, OK, USA) (Al-Ubaidi et al., 
2008). Validation of this cell line was carried out through RT-PCR analysis for cone specific 
opsin blue cone opsin (Opn1sw) and rod specific rhodopsin (Ait-Hmyed et al., 2013). 
Opn1sw yielded a positive result confirming a cone cell phenotype (Figure 2.7.1).  
 
 
2.7.1. 661W cell culture and treatment 
Cells were cultured in Dulbecco’s Modified Eagle’s medium (D6429) (Sigma) supplemented 
with 10% (v/v) foetal calf serum and 1% (v/v) penicillin streptomycin (to make complete 
dulbecco’s modified eagle’s medium) and maintained at 37°C in a humidified 5% CO2 
Figure 2.7.1. Validation of 661W 
cells as a cone photoreceptor-like 
cell line. RT-qPCR analysis of 
mRNA encoding cone specific 
opsin blue cone opsin (Opn1sw) 
and rod specific Rhodopsin from 
661W cone-photoreceptor like 
cells. Results are presented as 
mean ± SEM. N=3, n=4. 
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atmosphere. To analyse the effects of Norgestrel (N2260) (Sigma) and/or a treatment on 
661W cells by western blotting, one million cells were seeded in a T75 flask and allowed to 
attach overnight. To analyse the effects by RT-PCR, 7 x 105 cells were seeded in a 6 well 
plate and allowed to attach overnight. All cells were then washed three times with PBS and 
complete or serum-free medium supplemented with 20μM Norgestrel, treatment 
compound or the equivalent dimethyl sulfoxide (DMSO) (D2650) (Sigma) control was 
added. After incubation for the indicated times, cells for were detached using Accutase 
solution (A6964) (Sigma) and together with their supernatant, centrifuged to leave a whole 
cell pellet. Plates seeded with cells for RT-qPCR were washed and immediately placed at -
80° until needed.  
 
2.7.2. Culture of primary microglial cells 
A protocol for isolating and culturing retinal microglia was adapted from a previously 
published protocol (Weigelt et al., 2007). Briefly, retinas were dissected from the eyes of 
P16 rd10 mice, ensuring minimum contamination with vitreous body and retinal pigment 
epithelium. Four retinas were pooled, cut into small pieces and incubated for 40 min at 
37°C in 1ml PBS with 1mg/ml collagenase type I (Sigma), 0.3mg/ml DNase I (Roche), and 
0.2mg/ml hyaluronidase (Sigma). The cell suspension was filtered through a 70-μm cell 
strainer (Becton Dickinson). Cells were washed twice with 10ml DMEM/10% FBS/1% PS and 
resuspended in 15ml DMEM/10% (v/v) FBS/1% (v/v) PS. To isolate the mononuclear cells, 
the suspension was gently added to 15ml Ficoll paque premium reagent (GE Life Sciences) 
and centrifuged for 20 minutes at 2,000 rpm without the brake in a Beckmann GS-6R 
centrifuge. The interphase was removed carefully and washed twice with 10ml DMEM/10% 
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(v/v) FBS/1% (v/v) PS. The cells were cultured for 3 days, on either polylysine coated 
coverslips in 24 well plates or T25cm2 flasks containing DMEM/10% (v/v) FBS/1% (v/v) PS. 
2.7.3. Culture of 661W cells in microglial-conditioned media 
A total of six retinas from three P16 rd10 mice were used to make the primary culture for 
the conditioned media experiment. Primary microglia were cultured in T25 flasks for 2 days 
before treatment with 20μM Norgestrel or vehicle (DMSO) for 24 hours. Cells were washed 
with PBS and cultured in fresh DMEM/10% (v/v) FBS/1% (v/v) PS for a further 24 hours. This 
conditioned media was collected and added to 661W cells (Roque et al., 1999). 661W cells 
were seeded overnight in 96 well plates (Sarstedt) to allow for cell adherence. All cells were 
then washed three times in PBS and media replaced with either basal microglial media, or 
conditioned media from treated primary microglial cells (100μl/well). Cells were incubated 
for 20 hours before addition of MTS for a further 4 hours. 
 
2.7.4. Co-culture of rd10 microglia with 661W cells 
A total of sixteen retinas from eight P16 rd10 mice were used to make the primary culture 
for the co-culture experiment. Primary microglia were cultured on polylysine-coated 
coverslips in 24 well plates for 1 day before treating with Norgestrel or vehicle (DMSO). 
Primary cells were exposed to 20μM Norgestrel or vehicle control and left for 24 hours. 
Cells were washed with PBS prior to the addition of 661W cells that had been treated with 
Norgestrel or vehicle in the absence or presence of serum in the preceding 3 hours. 661W 
cells suspended in fresh DMEM/10% (v/v) FBS/1% PS (v/v) were added to the microglia at a 
density of 25 x 103 per well. Untreated microglia were also co-cultured with untreated 
661W cells. Co-cultures of microglia and 661W cells were left for a further 21 hours before 
fixation in 4% (v/v) PFA. 
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2.7.5. Quantification from immunohistochemical sections and cells 
Quantification of outer nuclear layer (ONL) thickness and outer segment length in retinal 
sections was carried out using ImageJ software. Average ONL thickness was measured by 
taking measurements from at least 20 sections per mouse. Per section, three distinct 
measurements were taken and averaged. Average outer segment length was measured by 
taking measurements from at least four sections per mouse. Per section, three distinct 
measurements of rod or cone outer segment length were taken and averaged. Three mice 
were analysed per group. Fluorescence intensity measurements of CD68, iNOS and MRC1 
in primary microglia were performed using ImageJ software, by measuring points of 
intensity within single cells.  
 
2.8. Western blot analysis 
 
2.8.1. Whole cell lysis 
Whole cells were centrifuged down to form a pellet, and solubilised with RIPA buffer: 
50mM Tris-HCL pH 7.4, 150mM NaCl, 1mM Na3VO4, 1mM NaF, 1mM EGTA, 1% Nonidet P-
40 (NP40) (v/v), 0.25% sodium deoxycholate, cocktail protease inhibitors (Roche, Welwyn, 
Hertforshire, UK) and 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride (0.2mM). 
Lysates were incubated on ice for 1 hour with occasional vortexing and debris was removed 
by centrifugation (10,000 x g) at 4°C. In all cases equivalent amounts of protein (15-50µg), 
as determined by the Bio-Rad Protein Assay (Bio-Rad, Oxford, UK) were resuspended in 
loading dye with Dithiothreitol (DTT) (Sigma) and boiled at 95°C for 5 minutes. This solution 
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was then centrifuged at 10,000 g for 1 min. Total supernatant was resolved using 
denaturing 12% (w/v) sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE), followed by transfer to nitrocellulose membrane (Schleicher and Schuell, Dassel, 
Germany). Membranes were blocked with 5% (w/v) bovine serum albumin (Sigma) in Tris-
buffered saline/0.1% (v/v) Tween-20 (Sigma) for 1 hour at 18-20°C and incubated at 4° 
overnight with the appropriate dilution of primary antibody. Blots were then incubated 
with the corresponding peroxidase-conjugated secondary antibody (dilution 1:10,000) (LI-
COR Biosciences UK Ltd, Cambridge, UK) for 1 hour. Antibody reactive bands were detected 
using a LICOR Odyssey infrared imaging. All experiments were carried out in triplicate (n=3 
biological samples per condition). Western blots shown in results are representative images 
of three independent experiments, using different samples each time. 
 
2.8.2. Subcellular fractionation 
Subcellular fractionation was performed to detect movement of progesterone receptors 
using the subcellular protein fractionation kit (Thermo Scientific Pierce). Manufacturer’s 
instructions were modified to ensure optimal amounts of protein were obtained from each 
fractionation step. In brief, for 661W cells, we assumed that 1 x 106 cells were the 
equivalent to 1μL packed cell volume. For cytoplasmic extraction, one tenth the 
recommended quantity of buffer was added and an additional vortexing step of 15s was 
carried out before gentle mixing for 10 minutes. When adding the membrane extraction 
buffer, one fifth the recommended quantity of buffer was added. Finally, for nuclear 
fraction extraction, RIPA lysate buffer was used as this was found to obtain better protein 
concentrations than the nuclear extraction buffers provided. RIPA lysate was added at a 
volume of 10μL per initial 1μL packed cell volume.  
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2.9. Immunofluorescence and live cell imaging 
 
2.9.1. Cell seeding for 661W immunofluorescence 
Cells were seeded overnight (25 x 103 per well) in 24 well plates (Starstedt AG & Co.) with 
glass coverslips. Cells were then washed with PBS, pH 7.4 before treated over the specified 
times. After treatment, cells washed again and fixed with 4% (v/v) PFA for 10 minutes at 
room temperature. Cells were subsequently blocked and permeabilised in 0.1% (v/v) Triton 
X-100 and 5% (v/v) donkey serum in PBS for 10 minutes at room temperature (18-20°C). 
 
2.9.2. Fixation and sectioning of retinal explants 
Following treatments, retinal explants were fixed at room temperature in 4% (v/v) 
paraformaldehyde (PFA) for 10 minutes (Samardzija et al., 2012). Following washes, eyes 
were cryoprotected in 30% (w/v) sucrose in PBS overnight, at 4°C. Explants were dabbed 
dry, submerged and frozen in cryochrome (Thermo Scientific) and sectioned on a cryostat 
(Leica). Sections (7µm) were collected on superfrost glass slides (Fisher Scientific) and 
stored at -80°C. Before use, sections were permeabilised and blocked for half an hour in 
0.1% (v/v) Triton X-100 and 5% (v/v) donkey serum in PBS at room temperature (18-20°C). 
 
2.9.3. Fixation and sectioning of whole retinas 
Eyes were enucleated and fixed at room temperature in 4% (v/v) PFA for 1.5 hours 
(Samardzija et al., 2012). Following washes, eyes were cryoprotected in 15% (w/v) sucrose 
in PBS for 1 hour, 20% (w/v) sucrose for 1.5 hours and 30% (w/v) sucrose overnight, all at 
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4°C. Eyes were submerged and frozen in cryochrome and sectioned on a cryostat. Sections 
(7µm) were collected on superfrost glass slides (Fisher Scientific) and stored at -80°C. 
Before use, sections were permeabilised and blocked for half an hour in 0.1% Triton X-100 
(v/v) and 5% (v/v) donkey serum in PBS at room temperature (18-20°C). 
 
2.9.4. Immunofluorescence 
After blocking, all sections and cells were incubated with primary antibody overnight at 
4°C. Table 2.1.1 lists the details of all primary antibodies used. Following washes, coverslips 
and sections were incubated with conjugated secondary antibody (1:500) antibody (Alexa 
Fluor donkey anti-mouse/rabbit/goat with either a 488 or 594 fluorescent probe; Molecular 
Probes &/or FITC –PNA (Vector Labs)) and Hoechst (0.1 μg/ml) in the dark for 1h at room 
temperature. Eliminating the primary antibody in solution served as a negative control. 
Sections were mounted, and cell-seeded coverslips were mounted on to glass slides, both 
using Mowiol.  
 
2.9.5. Microscopy 
Retinal sections and cell preparations were viewed using a Leica DM LB2 microscope with 
Nikon Digital Sight DS-U2 camera, using 40x and 100x objectives. Images were taken using 
the software NIS-Elements version 3.0, Nikon, Japan. Immunofluorescence on retinal 
sections was performed on at least three mice of each group, at each time-point. 
Immunofluorescence on cell preparations was also performed in triplicate. Confocal 
micrographs were taken using an Olympus Fluoview FV1000 laser scanning confocal 
microscope, using 20x and 60x objectives. Images were taken using the software Olympus 
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Fluoview Ver 4.1a and are represented as single slices in the XY plane or maximum intensity 
projections from acquisition of z-stacks. Identical microscope settings were used when 
visualizing specific markers across all time points and treatments. 
 
2.9.6. Live cell imaging: Visualisation of intracellular Ca2+ 
Cells required for visualisation of intracellular Ca2+ were seeded overnight (25 x 103 per 
plate) in 35mm with 2mm micro-well glass bottomed dishes (MatTek, MA, USA). Cells were 
then washed three times in PBS before treatment. Cytoplasmic Ca2+ levels were 
determined using the probe Fluo-4 AM (Healy et al., 2013). 30 minutes prior to treatment 
conclusion, 1μM Fluo-4 AM was added directly to the cells and incubated at 37°C in the 
dark. Cells were washed three times in warmed PBS and Ca2+ Fluo-4 AM cell loading 
medium added (see Flow Cytometry: Measurement of intracellular Ca2+ section). Plates 
were taken immediately to the confocal microscope and confocal micrographs imaged 
using an Olympus Fluoview FV1000 laser scanning confocal microscope, 20x objectives 
(Plank & Sussman, 2003). Images were taken using the software Olympus Fluoview Ver 4.1a 
and are represented as single slices in the XY plane. Identical microscope settings were 
used when visualising specific markers across all time points and treatments. 
 
2.10. Total RNA isolation and RT-qPCR  
Total RNA was isolated from whole cells using RNeasy Mini Kit (Qiagen, West Sussex, UK) 
following manufacturer’s protocol. All samples were DNase treated using RNase free DNase 
set (Qiagen) and 240ng-1μg cDNA was synthesised using QuantiTect Reverse Transcription 
Kit (Qiagen) according to manufacturer’s instructions. The resultant cDNA was then diluted 
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1:5-6 with RNase free water (Sigma) and RT-PCR was performed using QuantiTect SYBR 
Green PCR Kit (Qiagen) in a 384 well plate (Starstedt AG & Co.). Plates were run using the 
Applied Biosystems 7900HT Fast Real-Time PCR System (Life Technologies Ltd., Paisley, UK) 
and each set of reactions included both a non-reverse transcription control and a no 
template sample negative control (data not shown). The protocol consisted of a cycling 
profile of 30s at 95°C, 60s at 60°C, and 30s at 72°C for 40 cycles. Qiagen QuantiTect Primer 
assays were used for all genes (Table 2.2.1). Melt curve analysis confirmed that a single PCR 
product was present and subsequent gene sequencing of progesterone receptors was 
carried out by GATC Biotech, London, United Kingdom. Relative changes in gene expression 
were quantified using the comparative Ct (ΔΔCt) method as described by Livak & 
Schmittgen (2001; Schmittgen & Livak, 2008). The Ct value of the gene of interest was 
normalised to an average of the three endogenous housekeeping genes (Actb, Gapdh and 
Hprt). This was then compared to the normalised control sample – i.e. the equivalent 
DMSO timed control or control mouse. Alteration in mRNA expression of target genes was 
defined as fold difference in the expression level in cells after treatment, relative to that of 
the control. 
 
2.11. Enzyme-linked immunosorbent assay (ELISA) 
Cells were seeded (30 x 103) in 24 well plates (Starstedt) overnight to allow for cell 
adherence. Cells were stressed and treated with 20μM Norgestrel/DMSO control (500μl 
media). The supernatant was collected at the indicated times and samples were analysed 
for secreted bFGF using Abcam ELISA kit ab100670, according to manufacturer’s 
instructions.   
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2.12. siRNA transfection 
Cells were seeded overnight prior to transfection in 10cm petri dishes (750 x 103 per dish) 
(Starstedt) or 96 well plates (4 x 103 per well) (Starstedt) to allow for complete cell 
adherence. Qiagen GeneSolution siRNA (Table 2.12.1) was then transfected in to the cells 
using HiPerFect Transfection Reagent (Qiagen) (Table 2.12.2) and left for 24 – 48 hours 
before treatment.  
 
Gene Catalogue Number Concentration (nM) Incubation Time 
FGF2  #GS14173 25 48 
PGRMC1 #2968441 25 24 
Allstars Negative 
Control 
#1027280 10 As required 
 
Table 2.12.1. GeneSolution siRNA: Concentration and times used in siRNA Transfections 
 
 
Transfection Vessel Area (cm2) HiPerFect (μL) Total volume (mL) 
96 Well Plate 0.3 0.36 0.1 
24 Well Plate 2 2.4 0.5 
6 Well Plate 10 12 2.4 
T75 75 96 10 
 
Table 2.12.2. HiPerFect Transfection Reagent: Quantities used in siRNA Transfections 
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2.13. Assessment of cell viability 
MTS assay was used to quantify cellular viability (Penha et al., 2013; Sobolewska et al., 
2013). Cells (4 x 103 per well) were seeded 6 hours prior to treatment with siRNA in 96 well 
plates (Starstedt). Cells used to quantify cellular viability after serum starvation and 
treatment were seeded overnight (2 x 103 per well 96 well plate). This allowed for cell 
adherence. All cells were washed three times in PBS before treatment. After 20 hours of 
treatment incubation, 20μl of MTS solution (Promega, Madison, WI, USA) was added to 
each well and incubated for 4 hours at 37°C. Viable cells reduce the yellow MTS solution to 
form formazan. Detection and quantification of the formazan crystals is then carried out 
with a microplate reader (Molecular Device Corporation, Spectramax Plus 384, Sunnyvale, 
CA, USA) at 490nm. 490nm readings taken from non-template wells (media and MTS, 
without cells) were deducted from actual cellular readings. A further reading at 650nm was 
also taken from all wells and deducted from the 490nm readings to account for any cellular 
debris. The quantity of formazan product as measured by the amount of 490nm 
absorbance, is directly proportional to the number of living cells in culture. Therefore, the 
absorbance of the formazan formed in ‘control cell wells’, i.e. non-serum-starved, healthy 
661W cells, was taken as 100% viability. In experiments where cell death was evaluated 
after serum starvation, cell death was calculated as a percentage of non-stressed cells (0% 
cell death). 
 
2.13.1. Cell viability following dose response inhibitor treatments 
In all experiments entailing inhibitors, a control was carried out for every individual 
concentration, i.e. in an experiment where all cells were serum starved for 24 hours, cells 
treated with 0.5μM inhibitor plus Norgestrel were compared to cells treated with 0.5μM 
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inhibitor plus the equivalent amount of DMSO. In Figure 3.3.9, results obtained with 20μM 
Norgestrel administration were then graphed as a percentage of the viability of the DMSO 
control, where control viability was taken to be 100%. For graphical clarity however, only 
one DMSO 100% viability control bar has been shown.  
 
2.14. Flow cytometry 
 
2.14.1. Specific cell treatment for analysis by flow cytometry 
Cells undergoing specific inhibition treatments for serum starvation and subsequent 
analysis by flow cytometry were seeded (1 x 106) in a T75 flask overnight. Cells were then 
washed three times with warmed PBS and pre-treated for 10 minutes in serum-free media 
supplemented with AG205 (1 - 10μM) (Qin et al., 2015), dantrolene sodium salt (1μM) or 
calcium chelator EGTA (0.5mM) (Healy et al., 2013). 20μM Norgestrel or the equivalent 
DMSO control was then added directly to the flasks. After incubation for the indicated 
times, cells were washed with PBS and detached using accutase solution (A6964) (Sigma). 
Cells were then spun down to leave a whole cell pellet.  
 
2.14.2. Flow cytometry: Measurement of intracellular Ca2+ 
Cytoplasmic Ca2+ levels were determined using the probe Fluo-4 AM. 30 minutes prior to 
treatment conclusion, 1μM Fluo-4 AM was added directly to the cells and incubated at 37°C 
in the dark. After 30 minutes incubation, cells were washed with PBS, detached and spun 
down to form a whole cell pellet. Cells were resuspended in Ca2+ Fluo-4 AM cell loading 
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medium: 10% HBSS (#14180-046) (Gibco), 1mM CaCl22H2O (#223506) (Sigma), 1mM MgCl2 
(M8266) (Sigma), 1% foetal bovine serum (F7524) (Sigma), before analysis on a FACScan 
flow cytometer (Becton Dickinson, Oxford, UK). For experiments whereby the source of 
calcium was sought, cells were resuspended in Ca2+ Fluo-4 AM cell loading medium made 
up without CaCl22H2O. Intracellular Ca2+ production was measured at FL-1 (530nm) with 
excitation at 488nm. CellQuest software (Becton Dickinson) was used for data analysis. 
Healthy populations of cells were gated and a total of 10,000 gated events per sample were 
acquired. All FACS analyses were carried out in technical triplicates and all graphs represent 
data obtained from three independent experiments.  
 
2.15. Norgestrel-supplemented diet 
Norgestrel-supplemented and control diets were manufactured by Testdiet (Middlesex, 
UK). Norgestrel was added to the chow at a concentration of 0.05% (500ppm). Dam’s of 
rd10 pups were given a Norgestrel-supplemented diet (LabDiet 5053, custom diet 
containing D(-)-Norgestrel (N2260) (Sigma)) when the pups were P10 to allow pups to 
receive Norgestrel in the milk. This equates to a daily intake of approximately 80mg/kg, 
assuming a 30g mouse consumes around 5g of food/day.  Specialised diet soaked in water 
was also added to the cage in order for pups to receive Norgestrel directly, as soon as they 
began to eat. These pups were kept on the Norgestrel-supplemented diet post-weaning. 
With control litters, diet changes were replicated with a control diet (LabDiet 5053 control 
diet). Dams were given regular chow once pups were weaned. Supplementation of a mouse 
maternal diet with neuroprotective agents has previously been shown to provide 
neuroprotection in pups (Loren et al., 2005).  
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2.16. Statistical analysis 
Image Studio Lite Version 4.0 (LI-COR Biosciences UK Ltd, Cambridge, UK) was used to 
analyse all Western blots. Values in all graphs represented the mean ± standard error of 
the mean (SEM) and are representative of at least three individual experiments repeated in 
triplicate. Data were statistically analysed using the appropriate test (see individual figure 
legends) using Graph Pad, Prism 6. Values of p<0.05 were considered statistically 
significant.  
 
 
  
 
 
 
 
Chapter 3. The synthetic progesterone 
‘Norgestrel’ mediates its effects via basic 
fibroblast growth factor, protein kinase A 
and glycogen synthase kinase 3β 
signalling 
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3.1. Abstract 
 
The synthetic progesterone ‘Norgestrel’, has been shown to have proven neuroprotective 
efficacy in two distinct models of Retinitis Pigmentosa: the rd10/rd10 (B6.CXBI-Pde6brd10/J) 
mouse model and the Balb/c light damage model. However, the cellular mechanism 
underlying this neuroprotection is still largely unknown. Therefore, this study aimed to 
examine the downstream signalling pathways associated with Norgestrel both in vitro and 
ex vivo. 
 
In this work, we identify the potential of Norgestrel to rescue stressed 661W 
photoreceptor-like cells and ex vivo retinal explants from cell death over 24 hours. 
Norgestrel is hypothesised to work through an upregulation of neuroprotective basic 
fibroblast growth factor (bFGF). Analysis of 661W cells in vitro by real time polymerase 
chain reaction (rt-PCR), enzyme-linked immunosorbent assay (ELISA) and western blotting 
revealed an upregulation of bFGF in response to Norgestrel over 6 hours. Specific siRNA 
knock down of bFGF abrogated the protective properties of Norgestrel on damaged 
photoreceptors, thus highlighting the crucial importance of bFGF in Norgestrel-mediated 
protection. Furthermore, Norgestrel initiated a bFGF-dependent inactivation of glycogen 
synthase kinase 3β (GSK3β) through phosphorylation at serine 9. The effects of Norgestrel 
on GSK3β were dependent on Protein Kinase A (PKA) pathway activation. Specific inhibition 
of both the PKA and GSK3β pathways prevented Norgestrel-mediated neuroprotection of 
stressed photoreceptor cells in vitro. Involvement of the PKA pathway following Norgestrel 
treatment was also confirmed ex vivo. Therefore, these results indicate that the protective 
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efficacy of Norgestrel is at least in part, due to the bFGF-mediated activation of the PKA 
pathway, with subsequent inactivation of GSK3β.  
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3.2. Introduction 
 
In 2009, a study of the 661W cone photoreceptor-like cell line identified the synthetic 
progestin ‘Norgestrel’; a compound commonly found in the female oral contraceptive pill, 
as a neuroprotective agent to stressed photoreceptor-like cells in vitro (Doonan et al., 
2009). Successful treatment of two distinct models of RP: the rd10/rd10 (B6.CXBI-
Pde6brd10/J) mouse model and the Balb/c light damage model followed (Doonan et al., 
2011) and Norgestrel was thus identified as a potential drug candidate for the treatment of 
Retinitis Pigmentosa (Doonan & Cotter, 2012). This study therefore aimed to elucidate the 
intracellular signalling events associated with Norgestrel-induced protection in stressed 
photoreceptor cells. 
 
Progesterone is well documented to be protective in many different experimental models 
of disease and neurodegeneration (Gonzalez Deniselle et al., 2002a, 2002b; Gonzalez et al., 
2005; Compagnone, 2008; Espinosa-García et al., 2014; Yousuf et al., 2014; Qin et al., 
2015). Affecting several different cellular processes, it can effectively inhibit apoptosis and 
inflammation (Roglio et al., 2008; Choksuchat et al., 2009; Yu et al., 2010) – fundamental in 
its potential as a treatment of RP. Despite this, the mechanism by which progesterone 
works in the CNS and specifically in the retina, remains unclear. Progesterone acts through 
specific binding to cellular receptors (Friberg et al., 2009) and there is evidence mounting 
to suggest a subsequent progesterone-induced cascade of hormones and growth factors 
(Luciano et al., 1994; Peluso & Pappalardo, 1999). Indeed, it is the sequential expression of 
these factors that is believed to be what ultimately maintains cellular viability (Peluso & 
Pappalardo, 1999).  
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The relationship between progesterone and basic fibroblast growth factor (bFGF) plays a 
central role in the regulation of granulosa cell survival (Peluso & Pappalardo, 1999). 
Progesterone production promotes an increase in bFGF expression (Guthridge et al., 1992), 
which in turn maintains cellular viability (Peluso & Pappalardo, 1999). However, bFGF is 
also known to be neuroprotective in its own right: in the retina, bFGF has been shown to 
promote photoreceptor cell survival both in vitro and in vivo (O’Driscoll et al., 2007, 2008; 
Farrell et al., 2011); whilst in mice, photoreceptor targeted FGF-receptor inactivation leads 
to retinal degeneration (Campochiaro et al., 1996). Early studies on Norgestrel-injected 
mice implicated bFGF as a potential regulator of Norgestrel’s pro-survival activities (Doonan 
et al., 2011; Doonan & Cotter, 2012). Consequently, we proposed that Norgestrel could 
protect stressed photoreceptor cells through an upregulation of bFGF.  
Figure 3.2.1. Pathways previously shown to be activated by basic fibroblast growth factor (bFGF). (Cao et al., 
1997; Cheng et al., 1998; Désiré et al., 2000; O’Driscoll et al., 2007, 2008). 
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bFGF has been linked to several different pro-survival pathways (Figure 3.2.1). Shown in 
photoreceptor cells to stimulate the production of reactive oxygen species (ROS), it has 
been documented to activate the phosphatidylinositol 3-kinase-protein kinase B (PI3K-AKT) 
pathway, mediating neuroprotection (Farrell et al., 2011). bFGF has also been linked to 
extracellular signal-regulated kinase (ERK) activation (Désiré et al., 2000; O’Driscoll et al., 
2007, 2008) and to protein-kinase A (PKA) induced inactivation of glycogen synthase kinase 
3β (GSK3β) (Cao et al., 1997; Cheng et al., 1998; O’Driscoll et al., 2007). All taken, we 
hypothesised that Norgestrel may work to exert its neuroprotective effects through an 
upregulation of bFGF expression, with subsequent activation of pro-survival signalling 
pathways. This study aimed to examine this hypothesis in further detail. 
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3.3. Results 
 
3.3.1. Norgestrel prevents cell death in stressed 661W photoreceptor-
like cells in vitro  
In Retinitis Pigmentosa, cones cells are known to die secondarily to rods (Samardzija et al., 
2012). One hypothesis as to why this occurs is that they lose their rod-derived trophic 
support (Léveillard et al., 2004; Komeima et al., 2006; Finnegan et al., 2010). Though it is 
defined factors that are important to cone cell survival in vivo, rather than the mix of 
factors provided by serum; we have attempted to mimic this trophic loss in vitro by 
depriving cells of serum. Initiating cell death, serum starvation is an oft-used process by 
which to simulate photoreceptor activity and cell loss (Gómez-Vicente et al., 2005; Mackey 
et al., 2008; Guerin et al., 2011). Treatment with Norgestrel can protect from 
photoreceptor cell death in two models of RP (Doonan et al., 2011). However, in this study, 
we wished to determine if Norgestrel could also act to prevent from serum starved cell 
death in vitro. To this end, the immortalised 661W cone photoreceptor-like cell line was 
utilised. 
Figure 3.3.1. Treatment with 
20µM Norgestrel significantly 
increased cellular viability of 
stressed 661W cone 
photoreceptor-like cells over 24 
hours. (i) Cells were treated with 
DMSO (Control) or 20µM 
Norgestrel (Norgestrel) in the 
absence (i) or presence (ii) of 
serum over 24 hours and 
percentage cell viability was 
assayed (n=4). Results are 
presented as mean ± SEM. 
Asterisks indicate significant 
difference (t-test, **p<0.01). 
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661W cells were serum starved over 24 hours and treated with 20µM Norgestrel. Cell 
viability was then compared to non-serum starved control (100% viability) using the MTS 
assay; an assay frequently used in ocular studies as a measure of cellular proliferation and 
viability (Penha et al., 2013; Sobolewska et al., 2013). Norgestrel significantly increased 
cellular viability after serum deprivation (Figure 3.3.1i) and so it was demonstrated that 
Norgestrel is neuroprotective to stressed 661W cells.  
Analysis by western blotting confirmed this result. Treatment with Norgestrel decreased 
apoptotic induced cleavage of Poly (ADP-ribose) polymerase (PARP) and caspase-3 in 
Figure 3.3.2. Norgestrel inactivates pro-apoptotic signalling pathways. (A) 
(i) Western blotting demonstrates a decrease in PARP and Caspase-3 
cleavage after 24 hours serum starvation (Stressed) in response to 20µM 
Norgestrel. (B) (i) No change in PI3K and Beclin/LC3B necrotic-associated 
pathways was determined in stressed cells treated with 20μM Norgestrel. (A) 
(ii) and (B) (ii) Western blotting revealed no changes in PARP, Caspase-3, 
PI3K, Beclin or LC3B in healthy cells (Non-Stressed). Equal loading of protein 
was demonstrated by probing for GAPDH. Blots are representative of three 
independent experiments.  
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stressed cells comparison to DMSO-treated control (Figure 3.3.2Ai), though no changes 
were seen in the necrotic-associated Phosphoinositide 3-kinase (PI3K) and Beclin/Light 
Chain 3B (LC3B) pathways (Figure 3.3.2Bi). Norgestrel did not change cellular viability in 
non-stressed cells (Figure 3.3.1ii); nor could any changes be determined by western 
blotting (Figure 3.3.2A,Bii).  
 
3.3.2. Norgestrel causes an increase in bFGF production over 6 hours in 
661W cells  
Evidence in the literature suggests a role of bFGF in photoreceptor cell survival (O’Driscoll 
et al., 2007, 2008; Farrell et al., 2011). Therefore, we sought to investigate if bFGF is up-
Figure 3.3.3. Treatment with 20µM Norgestrel significantly increased levels of bFGF over 6 
hours. Cells were serum starved and treated with 20µM Norgestrel or the equivalent DMSO 
control for the indicated time periods. (A) RT-qPCR analysis detected a significant increase in 
bFGF mRNA levels over 1 hour in response to Norgestrel. Values are relative to timed DMSO 
control. (B) Analysis by ELISA revealed treatment with Norgestrel triggers significant release of 
the secreted, 18kDa form of bFGF (pg/mL) over 1 hour. (C) Western blotting demonstrated an 
increase of three distinct isoforms of bFGF (18kDA, 22kDa, 24kDa) over 6 hours. There is also 
faint banding for the 22.5kDa form, which may be methylated. Graphical results are presented as 
mean ± SEM from three independent experiments. Asterisks indicate significant difference (t-test, 
*p<0.05, **p<0.01, ***p<0.005, ****p<0.001). Equal loading of protein was demonstrated by 
probing for GAPDH. Blots are representative of three independent experiments. 
66 
 
regulated in photoreceptor cells in response to Norgestrel. Cells were stressed by serum 
starvation and treated with 20μM Norgestrel or the equivalent DMSO control for the 
indicated time periods. Figure 3.3.3A demonstrates a significant upregulation of bFGF 
mRNA over 1 hour relative to timed DMSO control. A single copy gene, bFGF is capable of 
encoding a secreted 18 kDa low molecular weight (LMW) bFGF isoform (Yu et al., 2007) and 
several non-secreted, high molecular weight (HMW) isoforms (Florkiewicz & Sommer, 
1989; Florkiewicz, et al., 1991a; 1991b; Arese et al., 1999). Analysis by enzyme-linked 
immunosorbent assay (ELISA) (Figure 3.3.3B) confirmed that treatment with 20μM 
Norgestrel causes a significant increase in LMW bFGF in the supernatant of photoreceptor 
cells over 1 hour. Total intracellular levels of bFGF were evaluated by western blotting 
(Figure 3.3.3C), demonstrating an increase in three distinct isoforms of bFGF over 6 hours. 
Two faint bands were also observed in Norgestrel treated samples between 22 and 24kDa. 
Total protein levels of intracellular bFGF were back down by 24 hours (Figure 3.3.3C).  
 
3.3.3. Transfection of 661W photoreceptor-like cells with small 
interfering ribonucleic acid targeted against bFGF abrogates Norgestrel-
mediated protection of stressed cells 
 
Figure 3.3.4. siRNA knock 
down of bFGF. 661W cells 
were transfected with siRNA 
targeted against bFGF (bFGF) 
or non-targeting scrambled 
control (Scrambled). 
Detection of bFGF mRNA 
levels by RT-qPCR (i) and 
immunofluorescence (ii). 
Results are presented as 
mean ± SEM. Asterisks 
indicate significant difference 
(t-test, ****p<0.001). Scale 
bars 30μm. 
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Norgestrel significantly inhibits 661W cells from serum starved cell death over 24 hours 
(Figure 3.3.1i, 3.3.5A). Having established that administration of Norgestrel causes an 
upregulation of bFGF over 6 hours (Figure 3.3.3), we then aimed to determine if bFGF is 
responsible for the neuroprotective effects afforded by Norgestrel. Photoreceptors were 
treated with small interfering ribonucleic acid (siRNA) against bFGF (Figure 3.3.4) and a 
significant decrease in bFGF expression (~80%) was verified through RT-qPCR (Figure 3.3.4i) 
and immunofluorescence (Figure 3.3.4ii).  
 
Knock down of bFGF did not decrease cellular viability relative to non-targeting scrambled 
control (Scrambled) as measured by MTS assay (Figure 3.3.5B). siRNA treated, stressed cells 
were then treated with either DMSO or 20µM Norgestrel over 24 hours. No change in 
viability in these cells was determined compared to the relative DMSO control (Figure 
3.3.5C).  
Figure 3.3.5. siRNA knock 
down of bFGF abrogates the 
neuroprotective effects of 
Norgestrel on stressed 661W 
cells. (A) Administration of 
20μM Norgestrel significantly 
decreases serum starved cell 
death over 24 hours. (B, C) 
661W cells were transfected 
with siRNA targeted against 
bFGF (bFGF) or non-targeting 
scrambled control 
(Scrambled). (B) Cells 
transfected with siRNA 
targeted against bFGF were 
assayed for cell death over 24 
hours (n=4). (C) Transfected 
cells were serum starved over 
24 hours in the presence of 
DMSO (Control) or 20µM 
Norgestrel (Norgestrel) and 
percentage cell death was 
assayed (n=4). Results are 
presented as mean ± SEM. 
Asterisks indicate significant 
difference (t-test, *p<0.05, 
****p<0.001).  
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3.3.4. Norgestrel mediates the inactivation of GSK3β in stressed 
photoreceptor cells through bFGF, but dos not activate AKT or ERK1/2 
 
The PI3-kinase/AKT pathway, the MAP-kinase/ERK1/2 pathway and the PKA pathway are 
known to converge on GSK3β (Figure 3.2.1). Established as pro-survival pathways in 
photoreceptor cells, they are activated in response to bFGF (Hossain et al., 2002; Mao & 
Lee, 2005; O’Driscoll et al., 2007, 2008). Therefore, we hypothesised that Norgestrel was 
likely protecting cells from cell death through one or several of these systems. 661W cells 
were serum starved over 3, 6 and 24 hours in the presence of DMSO (control) or 20μM 
Norgestrel. The phosphorylation states of GSK3β, AKT and ERK1/2 were measured by 
western blotting (Figure 3.3.6). Treatment of stressed cells with 20μM Norgestrel induced a 
gradual increase in the phosphorylation of GSK3β on serine 9 (pGSK3β(S9)) over 24 hours 
(Figure 3.3.6i). No changes could be determined in stressed photoreceptor cells in the AKT 
or ERK1/2 pathways over 24 hours (Figure 3.3.6ii). No changes in any pathway was seen in 
non-stressed cells (Figure 3.3.7i, Figure 3.3.7ii).  
Figure 3.3.6. GSK3β is 
inactivated in stressed 
photoreceptor cells treated 
with 20μM Norgestrel. (i) 
Cells were serum starved and 
treated with DMSO or 20µM 
Norgestrel for the indicated 
times. Western blotting 
revealed Norgestrel induced 
an inactivation of GSK3β 
through phosphorylation on 
serine 9 (GSK3β(S9)) over 24 
hours. (ii) No changes in 
phosphorylation of AKT or 
ERK was seen in stressed 
cells. Equal loading of protein 
was demonstrated by 
probing for GAPDH. Blots are 
representative of three 
independent experiments. 
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To determine if the changes seen in the phosphorylation state of GSK3β were bFGF-
dependent, 661W photoreceptor-like cells were treated with siRNA against bFGF. siRNA-
treated cells were then stressed by serum starvation and treated with either DMSO or 
20µM Norgestrel over 24 hours. siRNA treated, stressed cells saw no change in levels of 
pGSK3β(S9) when treated with Norgestrel (Figure 3.3.8).  Alternately, cells treated with a 
non-targeting scrambled siRNA retained the Norgestrel-mediated increase in both 
pGSK3β(S9) and total GSK3β seen in non-transfected, stressed, Norgestrel treated cells 
(Figure 3.3.8).  
Figure 3.3.8. Norgestrel-induced 
phosphorylation of GSK3β is bFGF 
dependent. 661W cells were transfected 
with siRNA targeted against bFGF (bFGF) 
or non-targeting scrambled control 
(Scrambled) and serum starved over 24 
hours in the presence of DMSO (Control) or 
20µM Norgestrel (Norgestrel). Western 
blotting analysis showed no change in 
phosphorylation of GSK3β when treated 
with bFGF specific-siRNA (bFGF). Equal 
loading of protein was demonstrated by 
probing for GAPDH. Blots are 
representative of three independent 
experiments. 
Figure 3.3.7. Norgestrel 
had no effect on 
phosphorylation of (i) 
GSK3β, (ii) AKT or ERK 
in non-stressed cells. 
Equal loading of protein 
was demonstrated by 
probing for GAPDH. 
Blots are representative 
of three independent 
experiments. 
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Figure 3.3.9. The neuroprotective effects of Norgestrel are mediated by protein kinase A. (A - 
D) (i) Dose response curve measuring cell viability of 661W cells treated with increasing 
concentrations (μM) of inhibitors against Protein Kinase A (PKA) (H-89), Glycogen Synthase 
Kinase 3β (GSK3β) (SB216763), phosphatidylinositol 3-kinase (PI3K) (LY294002) and 
extracellular signal-related kinase 1/2 (ERK1/2) (UO-126), in the presence of Norgestrel 
(Norgestrel) or DMSO control (Control). Values are calculated as a percentage of viable cells, 
compared to the relevant 100% viable Norgestrel or DMSO control. (A, B) (ii) Abrogation of the 
Norgestrel-mediated rescue of photoreceptor cells was achieved through PKA (A) (ii) and 
GSK3β (B) (ii) inhibition with H-89 and SB216763 respectively. (C, D) (ii) Norgestrel-induced 
neuroprotection was not blocked by PI3K inhibition with LY294002 (C) (ii), nor by UO-126 
inhibition of ERK1/2 phosphorylation (D) (ii). Values are expressed as a percentage of control 
viability. An individual control was carried out for each inhibitor concentration. This is 
represented by the single control bar shown. Results are presented as mean ± SEM, n=4. 
Asterisks indicate significant difference (t-test, *p<0.05, **p<0.01, ***p<0.005, ****p<0.001 
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3.3.5. Inhibition of PKA but not AKT or ERK1/2 abolishes the 
neuroprotective effects of Norgestrel against serum starved cell death 
In order to discount the actions of the AKT and ERK1/2 pathways in the protective actions 
of Norgestrel, 661W cells were stressed and treated with increasing concentrations of 
pathway-specific inhibitors over 24 hours (Figure 3.3.9). Cell viability was assessed by MTS 
assay and a dose response curve measuring cell viability with increasing concentrations of 
inhibitor (both in the absence and presence of Norgestrel) was constructed, using either 
Norgestrel or DMSO-treated cells as the relevant 100% control (Figure 3.3.9A-Di). 
Norgestrel did not protect photoreceptor cells from serum starved cell death when treated 
with either PKA-inhibitor H-89 or GSK3β-inhibitor SB216763 (Figure 3.3.9A,Bii), indicating 
that Norgestrel is working at least in part through PKA-mediated inhibition of GSK3β. 
Conversely, when stressed cells were treated with either AKT-inhibitor LY294002 or ERK1/2 
inhibitor UO126, Norgestrel-mediated neuroprotection was conserved (Figure 3.3.9C,Dii).  
 
3.3.6. The protection afforded to SNP-treated retinal explants by 
Norgestrel, is abrogated through specific inhibition of PKA by H-89 
Postnatal day 30 (P30) explants from C57BL/6 mice, treated over 24 hours with 300μM 
nitric oxide donor Sodium Nitroprusside (SNP) (Doonan et al., 2011) undergo cell death in 
all layers of the retina compared to untreated control (Figure 3.3.10i). SNP-induced cell 
death was successfully inhibited through 1 hour pre-treatment with 20μM Norgestrel 
(Figure 3.3.10ii). To determine if PKA was responsible for the protective properties of 
Norgestrel ex vivo, retinal explants were treated with PKA specific inhibitor H-89. Optimum 
inhibitor concentration was determined in 661W cells (Figure 3.3.9Ai), whereby 0.5μM H-
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89 did not decrease cellular viability compared to control, yet still prevented Norgestrel-
induced protection. Therefore, this concentration was carried forward for use in retinal 
explants. Explants incubated with 0.5μM H-89 alone over 24 hours did not show an 
increase in TUNEL-positive cells compared to control (Figure 3.3.11i). Explants were then 
pre-treated for 1 hour with 0.5μM H-89 and 20μM Norgestrel or equivalent DMSO control, 
before the addition of 300μM SNP for a further 24 hours. It was not possible to determine 
any major differences in TUNEL-positive staining across any of the PKA-inhibited explants, 
when treated with 20μM Norgestrel, compared to control (Figure 3.3.11ii).  
Figure 3.3.10. Norgestrel prevents SNP-induced cell death ex vivo. Retinal explants from postnatal day 30 
C57BL/6 mice were cultured over 24 hours. Apoptosis of retinal cells was detected by terminal dUTP nick 
end-labelling (TUNEL) of DNA strand breaks in cell nuclei. (i) Treatment with 0.3mM sodium nitroprusside 
(SNP) increases apoptotic cell death in all nuclear layers of the retina compared to untreated control. (ii) 
Treatment with 20μM Norgestrel inhibits SNP-induced apoptosis in all nuclear retinal layers. Results are 
representative of three independent experiments. GCL, Ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer. Scale bars 50µm. 
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Figure 3.3.11. Specific inhibition of PKA by H-89 
prevents Norgestrel-induced protection ex vivo. 
Retinal explants from postnatal day 30 C57BL/6 mice 
were cultured over 24 hours. Apoptosis of retinal cells 
was detected by terminal dUTP nick end-labelling 
(TUNEL) of DNA strand breaks in cell nuclei. (i) 
Retinal explants were treated with 0.5μM PKA 
inhibitor H-89 over 24 hours. (ii) PKA inhibited, SNP-
stressed explants treated with either 20μM 
Norgestrel or DMSO control demonstrated 
comparable TUNEL staining. Results are 
representative of three independent experiments. 
GCL, Ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer. Scale bars 50µm. 
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3.4. Discussion 
 
Studies from our laboratory identified Norgestrel, a synthetic progestin, as a potential 
therapeutic in the treatment of Retinitis Pigmentosa (RP) (Doonan et al., 2011; Doonan & 
Cotter, 2012). However, to date, limited study has been carried out in to the potential 
downstream signalling targets of this compound. The present study provides the first 
evidence that Norgestrel initiates its pro-survival cellular activities both in vitro and ex vivo 
through bFGF-mediated activation of the protein kinase A (PKA) pathway.  
 
Serum starvation of 661W cells induces cell death (Gómez-Vicente et al., 2005). Poly (ADP-
ribose) polymerase (PARP) and Caspase 3 cleavage are documented as key events in the 
initiation of apoptosis in photoreceptor cells (Gómez-Vicente et al., 2005; Miller et al., 
2006; Sahaboglu et al., 2013). Norgestrel was effectively able to prevent this cleavage in 
stressed cells (Figure 3.3.2Ai), though had no effect on non-apoptotic cell death pathways 
PI3K, Beclin and LC3B (Huang et al., 2013; Wang et al., 2013) (Figure 3.3.2Bi). Since 
Norgestrel significantly increased cellular viability in stressed cells by approximately 25% 
(Figure 3.3.1i) over 24 hours, we hypothesise that Norgestrel acts to protect 661W cells 
from cell death through prevention of apoptotic PARP and caspase-3 cleavage. However, 
due to emerging evidence suggesting that photoreceptor cell death in retinal 
degenerations may also involve non-apoptotic mechanisms (Sancho-Pelluz et al., 2008; 
Arango-Gonzalez et al., 2014), we cannot rule out the possibility that Norgestrel may 
protect against cell death through prevention of another non-apoptotic cell death pathway. 
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Intraperitoneal injection of Norgestrel to wild-type C57BL/6 mice and the rd10/rd10 
(B6.CXBI-Pde6brd10/J) mouse model of RP causes an upregulation of basic fibroblast growth 
factor (bFGF) over just 3 hours (Doonan et al., 2011). bFGF is a pleiotropic growth factor 
that regulates a variety of processes including cellular growth, angiogenesis, tissue injury 
healing and neuroprotection (Szabo et al. 1994; Ernst et al. 2001; Yoshida et al. 2004; 
O’Driscoll et al. 2007; O’Driscoll et al. 2008; Zhao et al. 2014; Wang et al. 2015). Most of 
these actions have been demonstrated with regard to the 18 kDa low molecular weight 
(LMW) bFGF isoform (Szabo et al., 1994; Ernst et al., 2001), which is secreted by cells via an 
unconventional ER/Golgi-independent pathway (Florkiewicz et al., 1995) and activates cell 
membrane FGF receptors (Spivak-Kroizman et al., 1994; Chlebova et al., 2009). However, in 
many systems (e.g. cells exposed to stressors, or in some tissue such as the brain), the 
single copy bFGF gene additionally encodes non-secreted, high molecular weight (HMW) 
bFGF protein isoforms (Florkiewicz & Sommer, 1989; Florkiewicz et al., 1991a, 1991b; Arese 
et al., 1999). These are extended versions of 18 kDa LMW bFGF, containing two functional 
domains: a common 18 kDa amino acid sequence and an amino terminal extension 
(Florkiewicz et al., 1991a; Vagner et al., 1996; Arese et al., 1999; Chlebova et al., 2009). 
Each HMW isoform is a distinct gene product and is not a precursor of the 18 kDa isoform 
(Florkiewicz & Sommer, 1989; Florkiewicz et al., 1991a; Arese et al., 1999). Different 
cellular functions are attributable to differing bFGF isoforms (Pasumarthi et al. 1996; Davis 
et al. 1997; Joy et al. 1997; Grothe et al. 1998), suggesting that isoforms of bFGF may act 
through distinct pathways. Specifically, HMW isoforms appear to function intracellularly, 
independently of cell-surface FGF receptors (Arese et al., 1999).  
 
In this study, Norgestrel administration to stressed 661W cells caused a significant 
upregulation of bFGF mRNA expression (Figure 3.3.3A). Analysis by enzyme-linked 
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immunosorbent assay (ELISA) revealed a significant release of the LMW 18 kDa in to the 
cell culture supernatant over 1 hour (Figure 3.3.3B). This rapid, transient release is 
characteristic of LWM bFGF: LMW bFGF complexes with FGF receptors on the cell 
membrane, initiating internalisation of the ligand-receptor complex and subsequent 
trafficking back to the nucleus (Bikfalvi et al. 1995; Arese et al. 1999; Yu et al. 2007). 
Evaluation by western blotting revealed Norgestrel also caused an upregulation of 
intracellular HMW (22 and 24kDa) bFGF in stressed photoreceptor cells, in addition to LMW 
(18kDa) bFGF. This upregulation was maintained over 6 hours (Figure 3.3.3C). Two faint 
bands between 22 and 24kDa were also observed in Norgestrel treated samples. The HMW 
forms (22, 22.5, and 24 kDa) of bFGF may be post-translationally modified, resulting in a 1- 
to 2-kDa increase in apparent molecular mass (Pintucci et al., 1996; Klein et al., 2000). 
Consequently, we postulate that the extra banding may be accounted for by methylation of 
the HMW forms. The upregulation of HMW bFGF by Norgestrel is of interest, for it is HWM 
bFGF and not the secreted LMW bFGF, that have been shown to affect viability of cells 
under trophic factor deprivation (Quarto et al., 1991; Bikfalvi et al., 1995). Unsurprisingly, 
expression of bFGF was back down by 24 hours (Figure 3.3.3C). The half-life of bFGF is only 
4.7 hours and all mitogenic activity will be lost after 24 hours (Shiba et al., 2003). All taken, 
these results, along with previous knowledge from the literature, suggest that Norgestrel is 
initiating its pro-survival activity at least in part, through the upregulation of bFGF. The 
varying upregulation and release patterns of bFGF also imply that Norgestrel can initiate 
distinct cellular activities through the activation of different bFGF isoforms.  
 
Administration of Norgestrel to stressed 661W cells causes an upregulation of bFGF (Figure 
3.3.3) and significantly inhibits cell death (Figure 3.3.1). Consequently, we hypothesised 
that if Norgestrel was mediating its actions through bFGF, specific siRNA knock down of this 
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growth factor would abrogate the neuroprotection. Indeed, in the absence of bFGF (~80% 
siRNA knock down, Figure 3.3.4i), Norgestrel did not afford the same level of protection as 
the Norgestrel treated control (Figure 3.3.5C), demonstrating that Norgestrel-induced 
protection is bFGF-dependent.  
 
Worthy of note, is that specific siRNA targeted to bFGF did not result in any decrease in 
cellular viability in comparison to control (Figure 3.3.5B). This is key to our understanding of 
Norgestrel’s neuroprotective activities. Under conditions of trophic factor deprivation, 
photoreceptor cell death is initiated (Gómez-Vicente et al., 2005; Mackey et al., 2008) 
(Figure 3.3.1i). bFGF is known to be neuroprotective to many cells, including 
photoreceptors ( O’Driscoll et al., 2007, 2008; Del Río et al., 2011; Doonan et al., 2011; 
Florkiewicz et al., 2011; Wang et al., 2015). Stressed photoreceptors however, do not up-
regulate bFGF transcription (Figure 3.3.3C, 0h control) without an external stimulus, e.g. 
Norgestrel. Protective bFGF is not produced under basal conditions in photoreceptor cells 
and so specific siRNA knock down of bFGF does not affect cellular viability (Figure 3.3.5B). 
This further substantiates the particular importance of Norgestrel-induced bFGF activation 
in stressed photoreceptor cells and its subsequent neuroprotective actions (Figure 3.3.5C).  
 
It is well established in the literature that both Extracellular Signal-Regulated Kinase (ERK) 
and Protein Kinase B (AKT), can play a key role in multiple cellular processes in the retina. 
These include glucose metabolism, apoptosis, cell proliferation, transcription and cell 
migration (Yuan et al. 2012; Jin et al. 2013; Yang et al. 2013; Kucharska et al. 2014). 
Moreover, both AKT and ERK activation has been demonstrated to mediate the actions of 
bFGF (Eves et al., 1998; Désiré et al., 2000; Wahlin et al., 2000; Kinkl et al., 2001; Hossain et 
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al., 2002; Mao & Lee, 2005) and both pathways have been implicated in the 
neuroprotection of retinal neurons (Liu et al. 1998; Nakazawa et al. 2002; Soto et al. 2006). 
As a result, we decided to look at the activation of these pathways in response to 
Norgestrel. Norgestrel did not stimulate any change in the phosphorylation status of AKT or 
ERK1/2 in either stressed or non-stressed 661W cells over 24 hours (Figure 3.3.6ii, 3.3.7ii). 
This result was further validated through inhibitor studies with PI3K pathway inhibitor 
LY294002 (Figure 3.3.9C) and MAPK/ERK1/2 pathway inhibitor UO-126 (Figure 3.3.9D). 
Neither inhibitor had any effect on the capacity of Norgestrel to rescue photoreceptor cells 
from cell death. Therefore, we hypothesise that the actions of Norgestrel in the rescue of 
stressed 661W cells in vitro is independent of the PI3K and ERK1/2 pathways. This finding is 
consistent with several previous studies showing that neither pathway is critical in 
photoreceptor cell rescue following stress both in vivo and in vitro (O’Driscoll et al., 2007, 
2008; Bürgi et al., 2009). The possibility of the involvement of PI3K and ERK1/2 in 
photoreceptor cell rescue following other cell stressors however, cannot be ruled out 
(Forkwa et al., 2014; Makarev et al., 2014).  
 
Norgestrel increased levels of pGSK3β(S9) in stressed 661W cells over 24 hours (Figure 
3.3.6i), a process known to prevent apoptosis (Li et al., 2000; O’Driscoll et al., 2007). 
Selective inhibition of the GSK3β pathway by SB216763 abolished the protective effects of 
Norgestrel on stressed 661W cells (Figure 3.3.9B). GSK3β is reported to be an essential 
downstream regulator of PI3K/AKT (Crowder & Freeman, 2000), ERK-associated pathway 
RSK (Torres et al., 1999) and PKA (Li et al., 2000) (Figure 3.2.1). However, given that the 
protective capabilities of Norgestrel appear to be independent of the AKT and ERK 
pathways (Figure 3.3.9C,D), we looked to see if Norgestrel was working through PKA-
dependent phosphorylation of GSK3β. Treatment with PKA-selective inhibitor H-89 over 24 
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hours successfully prevented the protective capabilities of Norgestrel on stressed 661W 
cells (Figure 3.3.9A), implicating its role in Norgestrel-mediated neuroprotection. 
Interestingly, recently it has also been shown that increased total levels of GSK3β will also 
contribute to overall cell survival (Rådinger et al., 2011). Norgestrel appears to elevate 
levels of total GSK3β in stressed 661W cells (Figure 3.3.6i). Therefore, we theorise that it is 
not only Norgestrel’s ability to increase pGSK3β(S9) that contributes to its pro-survival 
capacity; but also its potential to maintain total levels of GSK3β.  
 
bFGF can stimulate PKA activation in several retinal systems (Cheng et al., 1998; O’Driscoll 
et al., 2008; Farrell et al., 2011). Therefore, in order to determine if the Norgestrel-induced 
phosphorylation of GSK3β is bFGF-dependent, cells were treated with specific siRNA 
targeted against bFGF. These cells were subsequently stressed and treated with Norgestrel 
and no ensuing change in pGSK3β could be determined. Alternately, cells treated with a 
non-targeting scrambled control retained the Norgestrel-mediated increase in both 
pGSK3β(S9) and total GSK3β (Figure 3.3.8). Thus, it is likely that Norgestrel is protecting 
through the bFGF-mediated, PKA-dependent inactivation of GSK3β. 
 
Thus far, all results indicated that Norgestrel acts to protect 661W cone photoreceptor-like 
cells from apoptotic cell death through the PKA pathway. Therefore, in order to determine 
if Norgestrel also acts through the PKA pathway in the retina ex vivo, the nitric oxide donor 
sodium nitroprusside (SNP) was used as previously described to induce retinal cell death 
(Mastrodimou et al., 2008; Doonan et al., 2011). C57BL/6 retinal explants, cultured with 
300μM of SNP over 24 hours (Doonan et al., 2011), stained for large amounts of DNA 
strand breaks (TUNEL-positive staining) in all nuclear layers of the retina (Figure 3.3.10i). 
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Pre-treatment with Norgestrel successfully reduced TUNEL-positive staining in all retinal 
layers (Figure 3.3.10ii), suggesting that Norgestrel is protective against SNP-induced cell 
death in retinal explants. Stressed retinal explants treated with PKA inhibitor H-89 alone or 
in combination with Norgestrel showed similar levels of cell death (Figure 3.3.11ii). 
Therefore, we can confirm that PKA is involved in Norgestrel-mediated neuroprotection not 
only in stressed 661W cells, but also in SNP-stressed retinal cells, ex vivo. 
 
To conclude, we have shown that Norgestrel is capable of rescuing 661W cells from 
apoptotic cell death through prevention of PARP and Caspase-3 cleavage (Figure 3.3.2Ai). 
Norgestrel significantly up-regulates the expression of both secreted low molecular weight 
(LMW) bFGF and non-secreted high molecular weight (HMW) bFGF over 6 hours (Figure 
3.3.3C). This upregulation is crucial in potentiating Norgestrel’s pro-survival capabilities, for 
specific siRNA knock down of this growth factor abrogates Norgestrel’s protective effects 
on stressed 661W cone photoreceptor-like cells in vitro (Figure 3.3.5C). Finally, we have 
Figure 3.4.1. Schematic to show the hypothesised pro-survival mechanism of action of 
Norgestrel in stressed photoreceptor cells. 
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demonstrated that Norgestrel-induced upregulation of bFGF in stressed cells leads to 
subsequent inactivation of GSK3β through phosphorylation on serine 9 (Figure 3.3.8). This 
inactivation is hypothesised to be through PKA, for selective inhibition of the PKA pathway 
by H-89 prevented Norgestrel from protecting 661W cells against serum starved cell death 
(Figure 3.3.9Aii) and SNP-induced cell death in stressed retinal cells, ex vivo (Figure 
3.3.11ii). A schematic has been provided in Figure 3.4.1. showing this hypothesised 
mechanism of action.  
 
 
  
  
 
 
 
 
Chapter 4. Progesterone receptor 
signalling in retinal cell neuroprotection: 
Norgestrel mediates its protective 
effects through progesterone receptor 
membrane complex one 
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4.1. Abstract 
 
‘Norgestrel’, identified as potential drug candidate for the treatment of the degenerative 
eye disease Retinitis Pigmentosa (RP), is a synthetic form of the female hormone 
progesterone. Consequently, it must signal through progesterone receptors. Unfortunately, 
no work has yet given a conclusive overview of the progesterone receptors present in the 
eye and so thus far, no work has looked at the Norgestrel’s specific cellular target. 
Therefore, this study aimed to identify the receptor target of Norgestrel and begin to 
examine its potential mechanism of action in the retina. 
 
In this work, we identify and characterise the expression of progesterone receptors present 
in the C57 wild type and rd10 mouse model of RP, and in the 661W cone photoreceptor cell 
line. Classical progesterone receptors A and B (PR A/B), progesterone receptor membrane 
components 1 and 2 (PGRMC1, PGRMC2) and membrane progesterone receptors (mPR) α, 
β and γ were found to be expressed. All receptors excluding PR A/B were also found in the 
661W photoreceptor cell line. PGRMC1 is a key regulator of apoptosis and its expression is 
up-regulated in the degenerating rd10 mouse retina. Activated by Norgestrel through 
nuclear trafficking, siRNA knock down of PGRMC1 abrogated the protective properties of 
Norgestrel on damaged photoreceptors. Furthermore, specific inhibition of PGRMC1 by 
AG205 blocked Norgestrel-induced protection in stressed retinal explants. Therefore, we 
conclude that PGRMC1 is crucial to the neuroprotective effects of Norgestrel on stressed 
photoreceptors.  
 
83 
 
4.2. Introduction 
 
In the previous chapter, we begin to elucidate the downstream signalling pathways 
associated with the neuroprotective properties of ‘Norgestrel’ in stressed photoreceptor 
cells. However, currently, very little is known as to the specific receptor associated with 
progesterone-induced retinal neuroprotection. This study therefore aimed to identify the 
receptor target of Norgestrel with the aim of further elucidating its specific mechanism of 
action. 
 
Steroid hormones and their metabolites in the central nervous system (CNS) are commonly 
thought of as neurosteroids (Baulieu, 1991). Their neuroprotective properties have been 
defined in several different systems (Compagnone, 2008; Borowicz et al., 2011). 
Progesterone is one of these neurosteroids, the effects of which are well documented in 
many different experimental models of disease and neurodegeneration: spinal cord injury, 
brain ischemia, stroke, Alzheimer’s disease and perhaps most prominently, traumatic brain 
injury (TBI) (Gonzalez Deniselle et al. 2002a, 2002b; Gonzalez et al. 2005; Compagnone 
2008; Espinosa-García et al. 2014; Yousuf et al. 2014; Qin et al. 2015). Furthermore, studies 
highlighting its safety and viability in a number of different models of TBI have ensured 
progesterone’s entry into human clinical trials (Stein 2011; Stein 2013; Stein et al. 2015). 
Progesterone is believed to exert its neuroprotective effects through several different 
pathways. Perhaps most relevant to our studies is its ability to inhibit apoptosis and 
inflammation (Roglio et al. 2008; Choksuchat et al. 2009; Yu et al. 2010) – crucial in the 
protection of our degenerative rd10 mouse model.  
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The exact mechanism by which progesterone works in the CNS remains unclear. Similar to 
most neurosteroids, progesterone acts through specific binding to cellular receptors 
(Friberg et al., 2009). The classic progesterone receptors A and B (PR A/B) are widely 
expressed in the central nervous system and have a variety of physiological functions (Wen 
et al., 1994; Lange, 2008). Known as nuclear-localised receptors that regulate gene 
transcription (Li et al., 1997), PR A/B has also been found localised to, or near the plasma 
membrane (Lange, 2008). Here they can interact with signal transduction kinases such as 
proto-oncogene tyrosine-protein kinase Src and can activate the mitogen activated protein 
kinase (MAPK) pathway (Faivre & Lange, 2007). Progesterone is a complex hormone 
however and there is growing evidence that progestins achieve their neuroprotective 
effects through non-classical progesterone receptors (Pang and Thomas 2011; Moussatche 
and Lyons 2012; Petersen et al. 2013; Qin et al. 2015). The progesterone receptor 
membrane component (PGRMC) family, featuring PGRMC1 and PGRMC2 (Cahill, 2007; 
Lösel et al., 2008), is a prominent candidate for mediating the anti-apoptotic actions of 
progesterone, as is the Progestin and AdipoQ (PAQR) family of receptors (Zhu, Bond, et al., 
2003).  
 
PGRMC1 is a small, complex molecule with multiple signalling domains (Petersen et al., 
2013). It is known to bind several steroid hormones, though progesterone is bound with 
the highest affinity (Meyer et al., 1996) initiating a number of different responses. The 
signalling mechanisms through which PGRMC1 may act are incredibly diverse, for PGRMC1 
has multiple partner proteins. These enable the regulation of functions such as damage 
repair, drug and hormone metabolism, apoptosis suppression, membrane trafficking and 
repression of gene transcription (Peluso et al. 2006; Cahill 2007; Peluso et al. 2008a, 2008b; 
Rohe et al. 2009; Peluso et al. 2012). One such binding partner is PGRMC2 (Intlekofer & 
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Petersen, 2011; Petersen et al., 2013). Structurally similar to PGRMC1 (Cahill 2007; 
Wendler and Wehling 2013), there is little information available on PGRMC2 and its role in 
progesterone signalling is not yet clear. The key structural differences are in the N-terminus 
and transmembrane domain - where PGRMC1 possesses a progesterone binding site 
(Ashley et al., 2006). PGRMC2 does not have this site and so cannot directly bind 
progesterone. Instead, it acts as a companion protein to PGRMC1 (Petersen et al., 2013).  
 
The Progestin and AdipoQ (PAQR) family of receptors, consisting of membrane 
progesterone receptors (mPR) α, β and γ (mPRα – PAQR7, mPRβ – PAQR8, mPRγ – PAQR5); 
were first cloned, identified and characterised in fish ovaries (Zhu, Rice, et al., 2003). mPR 
mRNA has also since been isolated from several vertebrate species, including human and 
mouse (Zhu, Bond, et al., 2003). Highly conserved in sequence and structural similarity, the 
mPRs are expressed on the plasma membrane of cells and bind progestins in a specific, 
displaceable, high-affinity, limited capacity manner – all characteristics of steroid 
membrane receptors (Zhu et al. 2003b; Thomas et al. 2007; Dressing et al. 2012). mPRs are 
expressed in both PR A/B positive and negative cells (Dressing and Thomas 2007; Pang and 
Thomas 2011). Thus it is now commonly accepted that mPRs can mediate progestin’s anti-
apoptotic effects in both a PR A/B dependent and independent manner (Dressing et al. 
2012).  
 
Unfortunately, studies looking specifically at PRs present in ocular tissue are limited 
(Wickham et al. 2000; Swiatek-De Lange et al. 2007). The classical PRs A and B (PR A/B), the 
membrane components PGRMC1 and PGRMC2 and the membrane PRs (mPRα, β, γ) are all 
well documented to be widely expressed in the CNS and exhibit anti-apoptotic effects both 
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in a variety of different cell lines and across several different diseases. For this reason, the 
major aim of this study was to determine which of these receptors are present in the 
retinal cells and specifically in the photoreceptors of the C57 wild type and rd10 mouse. 
From here, we hoped to gain insight in to which PRs are responsible for the 
neuroprotective effects of Norgestrel.  
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4.3. Results 
 
4.3.1. Identification of progesterone receptors in the adult wild type C57 
and degenerating rd10 mouse retina  
The neuroprotective compound Norgestrel is a synthetic progestin. Hypothesised to work 
through progesterone receptors present in the eye, we sought to determine the 
occurrence of the various progesterone receptors in the retina of both the wild type (WT) 
C57BL/6 mice and the homozygous rd10/rd10 mice (B6.CXBI-Pde6brd10/J).  
Quantitative RT-PCR detected the presence of all mRNAs encoding the classical 
progesterone receptor (PR A/B), progesterone receptor membrane complexes 1 and 2 
(PGRMC1, PGRMC2) and all three membrane progesterone receptor isoforms, α, β and γ 
(mPRα, mPRβ, mPRγ) in both the C57 and rd10 adult mouse retina (Figure 4.3.1). RT-qPCR 
gene product sequencing confirmed the expression of specific progesterone receptors in 
the retinal tissue. PGRMC1 was the most highly expressed PR at the RNA level, with 2-Δct 
Figure 4.3.1. Progesterone receptor expression in the adult (i) C57 and (ii) rd10 retina. RT-qPCR analysis 
detected similar levels of mRNAs encoding the classical progesterone receptor (PR A/B), progesterone receptor 
membrane complexes 1 and 2 (PGRMC1, PGRMC2) and all three membrane progesterone receptor isoforms, α, β 
and γ (mPRα, mPRβ, mPRγ) in the both the adult C57 wild type (i) and rd10 (ii) mouse retina. PGRMC1 was the 
most abundant PR in both retinas. Results are presented as mean ± SEM from three independent experiments. 
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analysis yielding an RNA abundance roughly 80 (C57, Figure 4.3.1i) and 30 (rd10, Figure 
4.3.1ii) times that of the next most abundant PR, PGRMC2. Western blotting for the 
progesterone receptors (PRs) confirmed the presence of all proteins in the retinas (Figure 
4.3.2), although the relative abundance of each mPR isoform cannot be directly inferred 
from these blots. Western blotting also showed a significant increase in the presence of 
PGRMC1 in the degenerated rd10 retina in comparison to its aged matched WT control.  
 
4.3.2. PGRMC1 is localised predominantly in the photoreceptor layer 
Immunohistochemical analysis showed differential expression of all progesterone receptors 
throughout the retina of both the C57 wild type and adult mouse retinas (Figure 4.3.3). 
PRA/B, mPRα and mPRβ were found predominately in both the inner and outer plexiform 
layers and photoreceptor outer segments. mPRα and mPRβ were also found in the ganglion 
cell layer (GCL). PGRMC2 co-localised with the nuclear stain of the ganglion cells and inner 
nuclear layer (INL), suggesting nuclear localisation in these cells. PGRMC1 and mPRγ were 
most abundantly expressed on the cell membranes in the photoreceptor cell layer (ONL). 
No co-localisation with the nuclear stain was apparent. PGRMC1 and mPRγ were also found 
in the photoreceptor outer segments and in the ganglion cell layer (GCL).  
Figure 4.3.2. Protein 
expression of the 
progesterone receptors 
expression in the adult 
C57 and rd10 retinas. 
Western blotting 
confirmed the presence of 
all progesterone receptors 
at the protein level. 
Detection of tubulin in 
western blots 
demonstrates equal 
loading of protein. Blots 
are representative of three 
independent experiments. 
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Progesterone is considered to be a ‘female hormone’. Therefore, to rule out any 
differences of expression between male and female progesterone receptor expression, 
Figure 4.3.3. Immunohistochemical analysis revealed expression of all progesterone receptors 
throughout the C57 and rd10 mouse retina. Specifically, PGRMC1 and mPRγ are the most prevalent 
progesterone receptors found in the photoreceptor cell layer (ONL). Arrows indicate non-specific binding 
of mouse secondary antibody to blood vessels. GCL, Ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer. Scale bars 50µm. 
90 
 
male C57 aged matched controls were also analysed (Figure 4.3.4). No differences in 
localisation or expression were determined. No staining of the cells was observed when 
incubated with secondary antibody alone (data not shown).  
Figure 4.3.4. There is a similar expression profile of progesterone receptors in the male and female adult 
C57 retina. Immunohistochemical analysis of receptors in the male and female adult C57 retina revealed 
expression of all progesterone receptors throughout the retina. Arrows indicate non-specific binding of 
mouse secondary antibody to blood vessels. GCL, Ganglion cell layer; INL, inner nuclear layer; ONL, outer 
nuclear layer. Scale bars 50µm. 
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4.3.3. PGRMC1 is highly expressed in the rd10 mouse retina in 
development 
Previous studies suggest that the mouse retina develops postnatally from P0, through eye 
opening at P12-P15 and up to full development at P18 (Young, 1984). The rd10 mouse then 
undergoes a large peak of photoreceptor cell loss from P18 (Samardzija et al., 2012; Barone 
et al., 2014; Roche et al., 2016). Therefore, to look at the importance of the various PRs 
throughout this development, rd10 and WT retinas were analysed at P10, P15 and P22 for 
their relative quantity of PR expression. Quantitative RT-PCR detected the presence of all 
PR mRNA at all stages of development and degeneration (in the case of the rd10 mice) 
(Figure 4.3.5).  
Western blotting for the PRs confirmed the presence of all PR protein in the developing 
retinas (Figure 4.3.6i). Densitometric analysis was performed (Figure 4.3.6ii) on all PRs 
excluding PR A/B, where blotting densities were deemed too little for accurate 
determination. Western blots revealed a decrease in protein expression of all PRs in the 
Figure 4.3.5. RT-qPCR analysis detected the presence of mRNAs encoding all progesterone 
receptors in the C57 and rd10 retina at P10, P15 and P22. Results are presented as mean ± SEM 
from three independent experiments. Asterisks indicate significant difference (t-test, * p<0.05). 
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degenerated rd10 (P22) in comparison to WT, except for PGRMC1 where a significant 
increase at both P15 and P22 was observed.  
Figure 4.3.6. PGRMC1 expression is up-regulated in the rd10 mouse retina in comparison to its aged matched 
C57 wild type control. (i) Western blotting confirmed the presence of all progesterone receptors in the retinas. 
Protein expression of PGRMC1 was increased in P15 and P22 rd10 retinas. (ii) Graphical representation of 
changes in progesterone receptor protein expression. PGRMC1 expression was significantly increased in the 
developing (P15) and degenerating (P22) rd10 retina. Values are relative to C57 P10 control and are expressed as 
mean ± SEM. Detection of actin and tubulin in western blots demonstrates equal loading of protein. Blots are 
representative of three independent experiments. Asterisks indicate significant difference (t-test, * p<0.05).  
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4.3.4. Identification of progesterone receptors in 661W photoreceptor 
cell line 
661W cells are used throughout this thesis as an in vitro model of photoreceptor-based 
retinal degeneration. Therefore, it was necessary to identify which PRs they express. RT-
qPCR detected the presence of all PR mRNAs except for classical progesterone receptor (PR 
A/B) (Figure 4.3.7A). This protein was thus excluded from further analysis. PGRMC1 mRNA 
was most abundantly expressed receptor in this cell line. Expression of these proteins was 
confirmed by western blotting (Figure 4.3.7B) and immunohistochemical staining revealed 
Figure 4.3.7. All progesterone receptors except classical progesterone receptor A/B are present in the 
661W cone photoreceptor cell line. (A) RT-qPCR analysis detected the presence of mRNAs encoding 
progesterone receptors PGRMC1, PGRMC2 and mPRs α, β and γ. PGRMC1 is the progesterone receptor most 
abundantly expressed at the mRNA level. Results are presented as mean ± SEM from three independent 
experiments. (B) Western blotting confirmed the presence of these progesterone receptors in photoreceptor 
cells. Detection of tubulin demonstrates equal loading of protein. Blots are representative of three 
independent experiments. (C) Immunohistochemical staining of progesterone receptors present in the 661W 
photoreceptor cells. PGRMC1 and mPRα, β and γ predominantly localise to the cell membrane whilst 
PGRMC2 is largely nuclear. Scale bars 50µm. 
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that expression of PGRMC1 and mPRα, β and γ are predominantly localised on the cell 
membrane. PGRMC2 appears to be mostly nuclear (Figure 4.3.7C).  
 
4.3.5. Treatment with Norgestrel over 6 days causes upregulation of all 
progesterone receptors 
In order to determine if Norgestrel treatment induces an upregulation of progesterone 
receptor expression over time, 661W cone photoreceptor cells were treated with 20µM 
Norgestrel or equivalent DMSO control over 6 days. Quantitative RT-PCR analyses did not 
detect any significant changes in mRNA expression of any receptor over time (Figure 
4.3.8A). Western blotting revealed an increase in protein expression of all progesterone 
receptors (Figure 4.3.8B), most evident in receptors PGRMC1 and PGRMC2.  
Figure 4.3.8. Norgestrel treatment induces an increase in progesterone receptor protein expression. 661W cells 
were treated over six days with 20µM Norgestrel and analysed for increases in progesterone receptor expression. 
(A) RT-qPCR analysis detected no significant increase in mRNA encoding progesterone receptors PGRMC1, 
PGRMC2 or mPRs α, β or γ. Results are presented as mean ± SEM from two independent experiments. (B) Western 
blotting revealed an increase in protein expression of all progesterone receptors. Detection of tubulin 
demonstrates equal loading of protein. Blots are representative of three independent experiments.  
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4.3.6. Treatment with Norgestrel causes activation of PGRMC1, 
trafficking it in to the nucleus 
Previous data consistently identified PGRMC1 as the most abundantly expressed PR in the 
retina of the degenerating rd10 mouse. Therefore, to investigate the potential role of 
PGRMC1 in the protection afforded by Norgestrel, we decided to look at activation of this 
receptor and its companion protein, PGRMC2, upon administration of the compound.  
Figure 4.3.9. Treatment 
of 661W photoreceptor 
cells with 20µM 
Norgestrel causes 
activation of PGRMC1 
with subsequent 
trafficking to the 
nucleus. (A) 
Photoreceptor cells were 
treated with 20µM 
Norgestrel over 60 
minutes and harvested 
for subcellular 
fractionation. Movement 
of PGRMC1 was detected 
by western blotting. 
Graphical analysis of 
western blots revealed 
both monomeric and 
dimerised nuclear 
PGRMC1 was 
significantly up-regulated 
over 60 minutes in 
comparison to membrane 
PGRMC1. (B) Movement 
of PGRMC1-companion 
protein PGRMC2 was also 
analysed by western 
blotting. Equal loading of 
membrane and nuclear 
fractions was 
demonstrated by probing 
for membrane localised 
calreticulin and nuclear 
localised histone H3 
protein. Blots are 
representative of four 
independent 
experiments. Graphical 
analyses are in relative 
values and are expressed 
as mean ± SEM. Asterisks 
indicate significant 
difference (t-test, * 
p<0.05, ** p<0.01). 
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Activation of PGRMC1 is initiated through ligand binding, causing a conformational change 
that allows the membrane complex to translocate to the nucleus (Peluso et al., 2012). This 
is demonstrated clearly by western blotting (Figure 4.3.9A), showing that Norgestrel 
administration causes a significant increase in the quantity of both monomeric and 
dimerised PGRMC1 present in the nuclei of the photoreceptor cells. PGRMC2 is not 
significantly increased in the nucleus after 60 minutes of Norgestrel treatment (Figure 
4.3.9B), leading us to conclude that Norgestrel may be driving its neuroprotective effects 
primarily through activation of PGRMC1. No changes in subcellular movement of the mPRs 
was determined by either western blotting (Figure 4.3.10A) or subsequent densitometric 
analysis (Figure 4.3.10B).  
Figure 4.3.10. Treatment of 
661W photoreceptor cells 
with 20µM Norgestrel does 
not cause any significant 
trafficking to the nucleus of 
mPRs α, β or γ. Photoreceptor 
cells were treated with 20µM 
Norgestrel over 60 minutes 
and harvested for subcellular 
fractionation. (A) Movement 
of mPRs α, β and γ was 
detected by western blotting. 
(B) Graphical analysis of 
western blots revealed no 
significant movement of mPRs 
from the membrane in to the 
nucleus compared to DMSO 
control. Equal loading of 
membrane and nuclear 
fractions was demonstrated 
by probing for membrane 
localised calreticulin and 
nuclear localised histone H3 
protein. Blots are 
representative of four 
independent experiments. 
Graphical analyses are in 
relative values and are 
expressed as mean ± SEM. 
Asterisks indicate significant 
difference (t-test, * p<0.05, ** 
p<0.01). 
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4.3.7. PGRMC1 is responsible for the neuroprotective actions of 
Norgestrel in photoreceptor cells 
In the previous chapter, we have shown that administration of 20µM Norgestrel can 
successfully prevent 661W cells from serum starved cell death over 24 hours (also shown in 
Figure 4.3.11A). Having established that PGRMC1 is activated by Norgestrel after just 60 
minutes of exposure, we then wanted to determine if this membrane complex was 
responsible for the neuroprotective effects afforded by Norgestrel. Photoreceptors were 
treated with PGRMC1 siRNA and a significant decrease in PGRMC1 expression (~50%) was 
verified through RT-qPCR and western blotting (Figure 4.3.11B). Knock down of PGRMC1 
also caused a significant decrease in cell viability as measured by MTS assay (Figure 
4.3.11C). siRNA treated, stressed cells were then administered with 20µM Norgestrel over 
24 hours. There was no change in viability in Norgestrel, PGRMC1 siRNA treated cells 
(Figure 4.3.11D).  
Figure 4.3.11. siRNA knock 
down of PGRMC1 abrogates 
the neuroprotective effects of 
Norgestrel on stressed 
photoreceptor cells. (A) 
Treatment with 20µM 
Norgestrel significantly 
decreases cell death in stressed 
661W photoreceptor cells over 
24 hours. (B-D) 661W cells 
were transfected with siRNA 
targeted against PGRMC1 
(PGRMC1) or non-targeting 
scrambled control (Scrambled). 
(B) Detection of PGRMC1 
mRNA and protein levels by RT-
qPCR and western blot. 
Transfected cells were serum 
starved over 24 hours in the 
absence (C) or presence of (D) 
DMSO or 20µM Norgestrel and 
percentage cell death was 
assayed (n=4). Results are 
presented as mean ± SEM. 
Asterisks indicate significant 
difference (t-test, * p<0.05, 
**p<0.01). 
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4.3.8. The protection afforded to SNP-treated retinal explants by 
Norgestrel, is abrogated through specific inhibition of PGRMC1 by 
AG205 
In the previous chapter, we have shown that postnatal day 30 (P30) explants from C57BL/6 
mice, treated over 24 hours with 300μM nitric oxide donor Sodium Nitroprusside (SNP) 
undergo apoptosis in all layers of the retina compared to untreated control (Figure 3.3.10i). 
SNP-induced apoptosis was successfully inhibited through 1-hour pre-treatment with 20μM 
Norgestrel (Figure 3.3.10ii). Consequently, to determine if PGRMC1 was responsible for the 
protective properties of Norgestrel ex vivo, retinal explants were treated with PGRMC1 
specific inhibitor AG205. Preliminary experiments to determine optimum inhibitor 
concentration were undertaken in 661Ws (Figure 4.3.12). Stressed cells were treated with 
Norgestrel and AG205 and cellular viability was subsequently assessed by MTS assay. 
Norgestrel-induced protection was not afforded to AG205 treated cells (Figure 4.3.12ii). 
Treatment with up to 10μM AG205 did not decrease the viability of 661Ws (Figure 4.3.12i) 
and so this concentration was carried forward for use in retinal explants.  
Figure 4.3.12. Specific inhibition of PGRMC1 by AG205 prevents Norgestrel-induced protection in stressed 661W 
photoreceptor cells. 661W cells were serum starved over 24 hours and treated with increasing concentrations of 
PGRMC1 specific inhibitor AG205. (i) Percentage cell death was assayed (n=4). AG205 decreases viability of 
stressed 661W cells in a dose dependent manner. (ii) AG205 treated cells were serum starved over 24 hours in the 
presence of DMSO (control) or 20µM Norgestrel. AG205 attenuates Norgestrel-induced cell survival. Results are 
presented as mean ± SEM. Asterisks indicate significant difference (t-test, * p<0.05, ***p<0.005, ****p<0.001).  
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Explants incubated with 10μM AG205 alone over 24 hours did not show an increase in 
TUNEL-positive cells compared to control (Figure 4.3.13i). Explants were then pre-treated 
for 1 hour with 10μM AG205 and 20μM Norgestrel or equivalent DMSO control, before the 
addition of 300μM SNP for a further 24 hours. No difference in TUNEL staining could be 
determined in these explants when treated with 20μM Norgestrel, compared to control 
(Figure 4.3.13ii).  
  
Figure 4.3.13. Specific inhibition of PGRMC1 by 
AG205 prevents Norgestrel-induced protection in 
an ex vivo model of retinal degeneration. Retinal 
explants from postnatal day 30 C57BL/6 mice were 
cultured over 24 hours and treated with 10μM 
AG205 or equivalent control over 24 hours. 
Apoptosis of retinal cells was detected by terminal 
dUTP nick end-labelling (TUNEL) of DNA strand 
breaks in cell nuclei. (i) Treatment with 10μM AG-
205 alone does not increase apoptotic cell death in 
any nuclear layer of the retina. (ii) PGRMC1 
inhibited, SNP-stressed explants treated with either 
20μM Norgestrel or DMSO control demonstrated 
comparable TUNEL staining. Results are 
representative of three independent experiments. 
GCL, Ganglion cell layer; INL, inner nuclear layer; 
ONL, outer nuclear layer. Scale bars 50µm. 
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4.4. Discussion 
The present study provides the first evidence that Norgestrel not only initiates its cellular 
activity through activation of PGRMC1, but it can also inhibit apoptotic cell death through 
this receptor. Both C57 wild type and rd10 mice retinas predominantly express PGRMC1 
over any other PR (Figure 4.3.1). PGRMC1 is also significantly up-regulated at the protein 
level in both the degenerating (P15 – P22) (Figure 4.3.6) and fully degenerated (adult) 
mouse retina in comparison to wild type control (Figure 4.3.2). High expression of PGRMC1 
is mimicked in the 661W photoreceptor cell line (Figure 4.3.7). All taken, this may suggest a 
role for PGRMC1 in retinal cell viability in the rd10 retina. Norgestrel causes a significant 
increase in nuclear PGRMC1 after 60 minutes of treatment (Figure 4.3.9A), which has 
implications for an increased amount of PGRMC1-dependent transcriptional activity. 
Crucially, through siRNA studies on 661W cells (Figure 4.3.11) and through specific PGRMC1 
inhibitor work on retinal explants (Figure 4.3.13), we have demonstrated the critical role 
that PGRMC1 plays in Norgestrel-induced cell survival. Taken together, these results 
suggest a mechanism by which Norgestrel acts to exert its neuroprotective effects in 
stressed photoreceptor cells.  
 
Progestins can elicit several different mechanisms of action. Many of these effects are 
attributed to binding to classical nuclear progesterone receptors A and B, regulating gene 
expression (Lange, 2008; Hanna et al., 2010). Studies have shown that progesterone does 
indeed protect against apoptosis by binding to PR A/B (Friberg et al., 2009). In support of 
this, mRNA for progesterone receptors is present in the human and rodent retina 
(Wickham et al., 2000) and progestins are also metabolised in various retinal tissues (Lu et 
al., 2008; Doonan et al., 2011). However, we found low basal mRNA expression of classical 
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PR A/B in the retinas (Figure 4.3.1) with little detectable protein (Figure 4.3.2). The PR A/B 
transcript was also completely absent from the 661W cells (Figure 4.3.7) and thus it was 
concluded that the protective mechanisms of Norgestrel in the 661W photoreceptor cells 
could not be ascribed to this receptor.  
 
The membrane progesterone receptors (α, β, γ) are non-classical membrane receptors that 
make up part of the Class II progestin and AdiopoQ receptor (PAQR) family of proteins (α – 
PAQR7, β – PAQR8, γ – PAQR5) (Kupchak et al., 2009; Thomas & Pang, 2012; Petersen et 
al., 2013). These mPRs are not structurally nor functionally related to either PGRMC1 or 
PGRMC2. Instead, studies have predicted them to be classical 7-transmembrane spanning 
G-protein coupled receptors (GPCR) (Zhu et al. 2003, Moussatche and Lyons 2012), linking 
them with the alkaline ceramidase protein family (Kupchak et al., 2009). In effect, evidence 
that the mPRs may mediate signalling through a combination of both pathways is mounting 
(Moussatche & Lyons, 2012; Petersen et al., 2013). The mPRs have specific and saturable 
high-affinity binding sites for progesterone (Petersen et al., 2013) and are often associated 
with rapid signalling events leading to the progesterone dependent inhibition of cAMP 
(Zhu, Bond, et al., 2003). In this study, we found no distinguishable change in expression of 
these receptors between the adult WT and rd10 retinitis pigmentosa mouse model (Figure 
4.3.2). In fact, protein levels of mPRα and mPRβ were reduced in the degenerating rd10 
retina (P22) (Figure 4.3.6), despite the fact that these receptors are not highly expressed in 
the photoreceptor layer, i.e. the layer suffering substantial cell loss in the rd10 animal 
(Figure 4.3.3). Therefore, we deemed it unlikely that these receptors could function as the 
major progesterone receptors responsible for Norgestrel’s mechanism of action within the 
retina. 
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Both C57 and rd10 adult mice primarily express PGRMC1, a finding consistent across 
development (P10 – P22) of the adult eye (Figure 4.3.6) and in the 661W cone 
photoreceptor cell line (Figure 4.3.7). Expression of this receptor appears to be highly 
concentrated in the retinal outer nuclear layer (ONL), where the photoreceptors are found 
(Figure 4.3.3). Interestingly, this receptor appears to be up-regulated in rd10 mice in 
comparison to their aged matched control (Figure 4.3.2), despite the loss of photoreceptor 
cells. This could implicate compensation from other retinal cell types during retinal 
degeneration, in an attempt to promote retina-wide cell survival. This would also support 
the vast body of research that links PGRMC1 to cell survival in a wide variety of cell types 
(Crudden et al. 2006; Peluso et al. 2008a, 2008b; Thomas and Pang 2012; Qin et al. 2015), 
including retinal glial cells (Swiatek-De Lange et al., 2007). Given that PGRMC1 showed the 
most profound change in expression in the degenerating rd10 retina (Figure 4.3.6) and is 
also the most abundantly expressed in the 661W photoreceptor cell line (Figure 4.3.7) and 
in the retina of the WT and rd10 (Figure 4.3.2) mice; we focussed our attention on PGRMC1 
as the major progesterone receptor responsible for the actions of Norgestrel in the eye.  
 
PGRMC1 is a member of the ‘membrane associated progesterone receptor family’ (MAPR), 
which is also a subclass of cytochrome b5 family of proteins (Cahill, 2007). In contrast to 
the mPRs, it comprises of a single transmembrane domain corresponding to amino acid 
residues 24-42 (Swiatek-De Lange et al., 2007). In the literature, PGRMC1 is predominantly, 
and incorrectly, thought of as a membrane protein; as it is also detectable in the nucleus, 
generally in a dimerised form (Lösel et al. 2008; Peluso et al. 2008a, 2008b; Peluso et al. 
2012). This PGRMC1 (often referred to as nuclear PGRMC1) is believed to be cell-cycle 
dependent (Lösel et al., 2008) and progesterone-dependent transport from the membrane 
into the nuclear compartment is an essential part of the receptor’s mechanism of action 
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(Peluso et al., 2012). For this reason, we decided to look at transport of this receptor into 
the nucleus upon treatment of 20µM Norgestrel. We found that levels of both monomeric 
and dimerised nuclear PGRMC1 increased fivefold over 60 minutes compared to that of 
control (Figure 4.3.9A) (** p<0.01 monomeric, * p<0.05 dimerised). From this we can 
deduce that Norgestrel is binding to PGRMC1 at the plasma membrane: the receptor-
progestin complex is then internalised and brought to the nucleus to initiate its mechanism 
of action. Although this trend was replicated with PGRMC1’s binding partner PGRMC2 
(Peluso et al., 2014) (Figure 4.3.9B), the translocation was not significant. Therefore, we 
cannot decisively state whether the action of PGRMC1 in the nucleus is PGRMC2-
dependent.  
 
Worthy of note, is that the dimerised form of PGRMC1 was also found in the nucleus of 
Norgestrel-treated 661W cells (Figure 4.3.9A). This is interesting, given that this form of 
PGRMC1 is believed to be sumoylated (Peluso et al., 2012) which is associated with the 
regulation of transcriptional activity (Geiss-Friedlander and Melchior 2007; Petersen et al. 
2013). This hypothesis is in support of our idea that Norgestrel may function through 
PGRMC1 to affect transcriptional activity and thus cellular viability of stressed 
photoreceptor cells. 
 
Norgestrel can rescue 661W cells from serum starved cell death (Figure 3.3.1). Thus, we 
theorised that if Norgestrel was mediating its neuroprotective effects through activation of 
PGRMC1, siRNA knock down of this receptor would abrogate the progesterone-induced 
protection. Indeed, in the absence of PGRMC1 (~50% siRNA knock down, Figure 4.3.11B) 
Norgestrel did not afford the same level of protection as the Norgestrel treated control. 
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This strongly suggests that Norgestrel acts to protect 661W cone photoreceptor cells from 
apoptotic cell death through activation of PGRMC1.  
 
Of particular relevance was the finding that siRNA targeted to PGRMC1 results in a 
significant (** p<0.01) decrease in cellular viability (Figure 4.3.11C). This indicates that the 
membrane complex plays a key role in inhibition of cell death under conditions of stress. 
This is consistent with several recent studies showing decreased viability in cells treated 
with siRNA to PGRMC1 (Peluso et al., 2014) and cells treated with high concentrations of 
PGRMC1-specific inhibitor AG-205 (Qin et al., 2015). Interestingly, studies have shown that 
siRNA knock down of mPRα has no effect on cellular viability (Dressing et al., 2012). This 
further corroborates the particular importance of PGRMC1 in Norgestrel-dependent 
regulation of cellular apoptosis and proliferation, over the mPRs.  
 
Serum starvation of 661W cone photoreceptors induces cell death, in part, through the 
caspase pathway (Gómez-Vicente et al., 2005). Depletion of PGRMC1 increases expression 
of caspases 3, 4 and 8 (Peluso et al., 2012). Therefore, the ability of nuclear PGRMC1 
protein to repress caspase expression could account, to some degree, for its ability to 
mediate the apoptotic pathway. In addition to this, there is a second set of PGRMC1-
dependent genes, regulated by progesterone, that are involved in the suppression of 
apoptosis and mitosis. This finding was verified through bioinformatic analysis which 
revealed that genes involved in apoptosis are highly affected when PGRMC1 levels are 
depleted by targeted siRNA (Peluso et al., 2012). This would thus be consistent with 
PGRMC1’s role in viable cell maintenance (Crudden et al., 2006; Peluso, Liu, et al., 2008) 
and is in agreement with PGRMC1 being central to the anti-apoptotic role of Norgestrel in 
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661W photoreceptor cells. Future work will be aimed at providing further mechanistic 
insight in to the downstream signalling pathways of PGRMC1 following Norgestrel 
administration.  
 
Lastly, with the idea that Norgestrel acts to protect 661W cone photoreceptor cells from 
apoptotic cell death through activation of PGRMC1, we looked to see if this was replicated 
in the retina ex vivo. Administration of 20µM Norgestrel to SNP-stressed retinal explants 
has previously been shown in this work to prevent against SNP-induced apoptosis (Figure 
3.3.10B). Therefore, we hypothesised that if Norgestrel was working through PGRMC1 to 
rescue stressed retinal cells ex vivo, then treatment with the PGRMC1 specific inhibitor 
AG205 (Qin et al., 2015) should abrogate this protection. Preliminary experiments with 
AG205 were carried out in stressed 661W cone photoreceptor cells to determine the 
optimum concentration to be used in explanting, i.e. the highest possible dose that did not 
decrease photoreceptor cell viability (Figure 4.3.12A). Moreover, Norgestrel could not act 
to protect cells from serum starved cell death when treated with AG205 (Figure 4.3.12B). 
This further validated our siRNA findings that specific knock down of PGRMC1 prevented 
the protective effects of Norgestrel in stressed photoreceptor cells (Figure 4.3.11D). 
Stressed retinal explants treated with PGRMC1 inhibitor AG205 alone or in combination 
with 20μM Norgestrel showed similar levels of apoptotic cell death (Figure 4.3.13ii). The 
results of this experiment therefore confirm that PGRMC1 is involved in Norgestrel-
mediated neuroprotection in an ex vivo model of retinal degeneration.  
 
 To conclude, we have shown that although there are several progesterone receptors 
expressed in retinal cells, PGRMC1 is likely to be the critical progesterone receptor involved 
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in the neuroprotective effects of Norgestrel in the eye. Not only is PGRMC1 is expressed 
most abundantly in the photoreceptor cells (Figure 4.3.3), the cell type which ultimately 
undergo apoptosis in retinitis pigmentosa; its expression at the protein level is also up-
regulated in the degenerated rd10 mouse retina (Figure 4.3.2). This suggests a role in 
cellular protection in the rd10 animal. We have clearly shown that PGRMC1 responds to 
Norgestrel treatment through subcellular fractionation studies (Figure 4.3.9A). The 
receptor is shuttled to the nucleus, where it has the ability to modulate cellular 
transcriptional activities. Finally, we have demonstrated that the loss of PGRMC1 abolishes 
the protective effects of Norgestrel to stressed photoreceptor cells (Figure 4.3.11D), whilst 
specific inhibition of PGRMC1 in an ex vivo model of retinal degeneration prevents 
Norgestrel-mediated neuroprotection (Figure 4.3.13ii). A summary of the results presented 
in this chapter is presented in Figure 4.4.1. Taken together, these data validate the 
significance of this receptor in the anti-apoptotic properties of this progestin.   
 
 
Figure 4.4.1. Schematic showing the protective effects of Norgestrel-PGRMC1 binding in photoreceptor 
cells. This schematic details a summary of the results presented in this chapter. 
  
 
 
 
 
Chapter 5. Norgestrel induces a 
protective calcium influx in stressed 
photoreceptor cells through PGRMC1-
induced activation of basic fibroblast 
growth factor 
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5.1. Abstract 
 
So far in this work, we have identified the potential of Norgestrel to work through the 
activation of progesterone receptor membrane component 1 (PGRMC1) activation. In 
addition, we have shown that Norgestrel induces a neuroprotective upregulation of basic 
fibroblast growth factor (bFGF) in stressed photoreceptor cells. Until now however, the link 
between these two signalling events has not been determined. Using trophic factor 
deprivation of 661W photoreceptor-like cells, this work aimed to further elucidate the 
mechanism leading to Norgestrel-induced neuroprotection.  
 
In the present study, we show by flow cytometry and live-cell immunofluorescence that 
Norgestrel induces an increase in cytosolic calcium in both healthy and stressed 661Ws 
over 24h. Specific PGRMC1 inhibition by AG205 showed this rise to be PGRMC1-dependent, 
primarily utilising calcium from extracellular stores. Calcium influx was also shown to be 
bFGF-dependent, for siRNA knock down of bFGF prevented Norgestrel-PGRMC1 induced 
changes in cytosolic calcium. Notably, we demonstrate PGRMC1-activation is necessary for 
Norgestrel-induced bFGF upregulation. We propose that Norgestrel protects through the 
following pathway: binding to and activating PGRMC1 expressed on the surface of 
photoreceptor cells, PGRMC1 activation drives bFGF upregulation and subsequent calcium 
influx. Importantly, raised intracellular calcium is critical to Norgestrel’s protective efficacy, 
for calcium chelation by EGTA abrogates the protective effects of Norgestrel on stressed 
661W cells in vitro.  
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5.2. Introduction 
 
Progesterone signalling improves neuronal survival, reduces swelling, inhibits apoptosis 
and reduces damaging inflammatory processes (Gonzalez Deniselle et al. 2002a; Lu et al. 
2008; Garay et al. 2011; Allen et al. 2015). Some of this signalling has been linked to 
changes in intracellular retinal cytosolic calcium concentrations ([Ca2+]i), both increased 
(Samadi et al. 2002; Koulen et al. 2008) and decreased (Luoma et al., 2012). These 
fluctuations have important functional implications on a number of different pro-survival 
signalling events, for calcium is a multifaceted second messenger. Regulating a number of 
different cellular functions, calcium signalling is required to be highly versatile. In terms of 
timing, calcium can trigger exocytosis of vesicles from synaptic terminals within a number 
of microseconds. However, in order to drive gene transcription and proliferative events, 
calcium requires a longer signalling period: minutes to hours (Berridge et al., 2003). 
Alternately to timing, differing cytosolic calcium concentrations will also differentially affect 
signalling. For example, a paper released in 2004 found that intermediate levels of [Ca2+]i 
(50-200nM in rat hippocampal neurons) induced a long-term tolerance of ischemia, 
promoting calmodulin activation and increasing levels of pro-survival AKT and mitogen-
activated protein kinase (MAPK). Neurons exposed to higher or lower levels of calcium died 
upon glucose and oxygen deprivation (Bickler & Fahlman, 2004). Interestingly, this paper 
also found that the protective, moderate increases in [Ca2+]i increased the tolerance of 
subsequent larger increases in [Ca2+]i, which have previously been shown to induce cell 
death (Sharma and Rohrer 2004; Guerin et al. 2011). 
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One of the major challenges in the field at the moment is understanding how calcium 
signalling mechanisms control so many divergent processes. Dynamic changes in calcium 
concentrations and timing effects play a huge role. Still, these processes require tight 
regulation. In order to do this, cells adjust their [Ca2+]i through a balancing act of ‘on’ and 
‘off’ reactions. These reactions occur through a combination of buffers, pumps and 
exchangers: ‘on’ reactions bring calcium in to the cell whilst ‘off’ reactions remove calcium 
signals (Berridge et al., 2003; Déliot & Constantin, 2015). Accordingly, the activity of 
calcium refers to signalling in a form of peaks and waves, from microseconds to hours and 
even days (Pinto et al., 2016). Steroid binding to cellular receptors causes calcium ion influx 
during the ‘on’ period. These ions bind to various effectors in the cell, stimulating a variety 
of calcium-dependent processes. These events include steroid mediated activation of 
calcium-dependent PKC isoforms (Quest, 1996), modulation of the MAPK ERK-1/2 (Lee et 
al., 2010) and activation of PKA (Sancho-Pelluz et al., 2008), phosphoinositide 3-kinase 
(Revankar et al., 2005) and protein kinase B/AKT (Yu et al., 2004) pathways. 
 
Time/concentration dynamics of calcium allow for heterogeneity in calcium-dependent 
pro-survival systems. However, upstream of these pathways is also an extensive machinery 
driving cytosolic influx. This machinery, comprised of neurotransmitters and their 
receptors, intracellular signalling factors and transcription factors to name a few (Pinto et 
al., 2016), forms a diverse network of interactions. These interactions can then associate 
and drive a variety of different processes. In this study, we look at the potential of 
neuroprotective basic fibroblast growth factor (bFGF) (Désiré et al. 2000; O’Driscoll et al. 
2007; O’Driscoll et al. 2008; Yang et al. 2014) to drive cytosolic calcium influx. bFGF has 
previously been shown to affect [Ca2+]i through calcium channel modulation (Puro and 
Mano 1991; Rosenthal et al. 2005; Zamburlin et al. 2013). For example, bFGF-dependent 
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calcium influx through L- and N-type voltage-dependent calcium channels stimulates 
neurite outgrowth ex vivo (Zamburlin et al., 2013), driving retinal axon extension through 
Ca2+/calmodulin-dependent kinase II (Lom et al., 1998). bFGF induced proliferation is also 
postulated to be calcium dependent (Puro & Mano, 1991). Consequently we hypothesised 
a link between bFGF-dependent neuroprotection and raised cytosolic calcium in stressed 
photoreceptors.  
 
Unfortunately, the mechanisms which link moderate increases in calcium to cell survival 
are incompletely defined. Indeed, of even more uncertainty is the capacity for 
progesterone-induced calcium-dependent cell survival. Therefore, we tested a number of 
hypotheses: firstly, Norgestrel administration affects [Ca2+]i in stressed photoreceptor cells. 
Secondly, this effect is PGRMC1-Norgestrel binding-dependent. Thirdly, Norgestrel acts 
through bFGF to affect [Ca2+]i. And fourthly, an altered cytosolic calcium concentration is 
necessary for Norgestrel-induced cell survival. Through this work, we hope to further 
elucidate the pro-survival pathway involved in Norgestrel’s neuroprotective capabilities. 
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5.3. Results 
 
5.3.1. Norgestrel induces an increase in intracellular Ca2+ levels in 
healthy 661W photoreceptor-like cells over 3 hours 
Changes in [Ca2+]i mediate many critical signalling processes in neurons (Berridge 1997; 
Koulen and Thrower 2001). Whilst some signalling is regulated by rapid and transient 
calcium increases, others are designed to produce longer-lasting global elevations of 
calcium (Berridge and Dupont 1994; Lopez et al. 2012). Knowing this, we wished to 
determine if changes in [Ca2+]i occurred in photoreceptors in response to Norgestrel. 
Healthy 661W photoreceptor-like cells were treated with 20μM Norgestrel or equivalent 
DMSO control (control) over 3 and 24 hours. A healthy cell population was gated (Figure 
5.3.1i) and an increase in intracellular calcium was detected using the specific intracellular 
calcium probe Fluo-4 AM. Norgestrel significantly increased [Ca2+]i levels in healthy 661W 
cells over 3 hours but these changes were back down to control levels after 24 hours 
(Figure 5.3.1iii). All treatments are graphed compared to untreated control (Figure 5.3.1iii; 
unpaired t-test comparing Norgestrel treatments to timed DMSO control).  
Figure 5.3.1. Norgestrel induces changes in intracellular calcium levels in healthy cells over 3 hours. Calcium 
specific indicator, Fluo-4 AM was used to detect changes in intracellular calcium. (i) Healthy 661W cells were gated 
and treated with 20μM Norgestrel or equivalent DMSO control over 3 and 24 h. (ii) Fluo-4 AM fluorescence was 
measured using flow cytometry and plotted on a histogram. Y-axis represents cell counts, x-axis measures the level 
of fluorescence. A shift to the right along the x-axis represents an increase in Fluo-4 AM fluorescence and hence 
intracellular calcium level. Histograms show untreated cells (grey) compared to a timed DMSO control (black) or 
Norgestrel-treated cells (blue). (iii) Relative geomean of all treatments was determined and graphed compared to 
untreated cells (t-test comparing individual Norgestrel treatments to their timed DMSO control, ****p<0.001). 
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5.3.2. Serum withdrawal induces an increase in intracellular Ca2+ levels 
in 661W photoreceptor-like cells 
Previous studies detailed in this thesis have shown that the protective effects of Norgestrel 
on photoreceptor cells is dependent upon cellular stress. Deprivation of trophic factor 
support has been shown both by our group and throughout this thesis, to be a suitable in 
vitro model by which to study photoreceptor cells in the diseased state (Gómez-Vicente et 
al., 2005). Interestingly, serum starvation induces a morphological change in 661W cells in 
vitro (Figure 5.3.2). After just 30 minutes the extended processes normally apparently in 
these cells withdraw. Processes in these cells stick to tissue culture plastic through a series 
of Ca2+ and Mg2+ bonds. Serum starvation induces a change in the ion composition of the 
media, thus this is likely what causes the cellular morphological change. This amoeboid 
morphology persists for approximately one hour before the cells appear to begin to adjust 
and settle again (Figure 5.3.2. 2h panel).   
Figure 5.3.2. Live, representative confocal microscopic images of the changes in 661W 
cell morphology following serum starvation for the indicated times. Serum starvation of 
causes an initial retraction of cellular processes. Cells begin to settle again, extending 
spindle like processes out after 2h serum starvation. Samples prepared by Alice Wyse 
Jackson. Confocal microscopic images generated by Dr Sarah Roche. 
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661W cells were subsequently serum starved and the resulting changes in [Ca2+]i measured 
using the specific intracellular calcium probe, Fluo-4 AM. Serum starvation alone 
significantly increased [Ca2+]i in 661W cells three-fold over one hour compared to untreated 
control (Figure 5.3.3). This increase was maintained over three hours, but returned to 
normal, untreated levels after 24 hours of serum deprivation. All treatments are graphed 
compared to untreated control.  
 
Live imaging of intracellular calcium using the intracellular calcium probe, Fluo-4 AM in 
serum starved 661W cells corroborates this morphological change and supports the FACs 
quantification of intracellular calcium increases following serum starvation (Figure 5.3.4) – 
the changes in intracellular calcium are evident over 3 hours but are back down after 24 
hours.  
Figure 5.3.3. Serum starvation triggers cytosolic calcium influx in 661W cone photoreceptors cells over three 
hours. (i) 661W cells were serum starved over 24h and Fluo-4 AM fluorescence was measured using flow 
cytometry and plotted on a histogram. Y-axis represents cell counts, x-axis measures the level of fluorescence. A 
shift to the right along the x-axis represents an increase in Fluo-4 AM fluorescence and hence intracellular calcium 
level. All histograms show untreated control (grey line) compared to a timed serum starved sample (black line). (ii) 
Geometric mean of the histogram curve was quantified. Bar chart showing the effect of serum starvation on 
intracellular calcium (ANOVA followed by Dunnett’s multiple comparisons test, ***p<0.005, ****p<0.001). Figures 
are representative of three independent experiments, repeated in triplicate. All results are presented as mean ± 
SEM. Asterisks indicate significant difference. 
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5.3.3. Norgestrel sustains an increase in intracellular Ca2+ levels over 24 
hours 
Progesterone signalling has been demonstrated to induce increases in cytosolic calcium 
(Samadi et al. 2002; Koulen et al. 2008). Therefore, further to the finding that serum 
Figure 5.3.4. Changes in intracellular calcium induced by serum starvation are evident through live cell 
immunofluorescence by intracellular calcium probe, Fluo-4 AM. Live imaging of intracellular calcium (Fluo-4 
AM; green) in serum starved 661W cells compared to untreated control. Scale bars 30µm. Samples prepared by 
Alice Wyse Jackson. Confocal microscopic images generated by Dr Sarah Roche 
Figure 5.3.5. Norgestrel causes an increase in cytosolic calcium in stressed 661W cells over 24 hours. (i) 
661W cells were serum starved over 24h and treated in the absence or presence of 20μM Norgestrel. An 
increase in intracellular calcium levels in response to Norgestrel was verified by flow cytometry using 
calcium specific indicator, Fluo-4 AM. Results were plotted on a histogram: Y-axis represents cell counts, x-
axis measures the level of fluorescence. A shift to the right along the x-axis represents an increase in Fluo-4 
AM fluorescence and hence intracellular calcium level. (ii) Geometric mean of the histogram curves was 
quantified and each Norgestrel-treated sample was normalised to the equivalent serum starved DMSO 
control (t-test, *p<0.05, ****p<0.001). Results are presented as mean ± SEM. Asterisks indicate significant 
difference. Figures are representative of three independent experiments, repeated in triplicate. 
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deprivation drives an increase in [Ca2+]i; we sought to determine if administration of the 
neuroprotective synthetic progestin Norgestrel affected this signalling. 661W cells were 
stressed by serum starvation and treated with 20μM Norgestrel or the equivalent DMSO 
control for the indicated time periods. Norgestrel significantly induced a further increase in 
[Ca2+]i over 24 hours compared to timed DMSO control (Figure 5.3.5). These changes were 
again evident through live cell immunofluorescence (Figure 5.3.6).   
 
5.3.4. Inhibition of progesterone receptor membrane complex 1 
signalling abrogates Norgestrel-induced increases in intracellular Ca2+ 
Whilst all known progesterone receptors are present in the retina, we have previously 
shown that Norgestrel signals predominantly through PGRMC1 (Chapter 4). Therefore, we 
hypothesised that the increase in [Ca2+]i in Norgestrel-treated stressed 661W cells was due 
to signalling downstream of Norgestrel-PGRMC1. AG205 is a potent and specific inhibitor of 
PGRMC1 activity. Altering the spectroscopic properties of the PGRMC1–heme complex, it 
has also been shown to inhibit cell cycle progression (Ahmed et al., 2010), likely affecting 
[Ca2+]i. Consequently, we trialled a number of different concentrations (1μM - 10μM) in 
Figure 5.3.6. Changes in intracellular calcium following Norgestrel treatment are apparent in live imaging of 
cells. Intracellular calcium was measured using Fluo-4 AM probe (green) in serum starved 661W cells treated 
with 20µM Norgestrel over the indicated time periods. Scale bars 30µm. Samples prepared by Alice Wyse 
Jackson. Confocal microscopic images generated by Dr Sarah Roche. 
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serum starved 661W cells to ensure [Ca2+]i was not affected by the dose of AG205 used 
(Figure 5.3.7A). These concentrations have been previously shown in this thesis to have no 
effect on 661W cell viability (Figure 4.3.12). Analysis by flow cytometry showed that 
addition of 1μM AG205 to stressed 661W cells showed comparable levels of [Ca2+]i 
compared to serum starved control (Figure 5.3.7A). This dose was also still able to 
effectively attenuate the protective effects of Norgestrel on stressed 661W cells, as 
measured by the MTS cell viability assay (Figure 5.3.7B). Thus the 1μM dose was taken 
forward to determine whether PGRMC1 was responsible for Norgestrel-induced increases 
in [Ca2+]i in stressed 661W cells.  
661W cells were serum starved and cultured in the absence and presence of 1μM AG205. 
After 10 minutes, 20μM Norgestrel or equivalent DMSO control was added directly to the 
flasks and incubated for the times indicated. Stressed cells pre-treated with 1μM AG205 do 
not exhibit any significant increase in [Ca2+]i in response to 20μM Norgestrel over any time 
point up to three hours (Figure 5.3.8).  
 
Figure 5.3.7. PGRMC1 inhibitor AG205 attenuates the protective effects of Norgestrel. (A) PGRMC1 specific 
inhibitor AG205 causes a dose dependent increase in intracellular calcium in stressed 661W cells, as measured by 
flow cytometry using calcium specific indicator, Fluo-4 AM. (B) 661W cells were serum starved over 24h and 
treated with 20μM Norgestrel or equivalent DMSO control in the absence or presence of 1μM AG205. Percentage 
cell death was assayed (n=4). AG205 attenuates Norgestrel-induced cell survival (ANOVA followed by Tukey’s 
multiple comparisons test, ****p<0.001). Results are presented as mean ± SEM. Figures are representative of 
three independent experiments, repeated in triplicate. 
117 
 
 
5.3.5. Norgestrel signals through PGRMC1 to induce an upregulation of 
basic fibroblast growth factor 
Previous studies identified bFGF signalling with sequential downstream targets of protein 
kinase A and glycogen synthase kinase 3β, as the major pro-survival pathway responsible 
for Norgestrel’s neuroprotective efficacy in stressed photoreceptor cells. Since we know 
Norgestrel signals primarily through PGRMC1, we sought to determine if Norgestrel-
PGRMC1 signalling was responsible for Norgestrel-induced increases in bFGF. 661W cells 
were serum starved and cultured in the absence and presence of 1μM PGRMC1 inhibitor 
AG205 for 10 minutes. After this pre-treatment, 20μM Norgestrel or equivalent DMSO 
control was added and cells were incubated for a further hour. Analysis by RT-qPCR showed 
that the Norgestrel-induced increase in bFGF mRNA in serum starved 661W cells, is 
Figure 5.3.8. Norgestrel acts through PGRMC1 to induce an increase in cytosolic calcium. (i) 661W cells were 
serum starved over 3h and treated with 20μM Norgestrel and/or 1μM AG205. AG205 treatment prevented the 
Norgestrel-induced increase in intracellular calcium levels as determined by flow cytometry using calcium specific 
indicator, Fluo-4 AM. Results were plotted on a histogram: Y-axis represents cell counts, x-axis measures the level 
of fluorescence. A shift to the right along the x-axis represents an increase in Fluo-4 AM fluorescence and hence 
intracellular calcium level. (ii) Geometric mean of the histogram curves was quantified and each Norgestrel 
and/or AG205-treated sample was normalised to the equivalent serum starved DMSO control (t-test, 
****p<0.001). Results are presented as mean ± SEM. Asterisks indicate significant difference. Figures are 
representative of three independent experiments, repeated in triplicate. 
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abrogated by pre-treatment with AG205 (Figure 5.3.9). From this, we suggest that 
Norgestrel-PGRMC1 signalling is responsible for the protective upregulation of bFGF.  
 
 
5.3.6. Norgestrel-induced increases in basic fibroblast growth factor 
drive subsequent increases in intracellular calcium 
bFGF signalling has previously been shown to directly modulate calcium activity in the 
retina (Lom et al. 1998; Niu et al. 2004). Therefore, we sought to investigate the potential 
role that bFGF plays in Norgestrel-induced changes in [Ca2+]i. 661W cells were treated with 
siRNA against bFGF over 48 hours and a significant decrease in bFGF expression (~75%) was 
verified through RT-qPCR and immunofluorescence (Figure 5.3.10A). siRNA-treated 
stressed cells were then treated with 20μM Norgestrel or equivalent DMSO control for one 
hour and changes in [Ca2+]i analysed using Fluo-4 AM. Stressed cells treated with siRNA 
against bFGF did not demonstrate the same Norgestrel-induced increase in [Ca2+]i seen in 
the non-targeting scrambled control (Figure 5.3.10B).  
Figure 5.3.9. Norgestrel activates 
PGRMC1 to induce an upregulation 
of bFGF. 661W cells were serum 
starved for 1h and treated with 20μM 
Norgestrel and/or 1μM PGRMC1 
specific inhibitor, AG205. RT-qPCR 
analysis detected a significant 
increase in bFGF mRNA levels over 1h 
in response to Norgestrel, relative to 
timed DMSO control. This increase 
was abrogated through treatment 
with 1μM AG205 (ANOVA followed 
by Tukey’s multiple comparisons test, 
ns=no significance, *p<0.05, 
****p<0.001). Results are presented 
as mean ± SEM. Asterisks indicate 
significant difference. Figure is 
representative of three independent 
experiments, repeated in triplicate. 
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Figure 5.3.10. Norgestrel-induced upregulation of bFGF drives a subsequent 
calcium influx. (A, B) 661W cells were transfected with siRNA against bFGF or 
non-targeting scrambled control (Scrambled). (A) Detection of bFGF mRNA levels 
by RT-qPCR and immunofluorescence. Scale bars 30μm. (B) Transfected cells were 
serum starved for 1h in the presence of 20μM Norgestrel or equivalent DMSO 
control and intracellular calcium levels were measured as determined by flow 
cytometry using calcium specific indicator, Fluo-4 AM. (B) (i) Results were plotted 
on a histogram: Y-axis represents cell counts, x-axis measures the level of 
fluorescence. A shift to the right along the x-axis represents an increase in Fluo-4 
AM fluorescence and hence intracellular calcium level. (B) (ii) Geometric mean of 
the histogram curves was quantified and each Norgestrel and/or AG205-treated 
sample was normalised to the equivalent serum starved DMSO control (t-test, 
ns=no significance, ****p<0.001). Results are presented as mean ± SEM. 
Asterisks indicate significant difference. Figures are representative of three 
independent experiments, repeated in triplicate 
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5.3.7. Norgestrel induces an increase in intracellular calcium, 
predominantly from extracellular stores 
Progesterone has previously been shown to evoke calcium signalling in retinal cells due to 
an activation of intracellular stores (Sharma & Rohrer, 2004) and also entry of extracellular 
calcium into the cell (Samadi et al., 2002; Swiatek-De Lange et al., 2007). However, the 
source of [Ca2+]i in stressed 661W cells in response to Norgestrel is unknown. To evaluate 
this, the effect of both of IP3/ryanodine receptor antagonists (dantrolene) and an 
extracellular calcium chelator (EGTA) (Healy et al., 2013) on Norgestrel-induced [Ca2+]i 
elevations were examined. 661W cells were serum starved and pre-treated for ten minutes 
with 0.5mM EGTA or 1μM dantrolene. After this incubation period, cells were directly 
stimulated with 20μM Norgestrel or equivalent DMSO control for one hour before analysis 
by flow cytometry (Figure 5.3.11).  
Figure 5.3.11. Norgestrel-induced increases in intracellular calcium come predominantly from 
extracellular stores. 661W cells were serum starved for 1h and treated with 0.5mM EGTA (extracellular 
calcium chelator) and/or 1μM dantrolene (antagonist of IP3/ryanodine receptors) in presence or absence 
of 20μM Norgestrel. Intracellular calcium levels were measured as determined by flow cytometry using 
calcium specific indicator, Fluo-4 AM. (i) Results were plotted on a histogram: Y-axis represents cell counts, 
x-axis measures the level of fluorescence. A shift to the right along the x-axis represents an increase in 
Fluo-4 AM fluorescence and hence intracellular calcium level. (ii) Geometric mean of the histogram curves 
was quantified and each sample was normalised to the 1h serum starved DMSO control (t-test, 
***p<0.005, ****p<0.001). Results are presented as mean ± SEM. Asterisks indicate significant difference. 
All figures are representative of three independent experiments, repeated in triplicate. 
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Cells pre-treated with 0.5mM EGTA did not show complete abrogation of Norgestrel-
induced [Ca2+]i increase. Despite this, there was still a significantly diminished response to 
Norgestrel and [Ca2+]i increase was comparable to the levels of serum starved control 
(Figure 5.3.11). Alternately, cells pre-treated with 1μM dantrolene did not show any 
difference in [Ca2+]i compared to non-pre-treated Norgestrel control. This intimates that 
the rise in [Ca2+]i in stressed 661W cells in response to Norgestrel is not due to cytosolic 
influx from intracellular stores. A double control whereby both extracellular calcium was 
chelated and intracellular IP3/ryanodine receptors were antagonised was carried out to 
account for compensation between these stores. Stressed cells pre-treated with both 
0.5mM EGTA and 1μM dantrolene showed only a slight increase in [Ca2+]i, compared to 
control. Taken together, these data suggest that Norgestrel-evoked calcium signalling 
utilises calcium predominantly from an extracellular source.  
 
5.3.8. The protection afforded to Norgestrel-treated stressed 661W cells 
is abrogated through specific extracellular calcium chelation by EGTA 
Norgestrel significantly inhibits 661W cells from serum starved cell death over 24 hours, as 
measured by the MTS cell viability assay (Figure 5.3.12A). Having established that 
administration of Norgestrel causes an upregulation of [Ca2+]i over 24 hours (Figure 5.3.5) 
and that this increase is coming predominantly from extracellular stores (Figure 5.3.11), we 
then sought to determine whether [Ca2+]i is required for the neuroprotective effects 
afforded by Norgestrel. Serum starved 661W cells were cultured with EGTA (0.5mM) and 
simultaneously treated with either DMSO or 20μM Norgestrel over 24 hours. No change in 
viability of these cells was determined compared to the relevant serum starved DMSO 
control (Figure 5.3.12A), thus EGTA abrogated Norgestrel’s neuroprotective effects on 
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stressed 661W cells. Serum starved 661W cells cultured with EGTA and treated in the 
absence or presence of 20µM Norgestrel or equivalent DMSO control, were subsequently 
analysed by western blotting. Changes in levels of phosphorylated GSK3β on serine 9 (S9) 
and total GSK3β were measured. No discernible change in the phosphorylation state of 
GSK3β was evident in EGTA 
cultured cells following Norgestrel 
treatment, either by western 
blotting (Figure 5.3.12Bi) or by 
subsequent densiometric 
quantification (Figure 5.3.12Bii).  
 
  
Figure 5.3.12. Extracellular calcium influx 
is necessary for Norgestrel-induced 
neuroprotection. 661W cells were serum 
starved for 24h and treated with 20μM 
Norgestrel or equivalent DMSO control in 
the absence or presence of 0.5mM EGTA. 
(A) Percentage cell death was assayed 
(n=4). EGTA attenuates Norgestrel-
induced cell survival. (B) Western blotting 
revealed no significant difference in 
phosphorylation of GSK3β post EGTA 
treatment. (ii) Densiometric analysis of 
results presented in (i).  (ANOVA followed 
by Dunnett’s multiple comparisons test, 
ns=no significance, *p<0.05, **p<0.01, 
***p<0.005, ****p<0.001). Results are 
presented as mean ± SEM. Asterisks 
indicate significant difference. All figures 
are representative of three independent 
experiments, repeated in triplicate.  
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5.4. Discussion 
 
In this study, we show that Norgestrel significantly increases intracellular calcium in 
photoreceptor-like cells following trophic factor deprivation (Figure 5.3.5, 5.3.6). It is often 
stated that sustained increases in intracellular calcium following neurological insult is 
responsible for neuronal cell death (Frasson et al. 1999; Sharma and Rohrer 2004; 
Rodríguez-Muela et al. 2014). However, this general assumption is hugely oversimplified. 
This is because the susceptibility of cells to calcium-induced neurotoxicity depends on a 
number of different factors (Friedman, 2006), for example the time span of calcium 
signalling vs. the concentration of intracellular cytosolic calcium (Berridge et al., 2003). 
Indeed, evidence is now mounting to suggest a neuroprotective role of calcium in activating 
downstream pro-survival signalling (Bickler and Fahlman 2004; Swiatek-De Lange et al. 
2007) and in regulation of cell cycle, proliferation, apoptosis, gene transcription, and cell 
migration (Berridge et al., 2003; Déliot & Constantin, 2015). 
 
Progesterone signalling has previously been shown to affect retinal cytosolic calcium 
concentrations. With such a variety of potential signalling capabilities however, the role 
that progesterone-induced calcium signalling plays in retinal neuroprotection is still unclear 
(Samadi et al. 2002; Luoma et al. 2012; Koulen et al. 2008). Despite this, progesterone, 
through modulation of calcium influx, has been shown to prevent osmotic swelling of 
retinal glial cells; a common feature of retinal oedema. Progesterone activates voltage 
gated calcium channels, causing [Ca2+]i levels to rise. This initiates the glutamatergic-
purinergic signalling cascade and consequently inhibits retinal glial cell swelling (Neumann 
et al., 2010). Retinal progesterone-induced calcium signalling, is further corroborated in the 
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retina in a study showing that progesterone-PGRMC1 binding induces calcium influx in to 
Müller glial cells (Swiatek-De Lange et al., 2007).  
 
Since evidence presented in the literature showed that progesterone can drive a protective 
retinal calcium influx, we investigated if Norgestrel-PGRMC1 binding, already shown to be 
crucial in Norgestrel-induced neuroprotection; was responsible for the Norgestrel-induced 
increase in [Ca2+]i. siRNA abrogation of PGRMC1 has a significant detrimental effect on 
661W cellular viability and thus PGRMC1 specific inhibitor AG205 was instead employed to 
block the effects of PGRMC1 in 661W cells. 1μM AG205 had no significant effect on 
cytosolic calcium levels (Figure 5.3.7A) but still prevented Norgestrel from protecting 
stressed cells in vitro (Figure 5.3.7B). Thus, using this AG205 pre-treatment, we found that 
Norgestrel-PGRMC1 binding was responsible for Norgestrel-induced [Ca2+]i increases in 
stressed 661W cells (Figure 5.3.8).  
 
In previous chapters, the actions of Norgestrel have been shown to act critically, through 
both PGRMC1 activation and bFGF upregulation, for knock down and inhibition of either 
PGRMC1 or bFGF, will prevent the protective actions of Norgestrel both in vitro and ex vivo. 
The link between these events however, has not yet been elucidated. In this work, we show 
in 661W cells that PGRMC1 activation by Norgestrel drives an influx and sequential rise in 
[Ca2+]i (Figure 5.3.8). Previous research showed the potential of bFGF to modulate calcium 
channels, consequently affecting [Ca2+]i (Puro and Mano 1991; Rosenthal et al. 2005; 
Zamburlin et al. 2013). Thus we proposed the following pathway of Norgestrel-induced 
neuroprotection: Norgestrel activates PGRMC1 expressed on the surface of photoreceptor 
cells. This activation drives the upregulation of bFGF which will subsequently affect [Ca2+]i. 
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In order to verify this hypothesis, stressed 661W cells treated with Norgestrel and/or 
PGRMC1 inhibitor AG205, were examined for bFGF upregulation. As in previous work, 
Norgestrel induced an increase in bFGF mRNA in stressed 661W cells over one hour (Figure 
5.3.9). Cells pre-treated with AG205 however did not exhibit this same increase in bFGF 
mRNA (Figure 5.3.9). Therefore, we conclude that activation of PGRMC1 is necessary for 
the Norgestrel-induced upregulation of neuroprotective bFGF (Désiré et al. 2000; O’Driscoll 
et al. 2007; O’Driscoll et al. 2008; Yang et al. 2014). Moreover, we found that when the 
actions of bFGF are attenuated by siRNA (~75% siRNA knock down, Figure 5.3.10A), 
Norgestrel can no longer stimulate an increase in [Ca2+]i (Figure 5.3.10B). These data 
suggest that Norgestrel-PGRMC1 binding leads to bFGF upregulation with a successive 
influx of cytosolic calcium.  
 
Cytosolic calcium levels can be raised through calcium release from both intracellular and 
extracellular stores. These sources differ in their release mechanisms. Extracellular calcium 
influxes through activation of plasma membrane calcium channels. These include both 
voltage-gated and non-voltage gated channels, though calcium entry in excitable cells such 
as photoreceptors occurs mostly though voltage-gated channels (Berridge et al. 2003; 
Déliot and Constantin 2015). Alternately, intracellular calcium is released in to the cytosol 
through ligand gated receptor-operated calcium channels, the most recognised being the 
inositol triphosphate (IP3) and ryanodine receptors found on the endoplasmic and 
sarcoplasmic reticulum (Bennett et al. 1996; Wójcik-piotrowicz et al. 2016). Release of 
calcium from either extra- or intracellular stores will lead to differential activation of 
cellular mechanisms, for many cellular activities are preferentially activated by different 
[Ca2+]i (Berridge et al. 2003; Wójcik-piotrowicz et al. 2016). For example, internal stores 
hold a large but finite amount of calcium and thus will activate processes that do not 
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require sustained influxes of calcium from extracellular sources (Berridge and Dupont 1994; 
Bootman and Berridge 1995; Berridge 1997). For this reason, the source of calcium 
released in stressed 661W cells in response to Norgestrel administration was of interest.  
 
Using the IP3/ryanodine receptor antagonist dantrolene and extracellular calcium chelators 
EGTA (Healy et al., 2013) both individually and in combination, we found that the source of 
calcium released in stressed 661W cells in response to Norgestrel administration was 
primarily from extracellular sources (Figure 5.3.11). We conclude this for when calcium was 
chelated using EGTA, cells did not respond as readily to Norgestrel as in the stressed 
control and indeed [Ca2+]i was only brought back to the levels of stressed 661W cells. This is 
interesting however, for when extracellular sources are blocked, there appears to be some 
compensation from intracellular stores. Using dantrolene and EGTA in combination, 
Norgestrel could not stimulate as large an increase in [Ca2+]i as when EGTA was used alone 
(Figure 5.3.11B). Finally, having found that bFGF was responsible for the increase in [Ca2+]i 
(Figure 5.3.10), we looked to see if this sequential calcium cascade was necessary for 
Norgestrel-induced 661W cell survival. When 661W cells are serum starved and treated 
with Norgestrel, cell viability is significantly rescued (Figure 5.3.12). Serum starved cells 
pre-treated with a concentration of EGTA that does not affect cell viability (0.5M) however, 
did not display an increase in cell viability when treated with Norgestrel. From this, we can 
conclude that a bFGF-mediated increase in [Ca2+]i is necessary in Norgestrel’s protective 
effects on stressed 661W cells.  
 
Calcium is becoming more prevalent in the literature as a pro-survival signalling molecule, 
affecting both cellular proliferative and apoptotic processes (Berridge et al. 2003; Bickler 
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and Fahlman 2004; Swiatek-De Lange et al. 2007; Déliot and Constantin 2015). One 
potential mechanism by which calcium signalling may be neuroprotective in this system is 
by the calcium-dependent activation of adenylate cyclase (AC). AC, once activated, can 
produce cAMP to mediate PKA activation (Sancho-Pelluz et al., 2008), previously shown to 
be critical in the neuroprotective actions of Norgestrel on stressed photoreceptor cells 
(Chapter 3). Active PKA can then phosphorylate and activate cAMP response element 
binding protein (CREB), a transcription factor crucial for neuronal survival (Finkbeiner 2000; 
Mantamadiotis et al. 2002). Since bFGF, driven up by Norgestrel (Figure 5.3.9), can 
promote the phosphorylation of CREB via PKA (O’Driscoll et al., 2007), we hypothesise that 
Norgestrel signals through the calcium dependent, cAMP-AC-PKA pathway to protect 
stressed photoreceptors. Further research will have to be carried out to substantiate this 
claim however.  
 
Figure 5.4.1. Schematic representation of the intracellular signalling events regulated by the synthetic 
progesterone Norgestrel. The diagram illustrates only the pathways reported in this study to be affected by 
Norgestrel signalling. We propose that it is this pathway through which Norgestrel exerts its neuroprotective effects 
in photoreceptor cells in vitro. 
128 
 
Through this study, we have further elucidated the potential of Norgestrel to up-regulate 
pro-survival signalling activities in stressed photoreceptor cells through PGRMC1 receptor 
binding. A schematic overview of the results of this study is presented in Figure 5.4.1. We 
reveal a novel role for PGRMC1 activation in the upregulation of bFGF, a growth factor 
shown previously to be crucial to Norgestrel’s neuroprotective capabilities. In addition to 
this, we show through specific siRNA knock down, that bFGF is responsible for the 
Norgestrel-induced increase in cytosolic calcium, in stressed 661W cells. Hypothesised to 
influx primarily from extracellular stores, we believe this increase in cytosolic calcium to be 
essential in regulating Norgestrel’s pro-survival capacity, for calcium chelation by EGTA 
abrogates the protective properties of Norgestrel on stressed 661W cells in vitro. 
  
  
 
 
 
 
Chapter 6. Norgestrel attenuates 
microglial-driven retinal degeneration 
and stimulates protective fractalkine-
CX3CR1 signalling in the rd10 mouse 
model of retinitis pigmentosa 
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6.1. Abstract 
 
Norgestrel provides significant protection to stressed photoreceptor cells. The retina 
however is a complex tissue with many different cell types. This study consequently aimed 
to see how Norgestrel’s effects on photoreceptors affect their interactions with other 
retinal cells. Specifically, we look to Norgestrel’s actions on microglia; for microglial-derived 
inflammation has been shown to potentiate retinal degeneration. 
 
Nursing rd10 mothers were put on a Norgestrel supplemented diet (80mg/kg) when pups 
were aged P10 and upon weaning, pups remained on Norgestrel-supplemented diet. 
Retinal tissue was harvested from P15-P50. Norgestrel-treated rd10 mice showed a 
significant delay in disease progression up to P40. In this study, we delineate the potential 
of Norgestrel to act directly on microglia to reduce pro-inflammatory microglial activation. 
Observed at a time of significant photoreceptor protection, this implicates changes in 
microglial-response in Norgestrel-induced neuroprotection. Utilising primary cultures of 
P16 rd10 microglia and 661W photoreceptor-like cells, we show for the first time that 
Norgestrel directly down-regulates pro-inflammatory microglial activation, thereby 
reducing microglial-driven 661W cell death.  
 
Photoreceptors communicate with microglia through a variety of cellular messengers. 
Expressed by damaged cells, chemokine and damage associated molecular pattern (DAMP) 
release stimulates pro-inflammatory and migratory microglial responses. Norgestrel 
effectively suppresses chemokine (MIP1α, MIP1β, MCP1, MCP3) and DAMP (HMGB1, IL-1α) 
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expression, repealing microglia and preventing pro-inflammatory IL-1β and TNFα release. 
Remarkably, Norgestrel up-regulates fractalkine-CX3CR1 signalling 1,000-fold at the RNA 
level, in the rd10 mouse. Fractalkine-CX3CR1 signalling has been shown to protect neurons 
by regulating retinal microglial activation and migration. Ultimately, these results present 
Norgestrel as a promising treatment for RP, with dual actions as a neuroprotective and 
anti-inflammatory agent in the retina. 
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6.2. Introduction 
 
Throughout the course of this thesis, we have identified the capability of Norgestrel to 
directly work to protect photoreceptor cells through PGRMC1 activation (Chapter 4) with 
subsequent actions of bFGF (Chapter 3) and calcium signalling (Chapter 5). We are now 
beginning to understand more about the molecular mechanism driving this protection, 
however what has yet to be studied in detail is the effect that Norgestrel has on other cell 
types in the retina. Particularly, we still do not know if Norgestrel can work on the resident 
retinal macrophages, the microglia. Macrophages are essential in the clearance of cell 
debris, maintaining homestasis and facilitating tissue repair following injury in the CNS 
(Hanisch & Kettenman, 2007; Napoli & Neumann, 2009; Neumann, Kotter & Franklin 2009). 
However, macrophages have also been implicated in the pathology of many 
neurodegenerative diseases of the central nervous system, in which neuroinflammation is 
considered to be a hallmark (Amor et al., 2010). Previous studies have highlighted a 
detrimental role for microglia as drivers of retinal cell degeneration (Zhao et al., 2015, Peng 
et al., 2014, Yoshida 2013, Zeng et al., 2014). In mouse models of RP, studies have shown 
that when microglial cells are either genetically ablated (Zhao et al., 2015), their phagocytic 
ability inhibited (Zhao et al., 2015) or their pro-inflammatory activities dampened by anti-
inflammatory drug administration (Peng et al., 2014; Scholz et al., 2015), RP disease 
progression is mitigated.  
 
The aim of this study therefore, was to further our understanding of how Norgestrel works 
to provide neuroprotection in a mouse model of RP, the rd10 mouse, with particular 
interest being given to the response of retinal microglia to Norgestrel, if any. We knew that 
132 
 
the high IP dose of Norgestrel (100mg/kg) was protective to the diseased rd10 mouse 
(Doonan et al., 2011). However in this study we wished to trial a less invasive technique. A 
Norgestrel-supplemented diet was developed by Testdiet (Middlesex, UK) and dams of 
rd10 pups were given the Norgestrel-supplemented diet ad libitum when the pups reached 
P10. This allowed the pups to receive Norgestrel in the milk. This technique has previously 
been proven effective in protection of the neonatal brain against a hypoxic-ischemic insult 
(Loren et al., 2005). In this study, mouse dams were provided ad libitum access to drinking 
water with pomegranate juice during the last third of pregnancy and throughout the 
duration of litter suckling. At postnatal day 7, pups were exposed to a brain trauma and 
histological assessment was carried out after 1 week. Dietary supplementation with 
pomegranate juice resulted in markedly decreased brain tissue loss (>60%) and thus we 
concluded that a Norgestrel maternal dietary supplementation would likely be 
neuroprotective to the degenerating retina.  
 
Using the Norgestrel-supplemented diet, we examined interactions between rd10 retinal 
microglia and photoreceptors in vivo.  Photoreceptors communicate with microglia through 
a variety of cellular messages. Expressed by damaged cells, chemokine and damage 
associated molecular pattern (DAMP) release activates pro-inflammatory and migratory 
microglial responses. In this study, we therefore looked to see the potential of Norgestrel 
to suppress rd10 retinal chemokine (MIP1α, MIP1β, MCP1, MCP3) and DAMP (HMGB1, IL-
1α) release, with consequential actions on pro-inflammatory release of IL-1β and TNFα, 
likely from microglia.  
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We also aimed to determine if Norgestrel had any effect on the release of neuroprotective 
fractalkine in the diseased rd10 retina. Fractalkine is a chemokine that signals specifically to 
the CX3CR1 receptor, known to be present on microglial cells. Unlike most other 
chemokines, fractalkine has two distinct roles: 1. As a transmembrane adhesion protein 
and 2. as a chemoattractant for CX3CR1-expressing target cells (Stievano et al., 2004). 
Mouse fractalkine cDNA encodes a 395 amino acid chain that includes a signal sequence, a 
chemokine domain, a mucin stalk region, a transmembrane segment and a cytoplasmic tail 
(Harrison et al., 2001; Mizoue et al., 2001). Produced as a cell surface protein, in its full 
length form fractalkine protein has a molecular weight of approximately 95 - 100kDa, but 
cleavage can be induced by ADAM 10 and ADAM17 to generate the chemotactic 60 – 
80kDa soluble form (Tsou et al., 2001; Hundhausen et al., 2007). Through regulation of this 
signalling, photoreceptors can dampen pro-inflammatory and migratory microglial 
responses which therefore makes the fractalkine-CX3CR1 pathway an ideal neuroprotective 
signalling pathway to target in preventing microglia-induced retinal degeneration.  
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6.3. Results 
 
6.3.1. Norgestrel-supplemented diet from P10 results in significant 
protection of photoreceptors and outer segments in the rd10 mouse 
Norgestrel has been shown to provide significant neuroprotection to the rd10 retina when 
administered by intra-peritoneal injection (Doonan et al., 2011). In this study however, we 
sought to evaluate the protection offered when using the less invasive method of diet-
supplementation. 
Figure 6.3.1. Norgestrel-supplemented diet significantly protects against photoreceptor cell death out to P40 in 
the rd10 retina. (A) Apoptosis of retinal cells was detected by terminal dUTP nick end-labeling (TUNEL) of DNA 
strand breaks in cell nuclei. Norgestrel treatment (NORG diet) decreased TUNEL-positive staining in the central 
postnatal day (P) 15 and P20 retina compared to control mice (Control diet). TUNEL N=3, n=4. Hoechst (blue) 
staining reveals the cell layers in the retina. Scale bar 50µm. (B) Quantification of outer nuclear layer (ONL) thickness 
in the central and peripheral retina. Results are presented as mean ± SEM. Hoechst N=3, n=20. Asterisks indicate 
significant difference (t-test, *p<0.05, **p<0.01, ***p<0.005). INL, inner nuclear layer; ONL, outer nuclear layer. 
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Dams of newborn rd10s were given a Norgestrel-supplemented diet when their pups 
reached post-natal day 10 (P10) and all rd10s continued to receive a Norgestrel-
supplemented diet post-weaning. Control litters received an identical diet without 
Norgestrel. Norgestrel-supplemented rd10s demonstrated lower levels of TUNEL positivity 
in the outer nuclear layer (ONL) at P15 and P20 compared to control, coinciding with 
significant protection of photoreceptors (Figure 6.3.1A). As expected, control mice revealed 
a substantial loss of photoreceptors between P15 and P25 (Figure 6.3.1A) (Barhoum et al., 
2008). Measurement of ONL thickness confirmed significant Norgestrel-induced ONL 
protection up to P40 in both the central and peripheral retina (Figure 6.3.1B). 
Figure 6.3.2. Norgestrel preserves rod and cone outer segment morphology in the central rd10 retina. 
Confocal microscopic images of (A) rod (rhodopsin; red) and (B) cone outer segments (PNA; green) in the 
central retina from P15-P40 of control and NORG fed rd10 mice. Outer segments are shorter and sparser in 
the control  from P15 for rods (A) and from P20 for cones (B). Hoechst (blue) staining reveals the cell layers in 
the retina. Scale bar 50µm. (C) Quantification of rod and cone outer segment thickness in the central retina in 
control vs. NORG fed rd10 mice. Results are presented as mean ± SEM. N=3, n=4. Asterisks indicate significant 
difference (t-test, *p<0.05, ****p<0.001). Data generated by Dr Sarah Roche. 
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In order to assess preservation of photoreceptor outer segments with Norgestrel diet, 
markers for rod (rhodopsin; red) and cone (PNA; green) outer segments were used on 
retinal sections. Outer segments were longer and denser in the central retina of Norgestrel 
treated mice compared to control (Figure 6.3.2A, B). This morphological change was 
observed from P15 for rods and from P20 for cones in the central retina (Figure 6.3.2A, B). 
Quantification of rod and cone outer segment length confirmed significant preservation up 
to P25 (Figure 6.3.2C). 
 
6.3.2. Microglial response is significantly altered with Norgestrel 
treatment 
Previous studies have highlighted a role for microglia in potentiating cell death in models of 
retinitis pigmentosa by driving inflammatory processes, resulting in photoreceptor loss 
(Peng et al., 2014; Zhao et al., 2015). We therefore sought to study microglial dynamics in 
rd10 mice following administration of a Norgestrel-supplemented diet. Activation states of 
macrophages (including resident retinal microglia) have been well characterized. 
Macrophages can both adopt and switch between pro-inflammatory (M1) and anti-
inflammatory (M2) states (Mosser & Edwards, 2008) and thus specific state markers have 
been identified. Cluster of differentiation 68 (CD68) (Kobayashi et al., 2013) and inducible 
nitric oxide synthase (iNOS) (Yang et al., 2007) are markers for M1 macrophages. Markers 
of anti-inflammatory microglia (M2) have also been characterized, including mannose 
receptor (CD206/MRC1) (Karlstetter et al., 2010) and arginase (Kobayashi et al., 2013). 
CD68 is a lysosomal-associated membrane protein and scavenger receptor, expressed in 
phagocytic macrophages (Kobayashi et al., 2013). iNOS is an enzyme responsible for the 
production of nitric oxide. Associated with neurotoxicity (Scholz et al., 2015), it competes 
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with arginase - an enzyme that inhibits the production of nitric oxide to promote an M2 
phenotype (Tenu et al., 1999). MRC1 is involved in the recognition and endocytosis of 
glycoproteins on other cell types and the neutralization of pathogens (Gazi & Martinez-
Pomares, 2009). Iba1 was used to identify microglia.  
 Amoeboid microglia could be observed surrounding the ONL at P15 and P20 in the control 
(Figure 6.3.3), during the peak of cell death (Figure 6.3.1A). Some of these microglia stained 
positively for CD68, indicative of an M1 phenotype. Interestingly, M1 microglia were 
observed in the inner plexiform layer (IPL) and retinal ganglion cell (RGC) layer, suggesting 
that microglia become activated even when not in close proximity to the ONL (Figure 
6.3.3). In contrast, microglia appeared more ramified in morphology in Norgestrel-fed mice 
(P15, P20), showing less CD68 immunoreactivity than control: fewer M1 microglia were 
present in the Norgestrel-diet retinas (Figure 6.3.3). Correlating with significant 
photoreceptor protection (Figure 6.3.1A), this implicates microglial-driven inflammation in 
the cell death observed in rd10 mice.  
Figure 6.3.3. Norgestrel prevents microglial migration and dampens pro-inflammatory microglial activity in 
vivo. Confocal microscopic images of microglia (Iba1; red) and pro-inflammatory (M1) microglia (CD68; green) 
in the central retina from P15-P40 control and NORG-fed rd10 mice. Hoechst (blue) staining reveals the cell 
layers in the retina. Scale bar 50µm. N=3, n=4. Data generated by Dr Sarah Roche. 
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This hypothesis is supported by the observation that phagocytic microglial activity (CD68) 
increased between P20 and P25 in mice on the Norgestrel diet, during a period of 
substantial photoreceptor loss (Figure 6.3.3). mRNA analysis was carried out on whole 
retina for M1 and M2 microglial state markers. This confirmed a protective, Norgestrel-
driven, significant decrease in iNOS (M1) (P20, P25) (Figure 6.3.4i) and increase in M2 
MRC1 (P20) and arginase (P25, P30) expression (Figure 6.3.4ii).  
 
High mobility group box 1 protein (HMGB1) and interleukin-1α (IL-1α) belong to the family 
of damage-associated molecular patterns (DAMPs), expressed and released by cells 
undergoing a loss of membrane integrity. These signals induce microglia to produce pro-
Figure 6.3.4. Norgestrel dampens pro-inflammatory microglial activity in vivo. RT-qPCR analysis of mRNA 
encoding (i) pro-inflammatory (M1) and (ii) anti-inflammatory (M2) microglial markers in whole retina from P20-
P30 control and NORG-fed rd10 mice. Results are presented as mean ± SEM. N=3, n=4. Asterisks indicate 
significant difference (t-test, ***p<0.005, ****p<0.001). 
Figure 6.3.5. Norgestrel decreases DAMP release from photoreceptors. RT-qPCR analysis of mRNA 
encoding danger associated molecular patterns (DAMP), high motility box group 1 (HMGB1) and 
interleukin-1α (IL-1α) in whole retina from P20-P30 control and Norgestrel-fed rd10 mice. Results are 
presented as mean ± SEM. N=3, n=4. Asterisks indicate significant difference (t-test, *p<0.05, 
***p<0.005, ****p<0.001). 
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inflammatory cytokines and reactive oxygen species, resulting in worsened disease 
progression (Scaffidi et al., 2002; Oppenheim & Yang, 2005; Chen et al., 2007; Lugrin et al., 
2015). mRNA analysis of DAMP expression showed that Norgestrel induced a significant 
decrease in HMBG1 and IL-1α (Figure 6.3.5), coinciding with less M1 microglial activation at 
P20 (Figure 6.3.4i). Interestingly, at P25 when some microglia appear to have adopted an 
M1 phenotype with the Norgestrel diet (Figure 6.3.3), DAMP gene expression is still 
significantly decreased (Figure 6.3.5). This leads us to hypothesis the following scenario as 
likely: microglia migrate to the ONL to clear cellular debris, but respond instead to the cell 
death taking place. These microglia consequently take on an M1 phenotype, producing 
harmful inflammatory cytokines and reactive oxygen species, thus contributing to 
photoreceptor cell death.  
  
6.3.3. Norgestrel significantly reduces rd10 microglial-driven, cell 
contact-dependent degeneration of 661W cells 
In order to evaluate the contribution of microglia to the course of photoreceptor cell loss in 
the rd10 retina in more detail, we utilized primary cell cultures of rd10 retinal microglia. 
Primary rd10 microglial cultures were made using a previously established method (Weiglet 
2007) and culture purity was confirmed. The absence of retinal astrocytes, Muller glia, rods, 
retinal ganglion, amacrine, horizontal and bipolar cells (Figure 6.3.6) in the cultures were 
confirmed by immunofluorescence. Although rare, some debris was present from these cell 
types was found in culture (Figure 6.3.6, inserts), however all isolated cells stained 
positively for Iba1 and so were confirmed to be pure microglia (Figure 6.3.6, 6.3.7).  
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Due to the difficulty in isolating pure photoreceptor primary cultures (Roque et al., 1999; 
Zhou et al., 2012) and in order to assess the interaction between microglia and 
photoreceptors, we utilized the cone photoreceptor-like 661W cell line. Both throughout 
this thesis and in previous works published by our group, 661W cells have been used 
successfully as an in vitro model to study how photoreceptors respond to stressful stimuli 
and to understand how Norgestrel works in providing neuroprotection to these cells. 
Results from studies in 661W cells have consistently been validated ex vivo and so we 
believe it to be a suitable model for the study of photoreceptors in vitro. We first sought to 
determine the effect that released factors from rd10 microglia have on the viability of 
661W cells, by culturing healthy 661W cells with conditioned media (CM) from rd10 
microglia pre-treated with 20μM Norgestrel or equivalent DMSO control. 661W cells were 
cultured in microglial CM for 24 hours (h) and viability assessed using the MTS assay. Whilst 
CM from DMSO-treated microglia resulted in a ~14% increase in 661W cell death, CM from 
Norgestrel-treated microglia resulted in only a ~7% increase compared to untreated control 
Figure 6.3.6. Characterisation of a pure microglial culture. Primary microglial cells were cultured in vitro from 
post-natal day 16 rd10 retinas. Fluorescent microscopic images of primary rd10 microglial cells in vitro 
confirmed a pure microglial cell population (Iba1; Red). Hoechst (blue) staining reveals the cell nuclei. Antibodies 
targeted against astrocytes (GFAP; red), Müller glial cells (glutamate synthase (GS); green), retinal ganglion cells 
(RGCs) (neurofilament M (NFM); green), amacrine cells (syntaxin 1; red), horizontal cells (calbindin; red), bipolar 
cells (CEH10 homeodomain-containing homolog (CHX10); green) and rods (rhodopsin (Rhod); red) showed no 
positive staining within the isolated population of cells. Small quantities of non-nuclear (hoechst negative) debris 
from these cells was found in culture (see panel inserts). Scale bars 10μm. Figure generated by Dr Sarah Roche 
141 
 
(Figure 6.3.7). This highlights a novel role for Norgestrel in modulating microglial immune 
responses in the rd10 retina. 
Direct cell-cell contact may regulate microglial responses (Duvall et al., 1985; Lucas et al., 
2006). In particular, in the rd10 retina, microglia associate closely with cells in the ONL 
throughout the early stages of photoreceptor loss (Zhao et al., 2015). Therefore, in order to 
assess the relationship between microglia and photoreceptors in a way that more closely 
resembles the in vivo state, we cultured microglia together with healthy 661W cells 
(example image of culture can be seen in Figure 6.3.8). To our knowledge, this has never 
before been carried out.  
Figure 6.3.7. Norgestrel significantly abrogates rd10 microglial conditioned-media induced 661W 
cell death. (A) Confocal microscopic XY image of primary rd10 microglial cells in vitro (Iba1; red). 
Secondary only control (panel insert) confirms specific staining of the antibody. Scale bar 10μm. (B) 
Conditioned media was collected from primary microglial cells cultured with (CM + NORG), or 
without (CM) 20μM Norgestrel over 24h. 661W cells were cultured over a further 24h in the 
absence (Control) or presence of conditioned media (CM, CM + NORG) and percentage cell death 
was assessed by the MTS assay. Results are presented as mean ± SEM. N=6, n=4. Asterisks indicate 
significant difference (One way ANOVA followed by Tukey’s post-hoc test, *p<0.05, **p<0.01, ns=no 
significance). 
Figure 6.3.8. Co-culture of rd10 microglia and 
661W cells. Representative fluorescent 
microscopic image of primary rd10 microglial 
cells (Iba1; red) in culture with 661W cells (Cone 
arrestin; green). Hoechst (blue) staining reveals 
cell nuclei. Scale bar 30μm. 
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Prior to co-culture, primary rd10 microglial and 661W cells were treated with 20μM 
Norgestrel or equivalent DMSO control (24h microglia, 3h for 661Ws). 661W cells were 
then lifted, added to the microglial cell culture and incubated for a further 24 hours. During 
this time, microglia appear to migrate and settle in clusters close to the 661W cells (Figure 
6.3.8). Subsequent cell viability of co-cultured 661W cells was assessed using the TUNEL 
assay (Figure 6.3.9).  
After 24h of co-culture, ~32% of 661W cells were TUNEL-positive (TUNEL+) compared to 
~1.8% of healthy 661W cells cultured in isolation (Figure 6.3.9). This strongly suggests that 
direct rd10 microglial-661W cell contact will result in higher levels of cell death, than when 
661W cells are exposed to secreted microglial factors alone (conditioned media study, 
compare Figure 6.3.7B to 6.3.9). Treatment of microglia with 20μM Norgestrel prior to co-
Figure 6.3.9. Norgestrel significantly abrogates rd10 microglial-induced death of healthy 661W cells. 661W 
cells were treated with either 20μM Norgestrel (661W NORG) or vehicle control (661W) over 3h. The treated 
661W cells were then placed in culture with microglia that had been treated with (Microglia NORG) or without 
(Microglia) 20μM Norgestrel over 24h. Co-cultures were incubated for a further 24h. Apoptosis of 661W cells 
was detected by TUNEL of DNA strand breaks in cell nuclei. TUNEL N=6, n=3. Scale bars 50µm. (i) 
Representative images of TUNEL-positive (TUNEL+) staining in co-cultures. (ii) Quantification of TUNEL-positive 
661W following Norgestrel or vehicle DMSO treatment and co-incubation with primary rd10 microglial cells 
pre-treated with Norgestrel or vehicle DMSO. All Norgestrel-treated co-cultures had significantly less TUNEL-
positive 661W cells staining than equivalent vehicle controls. Results are presented as mean ± SEM. N=6, n=10. 
Asterisks indicate significant difference (t-test, *p<0.05, **p<0.01, ***p<0.005). 
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culture significantly reduced their ability to damage the 661W cells (Figure 6.3.9), indicating 
that Norgestrel can work directly on microglia. Interestingly, pre-treatment of 661W cells 
with 20μM Norgestrel also resulted in increased protection of the photoreceptor-like cells 
Figure 6.3.9). Hence we demonstrate for the first time, Norgestrel’s ability to prime 
undamaged photoreceptors against microglial-derived harmful stimuli. 
These data highlight a novel and important finding that Norgestrel can significantly reduce 
microglial-driven contact-dependent degeneration of healthy 661W cells. To further 
elucidate this relationship, we investigated the response of microglia to damaged 
photoreceptors, like those present in the rd10 mouse retina. The previous experiment was 
therefore replicated with 661W cells pre-exposed to a stressful stimulus, for it is possible 
that microglia would react differently when cultured with stressed 661W cells. Throughout 
Figure 6.3.10. Norgestrel significantly abrogates rd10 microglial-induced death of stressed 661W cells. 
661W cells were cultured in the absence of (serum starved 661W) serum over 3 h. These cells were 
simultaneously treated with either 20μM Norgestrel (661W NORG) or vehicle control (661W). The treated 
661W cells were then placed in culture with microglia that had been treated with (Microglia NORG) or 
without (Microglia) 20μM Norgestrel over 24h. Co-cultures were incubated for a further 24h. Apoptosis of 
661W cells was detected by TUNEL of DNA strand breaks in cell nuclei. TUNEL N=6, n=3. Scale bars 50µm. (i) 
Representative images of TUNEL-positive (TUNEL+) staining in co-cultures. (ii) Quantification of TUNEL-
positive 661W cells cultured in the absence of (serum starved 661W) serum and following Norgestrel or 
vehicle DMSO treatment and co-incubation with primary rd10 microglial cells pre-treated with Norgestrel or 
vehicle DMSO. All Norgestrel-treated co-cultures had significantly less TUNEL-positive 661W cells staining 
than equivalent vehicle controls. Results are presented as mean ± SEM. N=6, n=10. Asterisks indicate 
significant difference (t-test, *p<0.05, **p<0.01, ***p<0.005). 
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the course of this thesis, we have induced stress in 661W cells via serum-starvation over 
24h. This results in an upregulation of pro-apoptotic pathways and ~40% cell death 
compared to control. Here, we serum starved 661W cells for 3h, resulting in ~8% cell death 
as assessed by the TUNEL assay (Figure 6.3.10ii). Addition of rd10 primary microglial cells to 
stressed 661Ws increased cell death to ~50% following 24h co-culture (as measured by 
TUNEL-positive (TUNEL+) staining). This was approximately a 42% increase in cell death 
compared to serum-starved 661W cells cultured in isolation (Figure 6.3.10).  
 
When rd10 microglia are present in 661W cell cultures, cell death increased by ~30% and 
~42% in healthy and serum starved 661W cells respectively. This implies that 
photoreceptors are more vulnerable to microglia-derived neurotoxic stimuli when they are 
already undergoing a stress response. Co-culture of microglia pre-treated with 20μM 
Norgestrel together with serum starved 661W cells significantly reduced the levels of 661W 
cell death (Figure 6.3.10ii). This suggests not only that Norgestrel can act directly on 
photoreceptors to protect against cell death, but also may work directly on microglia to 
both protect stressed photoreceptors from contact-dependent microglial-driven 
degeneration (Figure 6.3.10) and microglial-derived harmful stimuli (Figure 6.3.7B).   
 
6.3.4. Norgestrel modulates pro- and anti-inflammatory states in 
microglia 
Norgestrel can act directly on rd10 microglia and consequently prevent microglial-driven 
661W cell death (Figures 6.3.7, 6.3.9, 6.3.10). Thus, we wished to elucidate on Norgestrel’s 
mechanism of action on microglia. To do this, we first studied microglial progesterone 
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receptor expression, for we have previously shown that these receptors can mediate 
Norgestrel’s neuroprotective effects. mRNA analysis of cultured rd10 microglia revealed 
similar expression patterns of progesterone membrane complexes 1 and 2 (PGRMC1, 
PGRMC2), and membrane progesterone receptors α, β and γ (mPRα, β, γ) (Figure 6.3.11A). 
Expression of the classical progesterone receptors A and B (PRA/B), was not detected in 
these cells (Figure 6.3.11A). Immunofluorescence confirmed expression of these receptors 
(Figure 6.3.11B).  
 
Since all progesterone receptors except classical progesterone receptors A/B (PR A/B) were 
present in rd10 microglia, it is likely that Norgestrel will act on these receptors to affect 
microglia directly. Primary rd10 microglia were subsequently treated with 20μM Norgestrel 
and analysed by immunofluorescence for M1 and M2 state markers. rd10 microglia treated 
with Norgestrel, revealed lower levels of CD68 and iNOS (M1) and higher levels of MRC1 
(M2) compared to control (Figure 6.3.12A). Quantification of fluorescence intensity 
measurements confirmed a significant Norgestrel-induced decrease in M1 markers and 
Figure 6.3.11. Classification of progesterone receptors present in rd10 microglia. (A) RT-qPCR analysis detected 
similar levels of mRNAs encoding progesterone receptor membrane complexes 1 and 2 (PGRMC1, PGRMC2) and 
all three membrane progesterone receptor isoforms, α, β and γ (mPRα, mPRβ, mPRγ) in rd10 retinal microglial 
cells. Classical progesterone receptor (PR A/B) was not expressed. Results are presented as mean ± SEM. (B) 
Immunolabelling of protein confirmed the presence of these progesterone receptors in primary rd10 microglial 
cells. Scale bar 10µm. 
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increase in M2 MRC1 (Figure 6.3.12B). Thus we hypothesise that Norgestrel dampens pro-
inflammatory activity and stimulates anti-inflammatory states in rd10 microglia, resulting in 
increased protection of photoreceptors. 
6.3.5. Norgestrel acts as an anti-inflammatory in stressed 661W cells 
and in rd10 mice  
Macrophage infiltration is extremely important in the progression of retinal disease (Zhao 
et al., 2015). Chemokines, a family of structurally related cytokines are involved in the 
activation and directed migration of immune cells. Signalling to macrophages, these factors 
have been shown to drive microglial infiltration (Kunkel, 1999) and thus we looked at how 
Norgestrel treatment affected an array of CC chemokine gene expression: MIP-1α (CCL3), 
MIP-1β (CCL4), MCP1 (CCL2) and MCP3 (CCL7). These chemokines have all previously been 
Figure 6.3.12. Norgestrel reduces pro-inflammatory and promotes anti-inflammatory phenotypes in rd10 
microglia. (A) Fluorescent microscopic images of primary rd10 microglia immunolabelled for (A)(i) pro-
inflammatory (M1) markers CD68 and iNOS, and (A)(ii) anti-inflammatory (M2) activation state marker MRC1; 
after treatment with 20μM Norgestrel over 24h. Hoechst (blue) staining reveals the cell nuclei of the microglia. 
Scale bar 10µm. (B) Quantification of fluorescent intensity of (B)(i) CD68 and iNOS and (B)(ii) MRC1 in primary 
rd10 microglial cultures following Norgestrel treatment over 24h. Results are presented as mean ± SEM. N=4, 
n=4. (t-test, *p<0.05, ***p<0.005, ****p<0.001). Data generated by Dr Sarah Roche. 
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reported to be important in photoreceptor-microglial crosstalk (Rutar et al., 2015; Syeda et 
al., 2015) leading to retinal degeneration (Yang et al., 2007; Scholz et al., 2015). 
 
Norgestrel successfully acts as an anti-inflammatory, downregulating chemokine gene 
expression both in stressed 661W cells (Figure 6.3.13) and during the early stages (P15 – 
P20) of rd10 disease progression (Figure 6.3.14i). Norgestrel-induced downregulation of CC 
chemokine gene expression concomitantly associated with reduced gene transcription for 
pro-inflammatory mediators TNFα, IL-1β and IL-6 (Figure 6.3.14ii). Likely secreted from 
retinal microglia, these cytokines are documented to act both directly (Scuderi et al., 2015; 
Zhao et al., 2015) and indirectly (Liu, Ye, et al., 2015) on photoreceptors, potentiating cell 
death via pro-inflammatory mechanisms. A loss of photoreceptors at P25 correlates with 
an upregulation of chemokine gene expression (Figure 6.3.14ii) and a subsequent 
infiltration of microglia to the ONL (Figure 6.3.3). This is thought to be why there is an 
increase in pro-inflammatory gene transcription at P25 (Figure 6.3.14ii).  
Figure 6.3.13. Norgestrel reduces 
inflammation in stressed 661W cells. Retinal 
cytokine mRNA levels were measured by RT-
qPCR analysis, in serum starved 661W cells 
treated with 20µM Norgestrel or DMSO 
control. Relative chemokine (macrophage 
inflammatory protein 1α and 1β (MIP-1α, MIP-
1β), monocyte chemoattractant proteins 1 and 
3 (MCP1, MCP3)) and pro-inflammatory 
cytokine interleukin 6 (IL-6)) mRNA expression 
levels in 661W cells. Only one control bar is 
shown for graphical clarity (Control). Results 
are presented as mean ± SEM. N=3, n=4. 
Asterisks indicate significant difference (t-test, 
****p<0.001). 
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6.3.6. Norgestrel up-regulates CX3CR1-fractalkine signalling between 
microglia and photoreceptors 
It is now recognised that it is not solely the actions of chemokines that contribute to the 
maintenance of microglia in a quiescent state; but also the interaction of microglia with 
other cell types (Lyons et al., 2007, 2009; Costello et al., 2011). Recent studies have shown 
that complementary distribution of the chemokine fractalkine (also known as CX3CL1) on 
neurons and its receptor CX3CR1 present on microglia, can modulate and attenuate pro-
inflammatory microglial activation (Henkel et al., 2009; Lyons et al., 2009; Wang et al., 
Figure 6.3.14. Norgestrel reduces inflammation in the rd10 retina. Retinal 
cytokine mRNA levels were measured by RT-qPCR analysis, in post-natal (P) day 
15-30 rd10 mice. Relative (i) chemokine (macrophage inflammatory protein 1α 
and 1β (MIP-1α, MIP-1β), monocyte chemoattractant proteins 1 and 3 (MCP1, 
MCP3)) and (ii) pro-inflammatory cytokine (tumour necrosis factor α (TNFα), 
interleukin 1β (IL-1β) and interleukin 6 (IL-6)) mRNA expression levels in retinas 
of rd10 mice supplemented with or without (Control) Norgestrel. Results are 
presented as mean ± SEM. N=3, n=4. Asterisks indicate significant difference (t-
test, *p<0.05, **p<0.01, ****p<0.001). 
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2014). This pairing provides an ideal mechanism to mediate neural/microglial interactions 
(Harrison et al., 1998).  Therefore, we looked at the ability of Norgestrel to up-regulate the 
gene expression of fractalkine and its receptor CX3CR1, in the degenerating rd10 mouse 
retina. Norgestrel treatment significantly increased fractalkine levels in the P20 rd10 retina 
by over 1000-fold that of the control (Figure 6.3.15); coinciding with significant protection 
of the ONL (Figure 6.3.1). Interestingly, Norgestrel also up-regulated CX3CR1 gene 
expression at P20 (Figure 6.3.15), at a time when pro-inflammatory microglia are down in 
the retina (Figure 6.3.3, 6.3.4). Norgestrel-induced fractalkine signalling was dampened at 
later time points (P25, P30) compared to P20-Norgestrel treated mice, though gene 
expression of both fractalkine and receptor was still significantly over ten times that of the 
control (Figure 6.3.15). Dampened fractalkine signalling correlated with photoreceptor cell 
loss in the Norgestrel-treated mice (Figure 6.3.1).  
 
6.3.7. Fractalkine is produced in the ONL of Norgestrel-treated mice 
Fractalkine, a neuronal membrane-bound chemokine, can be proteolytically cleaved to 
shed a soluble chemoattractant domain (Bazan et al., 1997; Hundhausen et al., 2003). The 
two forms: soluble and full-length membrane-bound can therefore stimulate different 
Figure 6.3.15. Fractalkine 
signalling is up 1000-fold in P20 
Norgestrel-treated rd10s. 
Retinal cytokine mRNA levels 
were measured by RT-qPCR 
analysis, in postnatal (P) day 15-
30 rd10 mice. Relative mRNA 
expression levels in retinas of 
rd10 mice supplemented with or 
without (Control) Norgestrel. 
Results are presented as mean ± 
SEM. N=3, n=4. Asterisks 
indicate significant difference (t-
test, *p<0.05, **p<0.01, 
****p<0.001). 
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microglial activities. Membrane bound fractalkine maintains microglial in a quiescent state, 
preventing their infiltration towards neurons. Soluble fractalkine however, is more likely to 
activate microglial phagocytic activity and stimulate microglia migration (Zhang et al., 
2012). Since RT-qPCR studies showed a robust increase in fractalkine gene transcription in 
response to Norgestrel treatment from P20 onwards (Figure 6.3.15), we looked to see that 
this result was mimicked at the protein level. Fractalkine staining was increased in the ONL 
of all (P15 – P40) Norgestrel treated mice, compared to control (Figure 6.3.16). This staining 
was evident on the surface of the photoreceptors – indicative of an upregulation of full 
length membrane-bound forms.  
 
6.3.8. Fractalkine can signal directly to CX3CR1 receptors present on 
661W cells 
Norgestrel treatment of stressed 661W cells significantly up-regulated the gene expression 
of both fractalkine and, interestingly, CX3CR1 over 24 hours (Figure 6.3.17A). Recent 
literature suggests that fractalkine may also work on other cells apart from microglia, for 
the CX3CR1 receptor has been found upon a multitude of neuronal cells (London et al., 
2013; Dworzak et al., 2015). Indeed, we identified expression of CX3CR1 at both the 
genomic (Figure 6.3.17Aii) and translational protein level (Figure 6.3.17B) in 661W cells. 
Figure 6.3.16. Fractalkine is evident in the ONL of Norgestrel-treated rd10 mice from P15. Fluorescent 
microscopic images of fractalkine (green) in the central retina from post-natal day (P) 15-40 of control and 
Norgestrel (NORG) diet fed rd10 mice. Fractalkine staining is evident in the outer nuclear layer (ONL) of the retina 
in Norgestrel-supplemented mice. Hoechst (blue) staining reveals the cell layers in the retina. Scale bar 50µm. 
N=3, n=3. 
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Therefore, in order to identify if Norgestrel-induced fractalkine release could work directly 
on photoreceptors, we treated stressed 661W cells with increasing concentrations (0.01 – 
100nM) of soluble recombinant fractalkine, over 24 hours. Fractalkine-treated stressed 
cells exhibited similar levels of neuroprotection to those treated with 20μM Norgestrel 
(Figure 6.3.17C), indicating that fractalkine’s neuroprotective effects may be two tiered: 
both dampening microglial pro-inflammatory activation and working directly on stressed 
photoreceptors to induce cell survival.  
 
 
Figure 6.3.17. Fractalkine can act directly on 661W cells to prevent from serum starved cell death. (A) 
661W cells were serum starved and treated with 20µM Norgestrel (Norgestrel) or the equivalent DMSO 
control (Control) over 6 and 24h. RT-qPCR analysis detected a significant increase in mRNA levels of both (i) 
fractalkine and (ii) its receptor CX3CR1 in starved cells treated with Norgestrel. N=6, n=4. (B) Representative 
fluorescent microscopic image of CX3CR1 (green) present in 661W cells. Secondary only control (panel insert) 
confirms specific staining of the receptor. Hoechst (blue) staining reveals the cell nuclei. Scale bar 30µm. (C) 
661W cells were serum starved over 24 hours and treated with 20µM Norgestrel (Norgestrel), increasing 
concentrations (nM) of soluble recombinant fractalkine, or the equivalent DMSO control (Control). 
Percentage cell viability was assayed and compared to 100% viable DMSO control. Results are presented as 
mean ± SEM. N=6, n=4. Asterisks indicate significant difference (t-test, *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001). 
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6.4. Discussion 
 
This research demonstrates the protective properties of the synthetic progestin 
‘Norgestrel’, when administered via non-invasive diet supplementation. Previously shown 
to protect through an upregulation of basic fibroblast growth factor with subsequent 
actions on GSK3β (Chapter 3, 5), this study highlights a novel role for Norgestrel in acting 
directly upon microglial cells to dampen damaging inflammatory processes. This is 
important, as recent literature has shown that microglial cells may potentiate retinal 
disease (Arroba et al., 2011; Martínez-Fernández de la Cámara et al., 2015; Peng et al., 
2014; Scholz et al., 2015; Zhao et al., 2015). We also show provide further mechanistic 
insight in to Norgestrel’s neuroprotective effects, showing that Norgestrel drives up 
fractalkine expression in photoreceptors, dampening pro-inflammatory and migratory 
effects. In addition to this, we believe that fractalkine may also work to provide direct 
photoreceptor neuroprotection. 
 
Reactive microglia are known to promote retinal cell death through inflammation (Yang et 
al., 2007; Sivakumar et al., 2011; Wang et al., 2015). Initially involved in apoptotic cell 
clearance, microglia may accelerate photoreceptor cell loss through phagocytosis of 
stressed but viable neurons (Peng et al., 2014; Zhao et al., 2015). Certainly, in our study, we 
show microglial cells infiltrate the ONL during photoreceptor degeneration (Control, P20; 
Norgestrel-supplemented, P25) (Figure 6.3.3). Substantiating this, disease progression is 
significantly delayed when microglial cells are genetically ablated, or their phagocytic and 
pro-inflammatory activity dampened in the rd10 mouse (Peng et al., 2014; Zhao et al., 
2015). Microglial cells exist in differing states of ‘activation’. Known as the M1 ‘pro-
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inflammatory’ and M2 ‘anti-inflammatory’ activation states, a greyscale exists – microglia 
may exist exhibiting properties of both (Mosser & Edwards, 2008; Cherry et al., 2014). 
Therefore, to state conclusively that microglia are in the M1/M2 state is an over 
simplification and must be avoided. Our results however, suggest that Norgestrel can 
dampen M1 microglial activation and promote a protective M2 state (Figures 6.3.3, 6.3.4, 
6.3.12). From the literature, this suggests that Norgestrel-induced M1 microglial inhibition 
is protective to rd10 retinas (Peng et al., 2014). 
 
As such, we designed this study with a number of questions in mind: Are rd10 retinal 
microglia predisposed to act as ‘drivers’ of degeneration, as the literature suggests; or, are 
they responding to signals released from mutated photoreceptor cells inducing a damaging 
M1 phenotype? Alternately, it may be that quiescent microglia migrate towards the ONL 
initially to clear debris (Pearson et al., 1993). Once in contact with mutated photoreceptors 
however, they may then do they then adopt an M1 phenotype, further potentiating cell 
death through inflammation? In order to address the above questions, we utilised both in 
vivo models of retinal degeneration (rd10) and in vitro cultures of 661W cone 
photoreceptor-like cells and primary rd10 microglia both in isolation and in co-culture. 
These models enabled us to identify several novel mechanisms of action of Norgestrel.  
 
Firstly, 661W cells, cultured with conditioned media from primary rd10 microglial cells, 
revealed Norgestrel’s ability to act on microglial cells to attenuate damaging inflammatory 
factor secretion (Figure 6.3.7B), a process known to cause retinal cell death in vivo (Yang et 
al., 2007; Sivakumar et al., 2011; Zhou et al., 2012; Dworzak et al., 2015). Secondly, co-
culture studies showed that microglia-photoreceptor contact induces photoreceptor cell 
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death significantly more than conditioned media alone (compare Figure 6.3.7B to 6.3.9ii). 
In addition to this, microglia induced cell death by ~30% and ~42% in healthy and serum 
starved 661W cells respectively, suggesting that photoreceptors are more vulnerable to 
microglia-derived neurotoxic stimuli when already stressed (compare Figure 6.3.9ii to 
6.3.10ii). Thirdly, we provide mechanistic insight in to Norgestrel’s effect on microglia both 
in vivo and in vitro, working directly to reduce pro-inflammatory M1 and stimulate anti-
inflammatory M2 phenotypes (Figure 6.3.3, 6.3.4, 6.3.12), thus preserving photoreceptor 
cell viability. This finding was supported by RT-qPCR studies on whole retinas (Figure 
6.3.14ii), showing Norgestrel lead to a significant decrease in pro-inflammatory TNFα and 
IL-1β gene expression, both expressed by retinal microglia (Wang et al., 2005). 
 
Ultimately however, Norgestrel administration merely delays cell death in the rd10 mice 
(Figure 6.3.1). So what is driving this cell loss in the Norgestrel-treated mice? One potential 
theory is the loss of Norgestrel-induced fractalkine-CX3CR1 signalling at P25. Fractalkine 
can suppress TNFα release (Figure 6.3.14) from pro-inflammatory microglia (Figure 6.3.3, 
6.3.4, P20) (Mizuno et al., 2003) and fractalkine-CX3CR1 signalling has been shown to 
maintain quiescent microglia, preventing microglial migration and neurotoxicity (Mizuno et 
al., 2003; Lyons et al., 2009; Zhang et al., 2012; Peng et al., 2014). In the P20 rd10 retina, 
Norgestrel drives up fractalkine gene expression by a 1,000-fold change compared to 
control, however these levels are not maintained at P25 (Figure 6.3.15). Fractalkine 
appears to be mostly localised to the ONL and outer plexiform layer (OPL) (Figure 6.3.16). 
Since fractalkine signalling has been shown to prevent cell loss in a number of different 
disease models (Harrison et al., 1998; Mattison et al., 2013; Wang et al., 2014; Cardona et 
al., 2015; Dworzak et al., 2015; Febinger et al., 2015), we believe that there is a crucial 
importance of CX3CR1-fractalkine signalling in retinal neuroprotection. Thus when 
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Norgestrel-induced fractalkine signalling is lost at P25, microglial cells are able to infiltrate 
the ONL and drive disease progression (Figure 6.3.1, 6.3.3).  
 
The fractalkine-CX3CR1 pathway is coming to the forefront of the retinal field due to a. its 
neuroprotective capacities and b. because of its differential signalling capabilities. To detail: 
fractalkine is unlike most other chemokines, in that it is a type I transmembrane adhesion 
protein. Therefore, it can act as a chemoattractant for target cells expressing its receptor 
CX3CR1 (Stievano et al., 2004). Mouse fractalkine cDNA encodes a 395 amino acid chain 
that includes a signal sequence, a chemokine domain, a mucin stalk region, a 
transmembrane segment and a cytoplasmic tail. The chemokine domain contains binding 
and chemotactic regions whilst the mucin stalk region appears only to act as a spacer 
(Harrison et al., 2001; Mizoue et al., 2001). Produced as a cell surface protein, in its full 
length form fractalkine protein has a molecular weight of approximately 95 - 100kDa, but 
cleavage can be induced by ADAM 10 and ADAM17 to generate a 60 – 80kDa soluble form 
(Tsou et al., 2001; Hundhausen et al., 2007).  
 
Fractalkine can be cleaved to form two distinct products and thus it can consequently act in 
two distinct manners. In a paper released in 2012, fractalkine was shown to have discrete 
roles dependent upon whether it was added in its soluble or full length form. Soluble 
fractalkine induced an increased amount of microglial migration to photoreceptors in vitro, 
causing an increased quantity of TUNEL-positive photoreceptor cells. Full length fractalkine 
however, was protective to stressed photoreceptors through a prevention of microglial 
migration (Zhang et al., 2012).  
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This point may be significant in our capacity to understand what is happening at the P25 
time point; when Norgestrel-induced neuroprotection is lost and pro-inflammatory 
microglia infiltrate the ONL. At P20, Norgestrel up-regulates fractalkine signalling over 
1000-fold that of control. We postulate that it is this increase in fractalkine signalling that 
keeps the microglia in a quiescent state. At P20, fractalkine staining is predominantly 
localised to the cell membrane of photoreceptors; thus this is likely to be the full-length, 
membrane bound, protective fractalkine. Unfortunately, at P25 this staining is lost. There is 
still a significant increase of fractalkine at the mRNA level (approximately 10-15 fold), yet 
this is nowhere near the 1000-fold levels seen at the P20 time point. Corroborating this, at 
P25 membrane-bound fractalkine is no longer easily identifiable at the photoreceptors. 
Thus, we hypothesise the following: Norgestrel drives an upregulation of full-length 
fractalkine at P20, localised to the outer membranes of photoreceptors. At P25, the 
majority of Norgestrel-induced fractalkine transcription is lost and full length-fractalkine is 
cleaved to the soluble form. This will induce chemotaxis of CX3CR1-presenting microglia in 
to the ONL. Once here, these microglia will react to the damage of the diseased retina, 
engulfing both stressed and healthy photoreceptors alike. Work is continuing in our 
laboratory on fractalkine-CX3CR1 signalling following Norgestrel administration and the 
role of full length vs. soluble fractalkine in RP disease progression. 
 
Interestingly, in our 661W cells, fractalkine also appears to have a direct role in cell 
viability: stressed cells treated with increasing concentrations of soluble recombinant 
fractalkine were afforded similar protection compared to stressed 661W cells treated with 
Norgestrel alone (Figure 6.3.17C). This is particularly interesting for it shows a mechanism 
by which fractalkine may work on photoreceptors directly through the CX3CR1 receptor 
(Figure 6.3.17Aii, B). This result may initially appear controversial, for CX3CR1 is often 
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stated to be present solely on microglia (Lyons et al., 2009; Zhao et al., 2015). However, 
evidence is mounting to show that the CX3CR1 receptor is also present on neurons and 
astrocytes (Meucci et al., 2000; Gillard et al., 2002; Hatori et al., 2002; Hughes et al., 2002; 
Mizuno et al., 2003; Deiva et al., 2004; Limatola et al., 2005). Neuronal CX3CR1 appears to 
play a role in development and neuronal survival (Meucci et al., 2000; Tong et al., 2000; 
Gillard et al., 2002; Mizuno et al., 2003). Therefore, it would stand to reason that 
recombinant fractalkine is neuroprotective to stressed 661W cells in vitro (Figure 6.3.17C). 
 
In conclusion, this study outlines for the first time, the neuroprotective properties of the 
synthetic progestin ‘Norgestrel’, in acting directly on retinal microglia to dampen damaging 
microglial activation in vivo. In addition to this, we reveal novel aspects to Norgestrel’s 
protective effects within photoreceptors. The data presented suggest a critical role for 
Norgestrel-induced fractalkine signalling, not only in the dampening of microglial activation 
in vivo but also in the direct protection of damaged 661W photoreceptor-cells. Future 
studies will be aimed at further elucidating the role that fractalkine signalling plays in the 
neuroprotection associated with Norgestrel and considering therapeutic avenues that 
utilise a combination of drugs to include microglia-driven inflammation as a target. We 
believe direct photoreceptor neuroprotection should remain at the forefront of RP 
immunotherapy development, though a combined treatment with anti-inflammatory 
properties is still desirable. Targeting mutated photoreceptors directly would alleviate 
subsequent photoreceptor-microglial cell crosstalk, minimizing consequential microglial-
driven photoreceptor cell loss. Additional anti-inflammatory properties may then further 
prevent microglial responses shown to exacerbate disease progression. 
 
  
 
 
 
 
Chapter 7. Discussion 
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7. Discussion 
 
Affecting 1 in 4000 individuals, retinitis pigmentosa (RP) is the most common genetically 
inherited ocular disease worldwide (Boughman et al., 1980). Its genetic heterogeneity 
however makes it extremely complicated to treat at a genetic level. Consequently, a 
neuroprotective strategy remains at the forefront of retinal disease research. In 2009, our 
group followed along this line of research. A library of 1040 FDA approved drugs was 
screened for potential anti-apoptotic properties, using the retina-derived 661W 
photoreceptor cell line (Doonan et al., 2009). The Alamar Blue assay, a fluorometric 
indicator of cellular metabolic activity; measured the cellular proliferation, cytotoxicity and 
viability of the cells after treatment with these compounds. This screen identified the 
synthetic progestin ‘Norgestrel’, a common component of the female oral contraceptive 
pill, for further analysis. Our group subsequently published the first study on the 
neuroprotective effects of Norgestrel in 2011. Here, they found Norgestrel to be 
neuroprotective to stressed or diseased retinas in vivo in both a preventative (through the 
Balb/c albino light damage model) and a rescue (using the rd10 mouse model of retinal 
degeneration) situation (Doonan et al., 2011). 
 
Progestogenic hormones are thought to modulate pro-survival pathways in the central 
nervous system (CNS) (Gonzalez Deniselle et al. 2002a, 2002b; Gonzalez et al. 2005; 
Compagnone 2008; Espinosa-García et al. 2014; Yousuf et al. 2014; Qin et al. 2015) and 
since these hormones are produced naturally in the body (Gans & De Jongh, 1961), their 
value as potential therapeutic agents is clear. However, despite promising studies in the 
CNS, research has presented conflicting results as to the capabilities of progesterone to act 
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as a neurotherapeutic in retinal eye disease. For example, progesterone administered by 
intraperitoneal injection (IP) (4mg/kg) protected the inner nuclear and nerve fibre layers in 
a model of retinal ischemia in rats (Lu et al., 2008) but neither IP administration (60mg/kg 
for four days) nor daily dosage (2.5mg/day) with progesterone protected rat 
photoreceptors from cell death in models of light damage (O’Steen, 1977; Káldi & Berta, 
2004). Conversely, Sánchez-Vallejo et al. (2015) recently showed that oral administration 
(100mg/kg administered via oral gavage) worked on several mechanistic levels to prevent 
photoreceptor cell death in the rd1 mouse model of RP. Specifically, in this thesis, we 
highlight the capability of Norgestrel to protect through non-invasive diet-supplementation 
(80mg/kg).  
 
Obviously, there are inconsistencies in the literature regarding the protective capabilities of 
progesterone in the eye. This could be due to any number of different reasons. It may be 
simply that higher concentrations of the steroid are needed to induce retinal cell 
protection. For example, in attempting to protect from retinal degeneration in the light 
damage model, Káldi & Berta (2004) injected with progesterone (60mg/kg) for 4 days 
before light damage. This did not result in any significant preservation of the photoreceptor 
layer. Doonan et al. (2011) however achieved retinal neuroprotection through a 100mg/kg 
IP injection of Norgestrel just 1 hour prior to light damage. This dose was then repeated 
once every three days subsequently. In the rd genetic mouse models, successful 
progesterone/Norgestrel induced protection was achieved through administration of 
100mg/kg on alternate days (IP injection, Doonan et al., 2011; oral gavage, Sánchez-Vallejo 
et al., 2015). Therefore, perhaps the conflicting results of these studies simply emphasise 
that consistently high concentrations of the drug are required to achieve retinal 
neuroprotection. Alternately, it may be that the protection ascribed to Norgestrel is 
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because Norgestrel is a synthetic progestin, not naturally produced in the body. Synthetic 
progestins are rapidly absorbed in the body in comparison to natural progesterone. With a 
longer half-life, they maintain a more stable level in the blood (“Progesterone - Pharmacy 
Reviewer,” 2016) and thus it is probable that the higher concentrations of Norgestrel are 
available for longer.  
 
Indeed, there may be other, mechanistic reasons behind the neuroprotective effects of 
Norgestrel. Basic fibroblast growth factor has previously been trialled as a potential 
therapeutic approach to retinal eye disease (O’Driscoll et al., 2007, 2008). Shown to 
activate several pro-survival pathways, in this thesis we show for the first time the direct 
link between progesterone signalling and bFGF upregulation (Chapter 3, 4, 5). An early 
study carried out on the mouse mammary tumour line C4-HD suggested a crosstalk 
between steroid and growth factor signalling pathways (Lamb et al., 1999). bFGF is also 
known to be produced in response to progesterone administration in non-neuronal tissues 
such as the ovaries and uterus (Rider et al., 1997). However, to our knowledge, we are the 
only group to have demonstrated that that direct progesterone receptor stimulation will 
induce an upregulation in bFGF, crucial in Norgestrel-mediated neuroprotection (Chapter 
3).  
 
Norgestrel-mediated increases in bFGF drove the downstream pro-survival phosphorylation 
of GSK3β on serine 9 and this protein facilitated the actions of Norgestrel in the direct 
protection of stressed photoreceptors. This study, published in the European Journal of 
Neuroscience, Wyse-Jackson and Cotter (2016), was the first to establish a  significant 
Norgestrel-mediated pro-survival signalling pathway. However, one of the advantages to 
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giving a blanket neuroprotective as opposed to simply administering, for example, bFGF as 
a therapeutic; is that steroid binding to specific receptors may activate a whole cascade of 
downstream intracellular signalling events. To explain: bFGF activation may be as a result of 
Norgestrel-binding to one specific receptor. However, Norgestrel may also have other 
beneficial effects through differential receptor activation.  
 
Unfortunately, the retinal expression of progesterone receptors had not yet been fully 
studied. Before this work, all that was known was that both nuclear receptors A and B (PR 
A/B) were expressed in the retina (Wickham et al., 2000) and that progesterone receptor 
membrane complex one (PGRMC1) was also expressed by retinal Müller cells, 
photoreceptors and the retinal pigment epithelium (Swiatek-De Lange et al., 2007). Since 
androgen and oestrogen receptors had also been detected in the eye (Wickham et al., 
2000), it would appear that the retina is a bona fide target of progestogens and indeed 
steroids in general. Accordingly, we set out to characterise the progesterone receptors 
present in the retina, with the aim of exposing Norgestrel’s specific cellular target.  
 
In the following work (Chapter 4), we identified and characterized the complete expression 
of progesterone receptors present in the C57 wild type and rd10 mouse model of retinitis 
pigmentosa, and in 661W cone photoreceptor cells. In both mice retinas, regardless of 
genotype (C57 vs. rd10) or sex (male vs. female), classical progesterone receptors A and B 
(PR A/B), progesterone receptor membrane components 1 and 2 (PGRMC1, PGRMC2) and 
membrane progesterone receptors α, β and γ (mPR α, β and γ) were expressed. All 
receptors excluding PR A/B were also found in the 661W photoreceptor cell line. This work, 
published in the Journal of Neurochemistry (Wyse-Jackson et al., 2016), showed that 
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Norgestrel appeared to work primarily through activation of PGRMC1, for specific siRNA 
transfection (in vitro) and receptor blockade (ex vivo) prevented its neuroprotective 
actions. 
 
One thought as to the differing evidence behind progesterone in the CNS vs. the eye, is that 
that the protective effects of progesterone in the CNS are predominantly regulated by PR 
A/B (Schumacher et al., 2014). However, since we show that PR A/B is only sparsely 
expressed in the retina - and is indeed the least prevalent progesterone receptor present 
(Chapter 4), perhaps progesterone signalling through PR A/B is only weakly neuroprotective 
to the diseased or damaged retina. This could conceivably explain why O’Steen (1977) and 
Káldi & Berta (2004) did not find any significant progesterone-induced retinal protection: it 
requires PR A/B activation, difficult when it is so modestly expressed. Alternately, 
Norgestrel, signalling through the abundantly expressed PGRMC1, can act in a significantly 
protective manner.  
 
Interestingly, PGRMC1 in itself has been shown to be critical in cellular regulation (Lösel et 
al., 2008; Peluso, Romak, et al., 2008; Peluso et al., 2010, 2014). In fact, in our own study, 
siRNA knock down significantly decreased cellular viability of the 661W photoreceptor cell 
line by 20% (Figure 4.3.11). Despite this, there is limited knowledge available on the 
downstream activities of PGRMC1 signalling. Research on the function of this receptor is 
further exacerbated in the case of ocular tissue, where only two such studies exist (Samadi 
et al., 2002; Swiatek-De Lange et al., 2007). PGRMC1 has been identified however, as a 
novel non-transcriptional mechanism of signal transduction in retinal Müller glial cells. In 
2007, Swiatek-De Lange et al. found that activation of PGRMC1 caused a rapid elevation of 
163 
 
cytosolic [Ca2+], which we show in this thesis to be protective to stressed 661W 
photoreceptor cells in vitro (Chapter 5). Furthermore, they showed that there is a PGRMC1-
progesterone initiated, calcium-dependent induction of extracellular signal-regulated 
kinases (ERK); which has also been shown by our group to be up-regulated in the rd10 
mouse model in response to IP administration of Norgestrel (Doonan et al., 2011; Doonan 
& Cotter, 2012). 
 
The first three results chapters of this thesis (Chapters 3, 4 and 5) nicely tie together one of 
the pro-survival signalling mechanisms of Norgestrel: from the activation and subsequent 
nuclear trafficking of cell membrane receptor PGRMC1, right through to the bFGF/calcium 
induced inactivation of pro-death protein GSK3β. The above work was crucial in identifying 
Norgestrel’s protective mechanisms directly on photoreceptors. However, considering that 
the retina is a highly complex tissue composed of various cell types and inter-cellular 
interactions, we wished also to investigate the effects of Norgestrel on other retinal cell 
types. In particular, we were interested in exploring photoreceptor-microglia crosstalk in 
the context of Norgestrel-dependent neuroprotection.  
 
Throughout the course of the three years that this thesis has spanned, more and more 
research has been published highlighting the critical role of microglia in the potentiation of 
retinal degeneration. In several ground-breaking studies by our own group (Roche et al., 
2016) and by others (Arroba et al., 2011; Peng et al., 2014; Zhao et al., 2015), microglia 
have been shown to infiltrate in to the ONL in retinal degenerative models, ameliorating 
photoreceptor cell death. These studies critically show that when microglial activation is 
prevented, photoreceptor degeneration is slowed. However, no study has yet determined 
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whether microglia in a diseased retina, such as the rd10; become primed to target healthy 
photoreceptors during disease progression or if they are instead responding to a signal 
from dying photoreceptors. This being the case, they may then have subsequent 
unintentional but detrimental effects on nearby viable photoreceptors: we set out to 
dissect this conundrum.  
 
Knowing that Norgestrel administration was protective against photoreceptor cell death, 
one of the major issues that we wished to overcome in this thesis was ease of 
administration. To date, all work on progesterone and Norgestrel-induced neuroprotection 
has used the invasive techniques of IP and oral gavage. These techniques have proven 
effective in preventing progressive retinal degenerations, however daily IP injection is time 
consuming, stressful for the animals and requires an administrative vehicle such as DMSO 
which can cause complications in itself. To emphasise this point, in the 2011 study, 
Norgestrel was made up in DMSO and injected intraperitoneally with peanut oil, a delivery 
vehicle used for lipophilic compounds. Whilst uncommon, about 1 in 20 mice suffered an 
adverse reaction to the mixture and had to be culled immediately as a result. With the 
complications of IP injection/oral gavage and also the time constraints of daily dosage in 
mind, we decided to trial a less invasive technique. The average adult mouse (18g – 30g, 
strain and sex dependent) eats 4-5g feed a day. A Norgestrel-supplemented diet was 
developed by Testdiet (Middlesex, UK) and dams of rd10 pups were given the Norgestrel-
supplemented diet ad libitum when the pups reached P10. This allowed the pups to receive 
Norgestrel in the milk and, assuming that the average 30g mouse consumes around 5g of 
food/day, equates to an approximate daily dose of 80mg/kg of Norgestrel.  
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Norgestrel-diet supplementation (80mg/kg/day) (Chapter 6) worked beautifully to 
significantly protect the photoreceptor layer of rd10 mice out to P40. In the rd10 mouse, 
cell loss peaks between P18 and ~P21 (Gargini et al., 2007; Barhoum et al., 2008; 
Samardzija et al., 2012; Roche et al., 2016). However, we found that absolutely no cell loss 
took place between P15 and P20 in the Norgestrel-treated mice. Such a protection as this 
has not been previously seen in the rd10 mouse model. The fact that it was achieved 
through such an easy, non-invasive method makes it all the more astonishing.  
 
Norgestrel-treated rd10 mice exhibited significantly dampened microglial reactivity and 
their migration in to the ONL was markedly reduced. We found that not only did Norgestrel 
work to protect damaged photoreceptors from cell death, but it could also work directly on 
rd10 microglia to prevent their entry in to the pro-inflammatory, damaging M1 state. 
Critically, through the use of novel primary rd10 microglia-photoreceptor co-cultures, we 
characterised for the first time the phagocytic activity of rd10 microglia. These cells, once 
exposed to an activating factor, will remain reactive and subsequently phagocytic. This is a 
vital point in the future of retinal degeneration treatment – for clearly more work is 
required in understanding what this initial signal is and how to prevent it. Most 
interestingly is that when this factor is removed (i.e. in the case of primary culture of rd10 
microglia), they will still remain reactive and consequently engulf and damage healthy, 
viable cells. Evidently, Norgestrel acts as an anti-inflammatory in damaged photoreceptor 
cells. We therefore postulate that this sequentially reduces damaging inflammatory factor 
secretion from microglia and prevents their migration to the ONL. 
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In this thesis, several key molecular mechanisms regulating the neuroprotective properties 
of Norgestrel have been elucidated. Clearly, our understanding of how this synthetic 
progesterone analogue works directly on photoreceptor cells to delay and prevent cell 
death is expanding. However, an unexpected result to have come out of our research is 
that Norgestrel can also work on other cell types in the eye. In chapter 6, we show that 
rd10 microglia express progesterone receptors and through ex vivo primary cell culture, 
have demonstrated Norgestrel’s ability to work directly on these cells to prevent pro-
inflammatory M1 activation. Only now are we beginning to appreciate the fact that 
Norgestrel works in a highly protective, multi-faceted manner in the retina. As such, we 
hope to bring our working knowledge of how the compound works to a point that is ready 
for clinical trials. It is evident from our initial results with Norgestrel diet supplementation 
that Norgestrel will likely work optimally as a combination therapy, alongside a more 
potent anti-inflammatory. However, before this is started, we should discern what it is that 
Norgestrel cannot protect from; i.e. the signal or event causing the photoreceptor cell loss 
at P25. Once we know this, we can truly and honestly think of bringing this treatment to 
the clinic and closer to patients suffering from retinal degeneration.  
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